<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:50.2pt;left:73.6pt;line-height:24.7pt"><b><i><span style="font-family:Times New Roman,serif;font-size:24.7pt;color:#224092">cancers</span></i></b></p>
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,539.93118,-28.080323)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,539.93118,-28.080323)" src="data:image/png;base64,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==">
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,539.93118,-28.080323)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,539.93118,-28.080323)" src="data:image/png;base64,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">
<p style="top:102.1pt;left:35.7pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Review</span></i></p>
<p style="top:114.6pt;left:35.3pt;line-height:17.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:17.9pt">An Alternative Pipeline for Glioblastoma Therapeutics: A</span></b></p>
<p style="top:133.4pt;left:36.0pt;line-height:17.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:17.9pt">Systematic Review of Drug Repurposing in Glioblastoma</span></b></p>
<p style="top:170.4pt;left:36.0pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Se</span></b><b><span style="font-family:VnURWPalladioL,serif;font-size:10.0pt">&#xe1;</span></b><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">n B. Lyne</span></b></p>
<p style="top:170.4pt;left:108.3pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and Bakhtiar Yamini *</span></b></p>
<p style="top:414.0pt;left:55.5pt;line-height:7.9pt"><span style="font-family:SourceSansRoman,serif;font-size:7.9pt">&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;</span><span style="font-family:SourceSansRoman.613wght,serif;font-size:7.0pt">&#xfffd;</span></p>
<p style="top:421.1pt;left:55.5pt;line-height:7.9pt"><b><span style="font-family:SourceSansRoman,serif;font-size:7.9pt">&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;</span></b></p>
<p style="top:439.1pt;left:36.0pt;line-height:7.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Citation:</span></b><span style="font-family:URWPalladioL,serif;font-size:7.0pt"> Lyne, S.B.; Yamini, B. An</span></p>
<p style="top:451.0pt;left:35.7pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Alternative Pipeline for Glioblastoma</span></p>
<p style="top:462.9pt;left:35.8pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Therapeutics: A Systematic Review of</span></p>
<p style="top:474.8pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Drug Repurposing in Glioblastoma.</span></p>
<p style="top:486.8pt;left:35.8pt;line-height:7.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:7.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:7.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:7.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:7.0pt">, 1953. https://</span></p>
<p style="top:498.7pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">doi.org/10.3390/cancers13081953</span></p>
<p style="top:522.6pt;left:35.7pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Academic Editor: Patrizia Limonta</span></p>
<p style="top:546.4pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Received: 8 March 2021</span></p>
<p style="top:558.4pt;left:35.7pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Accepted: 16 April 2021</span></p>
<p style="top:570.3pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Published: 18 April 2021</span></p>
<p style="top:595.7pt;left:36.0pt;line-height:7.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Publisher&#x2019;s Note:</span></b><span style="font-family:URWPalladioL,serif;font-size:7.0pt"> MDPI stays neutral</span></p>
<p style="top:607.6pt;left:35.7pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">with regard to jurisdictional claims in</span></p>
<p style="top:619.5pt;left:35.8pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">published maps and institutional af&#xfb01;l-</span></p>
<p style="top:631.4pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">iations.</span></p>
<img style="position:absolute;transform:matrix(.1511808,0,-0,.1511808,-164.20479,803.6891)" src="data:image/png;base64,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">
<p style="top:684.3pt;left:36.0pt;line-height:7.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Copyright:</span></b><span style="font-family:URWPalladioL,serif;font-size:7.0pt"> &#xa9; 2021 by the authors.</span></p>
<p style="top:696.2pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Licensee MDPI, Basel, Switzerland.</span></p>
<p style="top:708.1pt;left:35.8pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">This article is an open access article</span></p>
<p style="top:720.1pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">distributed</span></p>
<p style="top:720.1pt;left:76.6pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">under</span></p>
<p style="top:720.1pt;left:101.5pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">the</span></p>
<p style="top:720.1pt;left:117.5pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">terms</span></p>
<p style="top:720.1pt;left:141.3pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">and</span></p>
<p style="top:732.0pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">conditions of the Creative Commons</span></p>
<p style="top:743.9pt;left:35.7pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">Attribution (CC BY) license (https://</span></p>
<p style="top:755.8pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">creativecommons.org/licenses/by/</span></p>
<p style="top:767.8pt;left:36.0pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">4.0/).</span></p>
<p style="top:197.4pt;left:167.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Department of Neurological Surgery, University of Chicago Medicine and Biological Sciences,</span></p>
<p style="top:208.2pt;left:167.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Chicago, IL 60637, USA; sean.lyne@uchospitals.edu</span></p>
<p style="top:219.0pt;left:166.6pt;line-height:8.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">*</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> Correspondence: byamini@surgery.bsd.uchicago.edu</span></p>
<p style="top:239.7pt;left:167.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Simple Summary:</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Glioblastoma is a devastating malignancy that has continued to prove resistant to</span></p>
<p style="top:252.6pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">a variety of therapeutics. No new systemic therapy has been approved for use against glioblastoma</span></p>
<p style="top:265.5pt;left:167.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">in almost two decades. This observation is particularly disturbing given the amount of money</span></p>
<p style="top:278.6pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">invested in identifying novel therapies for this disease. A relatively rapid and economical pipeline for</span></p>
<p style="top:291.6pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">identi&#xfb01;cation of novel agents is drug repurposing. Here, a comprehensive review detailing the state</span></p>
<p style="top:304.5pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">of drug repurposing in glioblastoma is provided. We reveal details on studies that have examined</span></p>
<p style="top:317.6pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">agents</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, in animal models and in patients. While most agents have not progressed beyond the</span></p>
<p style="top:330.5pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">initial stages, several drugs, from a variety of classes, have demonstrated promising results in early</span></p>
<p style="top:343.4pt;left:167.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">phase clinical trials.</span></p>
<p style="top:368.4pt;left:166.9pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Abstract:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> The treatment of glioblastoma (GBM) remains a signi&#xfb01;cant challenge, with outcome for</span></p>
<p style="top:381.3pt;left:167.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">most pa-tients remaining poor. Although novel therapies have been developed, several obstacles</span></p>
<p style="top:394.3pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">restrict the incentive of drug developers to continue these efforts including the exorbitant cost, high</span></p>
<p style="top:407.3pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">failure rate and relatively small patient population. Repositioning drugs that have well-characterized</span></p>
<p style="top:420.3pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">mechanistic and safety pro&#xfb01;les is an attractive alternative for drug development in GBM. In ad-dition,</span></p>
<p style="top:433.3pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">the relative ease with which repurposed agents can be transitioned to the clinic further supports their</span></p>
<p style="top:446.2pt;left:167.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">potential for examination in patients. Here, a systematic analysis of the literature and clinical trials</span></p>
<p style="top:459.1pt;left:167.0pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">provides a comprehensive review of primary articles and unpublished trials that use repurposed</span></p>
<p style="top:472.1pt;left:167.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">drugs for the treatment of GBM. The &#xfb01;ndings demonstrate that numerous drug classes that have</span></p>
<p style="top:485.0pt;left:167.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">a range of initial indications have ef&#xfb01;cacy against preclinical GBM models and that certain agents</span></p>
<p style="top:498.0pt;left:167.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">have shown signi&#xfb01;cant potential for clinical bene&#xfb01;t. With examination in randomized, placebo-</span></p>
<p style="top:511.0pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">controlled trials and the targeting of particular GBM subgroups, it is pos-sible that repurposing can</span></p>
<p style="top:524.0pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">be a cost-effective approach to identify agents for use in multimodal anti-GBM strategies.</span></p>
<p style="top:548.9pt;left:167.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Keywords:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> glioblastoma; GBM; therapeutics; chemosensitization; radiosensitization; repurpos-</span></p>
<p style="top:561.9pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ing; repositioning</span></p>
<p style="top:611.2pt;left:167.3pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">1. Introduction</span></b></p>
<p style="top:626.8pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Glioblastoma (GBM) is the most common primary malignant brain tumor worldwide</span></p>
<p style="top:639.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and is also the most lethal, with a median survival of approximately 15 months after</span></p>
<p style="top:651.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">diagnosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">1</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. According to the recent analyses by The Central Brain Tumor Registry of</span></p>
<p style="top:664.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the United States (CBTRUS), GBM comprises 48.3% of primary malignant brain tumors</span></p>
<p style="top:676.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and has an overall &#xfb01;ve-year survival rate of 6.8% [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">2</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Currently, treatment for GBM</span></p>
<p style="top:689.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">involves maximal surgical resection followed by combination radiation therapy (RT) and</span></p>
<p style="top:702.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">chemotherapeutics, most often involving the alkylating agent, temozolomide (TMZ). In</span></p>
<p style="top:714.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">addition, the adjunctive use of tumor-treating &#xfb01;eld (TTF) technology has shown some</span></p>
<p style="top:727.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">survival bene&#xfb01;t [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">3</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Despite this multimodal approach, overall survival (OS) and quality of</span></p>
<p style="top:739.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">life remain poor for patients with GBM [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">5</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:752.2pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">While traditional drug development pipelines are hampered by high cost and low</span></p>
<p style="top:764.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">success rate, an alternative strategy is repurposing. Speci&#xfb01;cally, well-established drugs that</span></p>
<p style="top:814.3pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953. https://doi.org/10.3390/cancers13081953</span></p>
<p style="top:814.3pt;left:409.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">https://www.mdpi.com/journal/cancers</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:536.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2 of 29</span></p>
<p style="top:95.7pt;left:166.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">were previously developed to treat other diseases can be used as potential antineoplastic</span></p>
<p style="top:108.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">agents. Repurposed drugs are particularly attractive as they already have well-established</span></p>
<p style="top:120.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">safety pro&#xfb01;les and often require smaller cohorts for therapeutic ef&#xfb01;cacy analysis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">6</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. These</span></p>
<p style="top:133.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">factors help to streamline the passage of repurposed agents through the stringent FDA</span></p>
<p style="top:145.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">requirements for approval of novel agents. Repurposed drugs not only have a quicker</span></p>
<p style="top:158.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">approval time for an additional indication, but also have over 50% cost reduction in</span></p>
<p style="top:170.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">comparison to novel drug development [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">6</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], observations that are exempli&#xfb01;ed by the</span></p>
<p style="top:183.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">success of prior spontaneous and planned repurposing discoveries [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">7</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:196.2pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Important obstacles to repurposing drugs for GBM treatment include the presence of</span></p>
<p style="top:208.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the blood&#x2013;brain barrier (BBB), adverse effects when combining repurposed agents with</span></p>
<p style="top:221.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">other medications, intellectual property concerns and drug availability. The BBB can be</span></p>
<p style="top:233.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">bypassed using adjunctive strategies such as increasing its permeability or direct tumor</span></p>
<p style="top:246.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cell targeting with nanocarriers. Notably, overcoming these obstacles can potentially affect</span></p>
<p style="top:258.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">the cost of production and delivery [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">8</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">10</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. In addition, given the diverse molecular nature</span></p>
<p style="top:271.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of GBM, it is important to appreciate that novel therapeutics may only be bene&#xfb01;cial for</span></p>
<p style="top:283.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">speci&#xfb01;c subsets of patients. While DNA damage repair factors such as methylguanine</span></p>
<p style="top:296.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">methyltransferase (MGMT) or mismatch repair (MMR) activity are well known for modu-</span></p>
<p style="top:309.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">lating response to therapy, more recent prognostic factors such as isocitrate dehydrogenase</span></p>
<p style="top:321.7pt;left:166.9pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">(IDH) status also play a pivotal role in overall outcome [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">11</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">15</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. This molecular variability</span></p>
<p style="top:334.1pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">plays a central role in the success of repurposed agents. In this regard, GBM can be clus-</span></p>
<p style="top:346.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">tered into several expression-based subgroups that not only have different genetic make</span></p>
<p style="top:359.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">up but also response to therapy [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">12</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">14</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">15</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. These observations highlight the importance</span></p>
<p style="top:371.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">of examining novel repurposed agents in a variety of GBM subgroups to determine their</span></p>
<p style="top:384.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">overall potential for clinical use.</span></p>
<p style="top:397.0pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Identi&#xfb01;cation of repurposing candidates has involved computational bioinformatics,</span></p>
<p style="top:409.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">large-scale screening experiments or candidate-based approaches [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">16</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">18</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Moreover, the</span></p>
<p style="top:422.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">examination of agents has ranged from cell-based studies to large multi-institutional</span></p>
<p style="top:434.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">randomized clinical trials. Here, we present a systematic review of repurposed agents used</span></p>
<p style="top:447.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">for the management of GBM. We categorize the &#xfb01;ndings into two groups based on their</span></p>
<p style="top:459.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">stage of development: those in the early stage (i.e.,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> or animal model testing) and</span></p>
<p style="top:472.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">those that have transitioned to a clinical trial.</span></p>
<p style="top:494.7pt;left:167.3pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2. Materials and Methods</span></b></p>
<p style="top:510.2pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)</span></p>
<p style="top:522.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">guidelines were used for this study. A literature search was conducted using the PubMed</span></p>
<p style="top:535.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">database on 17 August 2020, with results restricted to articles written in the English lan-</span></p>
<p style="top:547.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">guage. The original search terms included glioblastoma, glioma, GBM, astrocytoma, drug,</span></p>
<p style="top:560.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">therapy, treatment, chemotherapy, radiotherapy, pharmacology, repurposing, repurposed,</span></p>
<p style="top:573.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">repurpose, repositioning, reposition and re-tasking. Any articles that were not fully avail-</span></p>
<p style="top:585.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">able online were excluded from systematic review. Studies were selected for inclusion</span></p>
<p style="top:598.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in the systematic review and analysis if they: (a) used a repurposed agent against GBM</span></p>
<p style="top:610.6pt;left:166.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">where the speci&#xfb01;c drug had been initially used to treat another disease; (b) used a repur-</span></p>
<p style="top:623.2pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">posed agent as an adjunctive therapeutic in the surgical resection of GBM; or (c) used the</span></p>
<p style="top:635.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">repurposed agent for chemo/radiosensitization in GBM. No prespeci&#xfb01;ed inclusion criteria</span></p>
<p style="top:648.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">regarding length of follow up, type of study or date of publication, were used. Capability</span></p>
<p style="top:660.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">of penetrating the BBB was not used as an exclusion criterion.</span></p>
<p style="top:673.4pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">ClinicalTrials.gov</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> was examined on 17 August 2020 as a second database to capture</span></p>
<p style="top:686.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">any clinical trials that did not have published results. Initial search criteria included glioma</span></p>
<p style="top:698.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">studies that were: (a) currently active and no longer recruiting patients; (b) currently</span></p>
<p style="top:711.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">recruiting; or (c) enrolling by invitation. Search criteria were limited to: pharmacologic</span></p>
<p style="top:723.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">interventional studies. An additional search was conducted with simple criteria including</span></p>
<p style="top:736.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">glioma and repurposed. The identi&#xfb01;ed trials were then excluded or included on the basis</span></p>
<p style="top:748.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of whether or not they were speci&#xfb01;cally interventional studies using a drug primarily</span></p>
<p style="top:761.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">developed for another disease.</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:536.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3 of 29</span></p>
<p style="top:97.4pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The PubMed search yielded a total of 135 articles for screening. In accordance with</span></p>
<p style="top:110.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">eligibility for inclusion in this review, six previous review studies with no new novel</span></p>
<p style="top:122.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">meta-analysis results or data were excluded along with 14 articles that were outside</span></p>
<p style="top:135.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the scope of this review. These latter articles fell under the following subheadings: (a)</span></p>
<p style="top:147.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">repurposing therapy for a disease other than glioma; (b) examination of a novel therapy</span></p>
<p style="top:160.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">for glioma; (c) studies that lacked an intervention; and (d) studies that used a therapeutic</span></p>
<p style="top:172.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">other than a chemical agent (e.g., RNA, virus or genetic manipulation). Based on the above</span></p>
<p style="top:185.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">criteria, a total of 115 articles remained for review. Any comments on original articles were</span></p>
<p style="top:197.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">examined and if the original article was not enveloped within the search, it was added.</span></p>
<p style="top:210.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Relevant pivotal articles that were cited in an article identi&#xfb01;ed in the literature search were</span></p>
<p style="top:223.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">included if they were not already included in the 115 articles. In addition, PubMed searches</span></p>
<p style="top:235.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">to encompass therapies targeting the tumor microenvironment (TME), major signaling</span></p>
<p style="top:248.2pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">pathways active in GBM and GBM stem cells, were performed, yielding a total of 15 novel</span></p>
<p style="top:260.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">articles that were not covered by the initial PubMed search.</span></p>
<p style="top:273.3pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">The</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt;color:#0774b7"> ClinicalTrials.gov</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> search conducted on 17 August 2020 yielded a total of 65 active</span></p>
<p style="top:285.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">clinical trials. These trials were either recruiting subjects or were active but no longer</span></p>
<p style="top:298.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">recruiting. Additionally, studies without results were included. Of the 65 active clinical</span></p>
<p style="top:310.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">trials, 35 met eligibility for inclusion in this review. Fourteen of the excluded trials investi-</span></p>
<p style="top:323.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">gated viral, cellular or other non-protein biologic intervention. Seven studies investigated</span></p>
<p style="top:336.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">repurposed or non-repurposed drugs for non-therapeutic effects in GBM such as symptom</span></p>
<p style="top:348.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">management. Nine trials were excluded as they examined completely novel therapies. A</span></p>
<p style="top:361.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">&#xfb01;gure detailing key mechanisms of action of repurposed drugs investigated at the preclini-</span></p>
<p style="top:373.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cal stage is presented in Figure</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt;color:#0774b7"> 1</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">. The data are also presented more comprehensively in</span></p>
<p style="top:386.2pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Table</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 1</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">. In Figure</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 2</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, the pathways targeted by repurposed drugs being investigated at the</span></p>
<p style="top:398.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">clinical stage are presented (also shown in Table</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 2</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">).</span></p>
<p style="top:4.2pt;left:31.1pt;line-height:8.0pt"><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:8.0pt">Cancers</span></i><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt"> </span><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:8.0pt">2021</span></b><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt">,</span><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:8.0pt"> 13</span></i><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt">, 1953 </span></p>
<p style="top:4.2pt;left:527.4pt;line-height:8.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt">3 of 29 </span></p>
<p style="top:10.6pt;left:31.1pt;line-height:8.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt"> </span></p>
<p style="top:765.0pt;left:31.1pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> </span></p>
<p style="top:44.4pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">interventional studies. An additional search was conducted with simple criteria including </span></p>
<p style="top:57.3pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">glioma and repurposed. The identified trials were then excluded or included on the basis </span></p>
<p style="top:70.1pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">of whether or not they were specifically interventional studies using a drug primarily de-</span></p>
<p style="top:82.9pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">veloped for another disease. </span></p>
<p style="top:95.7pt;left:182.8pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">The PubMed search yielded a total of 135 articles for screening. In accordance with </span></p>
<p style="top:108.5pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">eligibility for inclusion in this review, six previous review studies with no new novel </span></p>
<p style="top:121.4pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">meta-analysis results or data were excluded along with 14 articles that were outside the </span></p>
<p style="top:134.1pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">scope of this review. These latter articles fell under the following subheadings: (a) repur-</span></p>
<p style="top:147.0pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">posing therapy for a disease other than glioma; (b) examination of a novel therapy for </span></p>
<p style="top:159.8pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">glioma; (c) studies that lacked an intervention; and (d) studies that used a therapeutic </span></p>
<p style="top:172.6pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">other than a chemical agent (e.g., RNA, virus or genetic manipulation). Based on the above </span></p>
<p style="top:185.4pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">criteria, a total of 115 articles remained for review. Any comments on original articles were </span></p>
<p style="top:198.2pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">examined and if the original article was not enveloped within the search, it was added. </span></p>
<p style="top:211.1pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">Relevant pivotal articles that were cited in an article identified in the literature search were </span></p>
<p style="top:223.9pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">included if they were not already included in the 115 articles. In addition, PubMed </span></p>
<p style="top:236.7pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">searches to encompass therapies targeting the tumor microenvironment (TME), major sig-</span></p>
<p style="top:249.5pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">naling pathways active in GBM and GBM stem cells, were performed, yielding a total of </span></p>
<p style="top:262.4pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">15 novel articles that were not covered by the initial PubMed search. </span></p>
<p style="top:275.1pt;left:182.8pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">The ClinicalTrials.gov search conducted on 17 August 2020 yielded a total of 65 active </span></p>
<p style="top:288.0pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">clinical trials. These trials were either recruiting subjects or were active but no longer re-</span></p>
<p style="top:300.8pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">cruiting. Additionally, studies without results were included. Of the 65 active clinical tri-</span></p>
<p style="top:313.6pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">als, 35 met eligibility for inclusion in this review. Fourteen of the excluded trials investi-</span></p>
<p style="top:326.4pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">gated viral, cellular or other non-protein biologic intervention. Seven studies investigated </span></p>
<p style="top:339.2pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">repurposed or non-repurposed drugs for non-therapeutic effects in GBM such as symp-</span></p>
<p style="top:352.1pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">tom management. Nine trials were excluded as they examined completely novel thera-</span></p>
<p style="top:364.8pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">pies. A figure detailing key mechanisms of action of repurposed drugs investigated at the </span></p>
<p style="top:377.7pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">preclinical stage is presented in Figure 1. The data are also presented more comprehen-</span></p>
<p style="top:390.5pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">sively in Table 1. In Figure 2, the pathways targeted by repurposed drugs being investi-</span></p>
<p style="top:403.3pt;left:161.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">gated at the clinical stage are presented (also shown in Table 2). </span></p>
<p style="top:688.2pt;left:532.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> </span></p>
<p style="top:704.0pt;left:52.4pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">Figure 1. </span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Cellular pathways and interactions detailing the key proposed mechanisms of drugs that have completed pre-</span></p>
<p style="top:715.5pt;left:52.4pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">clinical investigation and have yet to be fully studied in the clinical setting. Abbreviations: Adenosine diphosphate recep-</span></p>
<p style="top:694.7pt;left:57.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Figure 1.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Cellular pathways and interactions detailing the key proposed mechanisms of drugs that have completed</span></p>
<p style="top:707.5pt;left:57.0pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">preclinical investigation and have yet to be fully studied in the clinical setting. Abbreviations: Adenosine diphosphate</span></p>
<p style="top:720.3pt;left:57.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">receptor (P2YR12); cyclic adenosine 3</span><sup><i><span style="font-family:CMSY10,serif;font-size:7.3pt">&#x2032;</span></i></sup><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,5</span><sup><i><span style="font-family:CMSY10,serif;font-size:7.3pt">&#x2032;</span></i></sup><span style="font-family:URWPalladioL,serif;font-size:9.1pt">-cyclic monophosphate (cAMP); adenosine 3</span><sup><i><span style="font-family:CMSY10,serif;font-size:7.3pt">&#x2032;</span></i></sup><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,5</span><sup><i><span style="font-family:CMSY10,serif;font-size:7.3pt">&#x2032;</span></i></sup><span style="font-family:URWPalladioL,serif;font-size:9.1pt">-cyclic monophosphate (AMP);</span></p>
<p style="top:733.1pt;left:57.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">phosphodiesterase (PDE); glycogen synthase kinase (GSK3B); phosphoinositide 3-kinase (PI3K); AMP-activated protein</span></p>
<p style="top:746.0pt;left:57.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">kinase (AMPK); microtubule-associated protein 1A/1B-light chain 3 phosphatidylethanolamine conjugate (LC3-II); signal</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:536.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4 of 29</span></p>
<p style="top:97.4pt;left:57.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">transducer and activator of transcription 3 (STAT3); (sex determining region Y)-box 2 (SOX2); octamer-binding transcription</span></p>
<p style="top:110.2pt;left:57.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">factor 4 (OCT4); focal adhesion kinase (FAK); phosphatase and tensin homolog (PTEN); protein kinase B (AKT); eukaryotic</span></p>
<p style="top:122.9pt;left:57.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">translation initiation factor (eIF4e); S-phase kinase-associated protein 2 (Skp2); microRNA-33b (miRNA-33b); Macrophage</span></p>
<p style="top:135.7pt;left:57.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">migration inhibitory factor (MIF); reactive oxygen species (ROS); tafazzin (TAZ); yes associated protein (YAP); &#xfb01;broblast</span></p>
<p style="top:148.5pt;left:57.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">growth factor-inducible 14 (Fn14); store-operated calcium entry (SOCE); isocitrate dehydrogenase 1 (IDH1); enhancer of</span></p>
<p style="top:161.4pt;left:57.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">zeste homolog 2 (EZH2); rat sarcoma (RAS); extracellular signal-regulated kinase (ERK); epidermal growth factor receptor</span></p>
<p style="top:174.3pt;left:57.0pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">(EGFR); t-type calcium channel (CaV3.2); Bcl-2-associated X protein (BAX); B-cell lymphoma 2 (BCL2); B-cell lymphoma-xL</span></p>
<p style="top:187.0pt;left:57.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">(BCL-XL); nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KB).</span></p>
<p style="top:212.8pt;left:167.0pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 1.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Drug class, speci&#xfb01;c drug, and drug targets of repurposed agents currently undergoing</span></p>
<p style="top:225.6pt;left:167.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">preclinical investigation.</span></p>
<p style="top:246.7pt;left:193.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Drug Class</span></b></p>
<p style="top:246.7pt;left:301.6pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Drugs</span></b></p>
<p style="top:246.7pt;left:397.6pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Targets</span></b></p>
<p style="top:246.7pt;left:484.9pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Reference(s)</span></b></p>
<p style="top:273.2pt;left:183.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Antiarrhythmics</span></p>
<p style="top:268.0pt;left:298.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Digoxin</span></p>
<p style="top:262.5pt;left:378.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Na+/K+ ATPase,</span></p>
<p style="top:273.4pt;left:402.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">AKT</span></p>
<p style="top:268.0pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">19</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:284.4pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Proscillaridin A</span></p>
<p style="top:284.4pt;left:398.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">GSK3</span><span style="font-family:EURM10,serif;font-size:9.0pt">&#x3b2;</span></p>
<p style="top:284.4pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">20</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:312.0pt;left:194.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Antibiotics</span></p>
<p style="top:300.2pt;left:288.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Tetracyclines</span></p>
<p style="top:300.2pt;left:385.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Mitochondria</span></p>
<p style="top:300.2pt;left:497.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">21</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">22</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:316.6pt;left:296.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Dapsone</span></p>
<p style="top:311.1pt;left:393.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">FPR, IL-8,</span></p>
<p style="top:322.1pt;left:381.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Leukotriene-B4</span></p>
<p style="top:316.6pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">23</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:333.0pt;left:290.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Clofazimine</span></p>
<p style="top:333.0pt;left:402.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cx46</span></p>
<p style="top:333.0pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">24</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:354.3pt;left:189.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Antidiabetics</span></p>
<p style="top:354.3pt;left:290.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Repaglinide</span></p>
<p style="top:348.8pt;left:370.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">BCL-2, PD-L1, Beclin</span></p>
<p style="top:359.8pt;left:409.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">1</span></p>
<p style="top:354.3pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">25</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:391.7pt;left:183.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Antidepressants</span></p>
<p style="top:375.5pt;left:290.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Imipramine</span></p>
<p style="top:375.5pt;left:400.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ATG7</span></p>
<p style="top:375.5pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:392.0pt;left:285.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Clomipramine</span></p>
<p style="top:386.5pt;left:388.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Complex III</span></p>
<p style="top:397.4pt;left:384.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cytochrome B</span></p>
<p style="top:392.0pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">27</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:408.4pt;left:288.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Fluvoxamine</span></p>
<p style="top:408.4pt;left:386.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">AKT/mTOR</span></p>
<p style="top:408.4pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:419.4pt;left:295.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Sertraline</span></p>
<p style="top:419.4pt;left:398.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MAPK</span></p>
<p style="top:419.4pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">29</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:457.9pt;left:175.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Anti-in&#xfb02;ammatories</span></p>
<p style="top:440.6pt;left:282.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">IP187B/Aspirin</span></p>
<p style="top:435.1pt;left:371.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">STAT3, NF-</span><span style="font-family:EURM10,serif;font-size:9.0pt">&#x3ba;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">B, IGFR,</span></p>
<p style="top:446.1pt;left:402.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PD-1</span></p>
<p style="top:440.6pt;left:490.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">30</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:457.0pt;left:295.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Celecoxib</span></p>
<p style="top:457.0pt;left:383.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">COX-2, NF-</span><span style="font-family:EURM10,serif;font-size:9.0pt">&#x3ba;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">B</span></p>
<p style="top:457.0pt;left:496.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">34</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">36</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:468.0pt;left:296.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Ibudilast</span></p>
<p style="top:468.0pt;left:404.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MIF</span></p>
<p style="top:468.0pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:484.4pt;left:288.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Sulfasalazine</span></p>
<p style="top:478.9pt;left:384.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">System X(c)(-)</span></p>
<p style="top:489.9pt;left:390.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Antiporter</span></p>
<p style="top:484.4pt;left:497.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">39</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:516.2pt;left:173.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Immunosuppressants</span></p>
<p style="top:505.7pt;left:291.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Everolimus</span></p>
<p style="top:516.8pt;left:383.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">mTOR, MCL-1</span></p>
<p style="top:516.8pt;left:496.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:516.6pt;left:295.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Sirolimus</span></p>
<p style="top:527.6pt;left:287.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Temsirolimus</span></p>
<p style="top:559.5pt;left:179.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Antihypertensives</span></p>
<p style="top:543.3pt;left:293.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Mibefradil</span></p>
<p style="top:543.3pt;left:384.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">NHEJ, Cav3.2</span></p>
<p style="top:543.3pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">43</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:554.3pt;left:297.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Prazosin</span></p>
<p style="top:554.3pt;left:402.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">AKT</span></p>
<p style="top:554.3pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:565.3pt;left:290.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Amlodipine</span></p>
<p style="top:565.3pt;left:380.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PKD, Caspase 3</span></p>
<p style="top:565.3pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:576.2pt;left:286.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pentoxifylline</span></p>
<p style="top:576.2pt;left:405.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">NA</span></p>
<p style="top:576.2pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:635.6pt;left:186.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Antipsychotics</span></p>
<p style="top:597.5pt;left:288.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Thioridazine</span></p>
<p style="top:592.0pt;left:398.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">AMPK,</span></p>
<p style="top:602.9pt;left:371.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MAP1/LC3-II, WNT</span></p>
<p style="top:597.5pt;left:496.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">48</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:619.4pt;left:297.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">DS00329</span></p>
<p style="top:613.9pt;left:375.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cyclin A, Cyclin B,</span></p>
<p style="top:624.9pt;left:392.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cyclin D1</span></p>
<p style="top:619.4pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">49</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:635.8pt;left:281.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Chlorpromazine</span></p>
<p style="top:635.8pt;left:378.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">CcO Complex IV</span></p>
<p style="top:635.8pt;left:497.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">50</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">51</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:646.8pt;left:290.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Fluspirilene</span></p>
<p style="top:646.8pt;left:399.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">STAT3</span></p>
<p style="top:646.8pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">52</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:657.7pt;left:291.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pen&#xfb02;uridol</span></p>
<p style="top:657.7pt;left:373.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">SOX2, OCT4, uPAR</span></p>
<p style="top:657.7pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">53</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:668.7pt;left:291.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Olanzapine</span></p>
<p style="top:668.7pt;left:398.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">AMPK</span></p>
<p style="top:668.7pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">54</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:679.7pt;left:292.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Quetiapine</span></p>
<p style="top:679.7pt;left:401.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">WNT</span></p>
<p style="top:679.7pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">55</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:690.6pt;left:286.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Brexpiprazole</span></p>
<p style="top:690.6pt;left:395.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Survivin</span></p>
<p style="top:690.6pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">56</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:712.8pt;left:196.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Antivirals</span></p>
<p style="top:706.4pt;left:292.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Simeprevir</span></p>
<p style="top:706.4pt;left:402.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PI4K</span></p>
<p style="top:706.4pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">57</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:717.3pt;left:295.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Ribavirin</span></p>
<p style="top:717.3pt;left:389.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">EZH2, ERK</span></p>
<p style="top:717.3pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">58</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:536.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">5 of 29</span></p>
<p style="top:97.3pt;left:167.0pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 1.</span></b><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cont.</span></i></p>
<p style="top:118.4pt;left:193.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Drug Class</span></b></p>
<p style="top:118.4pt;left:301.6pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Drugs</span></b></p>
<p style="top:118.4pt;left:397.6pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Targets</span></b></p>
<p style="top:118.4pt;left:484.9pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Reference(s)</span></b></p>
<p style="top:162.5pt;left:189.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Biologics and</span></p>
<p style="top:173.4pt;left:185.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Small-Molecule</span></p>
<p style="top:184.4pt;left:196.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Inhibitors</span></p>
<p style="top:134.1pt;left:295.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">AS602801</span></p>
<p style="top:139.6pt;left:403.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">JNK</span></p>
<p style="top:134.1pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">59</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:145.1pt;left:295.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">CEP-1347</span></p>
<p style="top:145.1pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">60</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:156.0pt;left:295.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">LY294002</span></p>
<p style="top:162.3pt;left:402.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PI3K</span></p>
<p style="top:156.0pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">61</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:167.0pt;left:300.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PX-886</span></p>
<p style="top:167.0pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">61</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:178.0pt;left:296.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Ibrutinib</span></p>
<p style="top:178.0pt;left:382.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">TK, BMX-STA3</span></p>
<p style="top:178.0pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">62</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:188.9pt;left:293.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Roscovitin</span></p>
<p style="top:188.9pt;left:402.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">CDK</span></p>
<p style="top:188.9pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">63</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:199.9pt;left:291.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Binimetinib</span></p>
<p style="top:199.9pt;left:402.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MEK</span></p>
<p style="top:199.9pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">64</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:210.8pt;left:290.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Encorafenib</span></p>
<p style="top:210.8pt;left:400.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">BRAF</span></p>
<p style="top:210.8pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">64</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:237.6pt;left:194.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Disul&#xfb01;ram</span></p>
<p style="top:237.6pt;left:292.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Disul&#xfb01;ram</span></p>
<p style="top:226.6pt;left:378.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PLK1, Ubiquitin&#x2013;</span></p>
<p style="top:237.6pt;left:370.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Proteasome Pathway,</span></p>
<p style="top:248.5pt;left:404.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">AIF</span></p>
<p style="top:237.6pt;left:496.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">65</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">68</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:270.2pt;left:182.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Methylxanthines</span></p>
<p style="top:259.5pt;left:287.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Theophylline</span></p>
<p style="top:271.3pt;left:403.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PDE</span></p>
<p style="top:270.4pt;left:287.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Theobromine</span></p>
<p style="top:270.4pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">69</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:281.4pt;left:297.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Caffeine</span></p>
<p style="top:318.7pt;left:185.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Neurocognitive</span></p>
<p style="top:308.1pt;left:297.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Riluzole</span></p>
<p style="top:297.2pt;left:379.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Na+ Transporter,</span></p>
<p style="top:308.1pt;left:379.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ITAF hnRNP A1,</span></p>
<p style="top:319.1pt;left:387.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">HIF1A, AKT</span></p>
<p style="top:308.1pt;left:496.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">70</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">72</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:330.0pt;left:276.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Dimethyl fumarate</span></p>
<p style="top:330.0pt;left:384.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ERK1/2, AKT</span></p>
<p style="top:330.0pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">73</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:341.0pt;left:293.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Idebenone</span></p>
<p style="top:341.0pt;left:405.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">p21</span></p>
<p style="top:341.0pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">74</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:368.5pt;left:202.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Statins</span></p>
<p style="top:356.8pt;left:293.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Lovastatin</span></p>
<p style="top:356.8pt;left:387.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">c-Myc, SKP2</span></p>
<p style="top:356.8pt;left:497.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">75</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">76</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:367.7pt;left:290.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Simvastatin</span></p>
<p style="top:367.7pt;left:372.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">EGFR, FGFR, c-SRC</span></p>
<p style="top:367.7pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">77</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:378.7pt;left:289.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Atorvastatin</span></p>
<p style="top:378.7pt;left:403.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">RAS</span></p>
<p style="top:378.7pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">78</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:422.7pt;left:204.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Other</span></p>
<p style="top:394.4pt;left:277.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Aurintricarboxylic</span></p>
<p style="top:405.4pt;left:306.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">acid</span></p>
<p style="top:399.9pt;left:399.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">NF-</span><span style="font-family:EURM10,serif;font-size:9.0pt">&#x3ba;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">B</span></p>
<p style="top:399.9pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">79</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:416.4pt;left:291.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Papaverine</span></p>
<p style="top:416.4pt;left:380.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">HMGB1/RAGE</span></p>
<p style="top:416.4pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">80</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:427.3pt;left:292.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Bacoside A</span></p>
<p style="top:427.3pt;left:391.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">CAMKIIA</span></p>
<p style="top:427.3pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">81</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:438.3pt;left:291.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Vertepor&#xfb01;n</span></p>
<p style="top:438.3pt;left:388.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">YAP, HIF1A</span></p>
<p style="top:438.3pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">82</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:449.2pt;left:289.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Clomiphene</span></p>
<p style="top:449.2pt;left:401.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">IDH1</span></p>
<p style="top:449.2pt;left:502.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">83</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:462.5pt;left:167.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Abbreviations: protein kinase B (AKT); glycogen synthase kinase (GSK3B); formyl peptide receptor (FPR);</span></p>
<p style="top:472.0pt;left:167.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">interleukin-8 (IL-8); connexin 46 (Cx46); B-cell lymphoma 2 (BCL2); programmed death-ligand 1 (PDL1); au-</span></p>
<p style="top:481.5pt;left:167.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">tophagy related 7 (ATG7); mechanistic target of rapamycin (mTOR); mitogen-activated protein kinase (MAPK);</span></p>
<p style="top:491.0pt;left:167.3pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">signal transducer and activator of transcription 3 (STAT3); nuclear factor kappa-light-chain-enhancer of activated</span></p>
<p style="top:500.5pt;left:167.3pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">B cells (NF-KB); insulin growth factor receptor (IGFR); programmed cell death protein 1 (PD-1); cyclooxygenase-2</span></p>
<p style="top:509.8pt;left:167.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(COX2); macrophage migration inhibitory factor (MIF); induced myeloid leukemia cell differentiation pro-</span></p>
<p style="top:519.3pt;left:167.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">tein (MCL-1); non-homologous end-joining (NHEJ); polycystin-1 (PKD); microtubule-associated protein 1A</span></p>
<p style="top:528.9pt;left:167.0pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(MAP1)/1B-light chain 3 phosphatidylethanolamine conjugate (LC3-II); cytochrome c oxidase (CcO, complex IV);</span></p>
<p style="top:538.2pt;left:167.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(sex determining region Y)-box 2 (SOX2); octamer-binding transcription factor 4 (OCT4); urokinase plasmino-</span></p>
<p style="top:547.7pt;left:167.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">gen activator surface receptor (uPAR); AMP-activated protein kinase (AMPK); phosphatidylinositol 4-kinase</span></p>
<p style="top:557.2pt;left:167.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(PI4K); enhancer of zeste homolog 2 (EZH2); extracellular signal-regulated kinase (ERK); S-phase kinase protein</span></p>
<p style="top:566.6pt;left:167.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(Skp2); epidermal growth factor receptor (EGFR); &#xfb01;broblast growth factor receptor (EGFR); proto-oncogene</span></p>
<p style="top:576.1pt;left:167.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">tyrosine-protein kinase Src (c-SRC); rat sarcoma (RAS); high-mobility group protein 1 (HMG-1); receptor for</span></p>
<p style="top:585.6pt;left:167.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">advanced glycation endproducts (RAGE); Ca2+/calmodulin-dependent protein kinase II (CAMKII); isocitrate</span></p>
<p style="top:595.1pt;left:167.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">dehydrogenase 1 (IDH1).</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:536.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">6 of 29</span></p>
<p style="top:682.7pt;left:46.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> </span></p>
<p style="top:-3.5pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">ducer and activator of transcription 3 (STAT3); (sex determining region Y)-box 2 (SOX2); octamer-binding transcription </span></p>
<p style="top:8.1pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">factor 4 (OCT4); focal adhesion kinase (FAK); phosphatase and tensin homolog (PTEN); protein kinase B (AKT); eukaryotic </span></p>
<p style="top:19.6pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">translation initiation factor (eIF4e); S-phase kinase-associated protein 2 (Skp2); microRNA-33b (miRNA-33b); Macrophage </span></p>
<p style="top:31.1pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">migration inhibitory factor (MIF); reactive oxygen species (ROS); tafazzin (TAZ); yes associated protein (YAP); fibroblast </span></p>
<p style="top:42.6pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">growth factor-inducible 14 (Fn14); store-operated calcium entry (SOCE); isocitrate dehydrogenase 1 (IDH1); enhancer of </span></p>
<p style="top:54.2pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">zeste homolog 2 (EZH2); rat sarcoma (RAS); extracellular signal-regulated kinase (ERK); epidermal growth factor receptor </span></p>
<p style="top:65.7pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">(EGFR); t-type calcium channel (CaV3.2); Bcl-2-associated X protein (BAX); B-cell lymphoma 2 (BCL2); B-cell lymphoma-</span></p>
<p style="top:77.3pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">xL (BCL-XL); nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KB). </span></p>
<p style="top:371.9pt;left:546.9pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> </span></p>
<p style="top:387.6pt;left:67.7pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">Figure 2. </span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Cellular pathways and interactions detailing the key proposed mechanisms of drugs that have completed pre-</span></p>
<p style="top:399.2pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">clinical investigation and have also been studied in clinically. Abbreviations: Histone deacetylase (HDAC); O</span><sup><span style="font-family:PalatinoLinotype,serif;font-size:5.5pt">6</span></sup><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">-methylgua-</span></p>
<p style="top:410.7pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">nine-DNA methyltransferase (MGMT); histone methyltransferase (HMT); carbonic anhydrase 2 (CA2); muli-drug re-</span></p>
<p style="top:422.3pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">sistance protein (MDR); N-methyl-D-aspartate receptor (NMDAR); Indoleamine 2,3-dioxygenase (IDO); glioma-associ-</span></p>
<p style="top:433.8pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">ated oncogene (GLI1); protein patched homolog 1 (PTCH1); programmed death-ligand 1 (PD-L1); polo-like kinase 1 (PLK); </span></p>
<p style="top:445.3pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">mitogen-activated protein kinase kinase (MEK); mechanistic target of rapamycin (mTOR); hexokinase II (HKII); glycogen </span></p>
<p style="top:456.9pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">synthase kinase (GSK3B); phosphoinositide 3-kinase (PI3K); signal transducer and activator of transcription 3 (STAT3); </span></p>
<p style="top:468.4pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">phosphatase and tensin homolog (PTEN); protein kinase B (AKT); reactive oxygen species (ROS); rat sarcoma (RAS); ex-</span></p>
<p style="top:479.9pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">tracellular signal-regulated kinase (ERK); vascular endothelial growth factor receptor (VEGFR); endothelial growth factor </span></p>
<p style="top:491.4pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">receptor (EGFR); Bcl-2-associated X protein (BAX); B-cell lymphoma 2 (BCL2); B-cell lymphoma-xL (BCL-XL): B-cell lym-</span></p>
<p style="top:503.1pt;left:67.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">phoma 3-encoded protein (BCL-3). </span></p>
<p style="top:526.5pt;left:176.9pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">Table 1. </span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Drug class, specific drug, and drug targets of repurposed agents currently undergoing </span></p>
<p style="top:538.1pt;left:176.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">preclinical investigation. </span></p>
<p style="top:557.1pt;left:212.7pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">Drug Class </span></b></p>
<p style="top:557.1pt;left:318.9pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">Drugs </span></b></p>
<p style="top:557.1pt;left:425.7pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">Targets </span></b></p>
<p style="top:557.1pt;left:515.9pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">Reference(s) </span></b></p>
<p style="top:575.8pt;left:202.5pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Antiarrhythmics </span></p>
<p style="top:569.7pt;left:315.6pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Digoxin </span></p>
<p style="top:569.7pt;left:397.5pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Na+/K+ ATPase, AKT </span></p>
<p style="top:569.7pt;left:533.8pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">[19] </span></p>
<p style="top:581.9pt;left:300.2pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Proscillaridin A </span></p>
<p style="top:581.9pt;left:426.9pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">GSK3</span><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">&#x3b2;</span><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt"> </span></p>
<p style="top:581.9pt;left:533.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">[20] </span></p>
<p style="top:606.6pt;left:213.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Antibiotics </span></p>
<p style="top:594.5pt;left:305.4pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Tetracyclines </span></p>
<p style="top:594.5pt;left:413.6pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Mitochondria </span></p>
<p style="top:594.5pt;left:528.1pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">[21,22] </span></p>
<p style="top:606.6pt;left:314.0pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Dapsone </span></p>
<p style="top:606.6pt;left:389.6pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">FPR, IL-8, Leukotriene-B4 </span></p>
<p style="top:606.6pt;left:533.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">[23] </span></p>
<p style="top:618.8pt;left:307.3pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Clofazimine </span></p>
<p style="top:618.8pt;left:430.8pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Cx46 </span></p>
<p style="top:618.8pt;left:533.8pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">[24] </span></p>
<p style="top:631.4pt;left:209.0pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Antidiabetics </span></p>
<p style="top:631.4pt;left:307.5pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Repaglinide </span></p>
<p style="top:631.4pt;left:395.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">BCL-2, PD-L1, Beclin 1 </span></p>
<p style="top:631.4pt;left:533.7pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">[25] </span></p>
<p style="top:644.1pt;left:203.0pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Antidepressants </span></p>
<p style="top:644.1pt;left:308.0pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">Imipramine </span></p>
<p style="top:644.1pt;left:429.0pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">ATG7 </span></p>
<p style="top:644.1pt;left:533.8pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">[26] </span></p>
<p style="top:165.9pt;left:213.9pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">B-catenin</span></p>
<p style="top:200.0pt;left:252.3pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">Degradation</span></p>
<p style="top:173.6pt;left:139.7pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">PI3K</span></p>
<p style="top:208.0pt;left:142.0pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">AKT</span></p>
<p style="top:214.5pt;left:201.3pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">mTOR</span></p>
<p style="top:171.7pt;left:127.8pt;line-height:6.2pt"><span style="font-family:Arial,sans-serif;font-size:6.2pt">EGFR</span></p>
<p style="top:222.5pt;left:341.6pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt">Nucleus</span></b></p>
<p style="top:304.7pt;left:263.0pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt">Mitochondria</span></b></p>
<p style="top:291.9pt;left:185.1pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">MEK</span></p>
<p style="top:101.4pt;left:175.0pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">CUSP9</span></b></p>
<p style="top:234.6pt;left:374.4pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">STAT3</span></p>
<p style="top:215.0pt;left:399.5pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Atovaquone </span></b></p>
<p style="top:103.1pt;left:209.1pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">WNT</span></p>
<p style="top:221.1pt;left:83.5pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Perifosine</span></b></p>
<p style="top:231.8pt;left:246.3pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Valproic acid, </span></b></p>
<p style="top:240.1pt;left:246.3pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Fimepinostat</span></b></p>
<p style="top:252.2pt;left:375.5pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt;color:#ffffff">HMT</span></p>
<p style="top:276.6pt;left:354.6pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Tranylcypromine</span></b></p>
<p style="top:303.3pt;left:245.2pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">HKII</span></p>
<p style="top:276.2pt;left:233.5pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Azoles</span></b></p>
<p style="top:194.0pt;left:387.7pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">IDO</span></p>
<p style="top:178.0pt;left:405.7pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Azoles</span></b></p>
<p style="top:329.4pt;left:419.3pt;line-height:6.2pt"><span style="font-family:Arial,sans-serif;font-size:6.2pt">MDR</span></p>
<p style="top:354.7pt;left:394.4pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Azoles</span></b></p>
<p style="top:275.3pt;left:448.6pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Chloroquine </span></b></p>
<p style="top:283.7pt;left:454.4pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Sirolimus</span></b></p>
<p style="top:100.0pt;left:243.8pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Mebendazole</span></b></p>
<p style="top:108.3pt;left:243.8pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Bevacizumab</span></b></p>
<p style="top:172.2pt;left:446.7pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Mebendazole</span></b></p>
<p style="top:126.1pt;left:368.0pt;line-height:6.2pt"><span style="font-family:Arial,sans-serif;font-size:6.2pt">PTCH1</span></p>
<p style="top:153.3pt;left:357.2pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">GLI1</span></p>
<p style="top:102.8pt;left:374.1pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Mebendazole</span></b></p>
<p style="top:321.2pt;left:246.8pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">BAX</span></p>
<p style="top:200.8pt;left:495.2pt;line-height:6.2pt"><span style="font-family:Arial,sans-serif;font-size:6.2pt">Cadherin</span></p>
<p style="top:199.4pt;left:452.4pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Celecoxib</span></b></p>
<p style="top:239.9pt;left:176.0pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Everolimus</span></b></p>
<p style="top:248.2pt;left:179.0pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Sirolimus </span></b></p>
<p style="top:257.1pt;left:172.2pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Temsirolimus</span></b></p>
<p style="top:265.8pt;left:179.1pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Metformin</span></b></p>
<p style="top:301.9pt;left:329.4pt;line-height:6.2pt"><span style="font-family:Arial,sans-serif;font-size:6.2pt">CA2</span></p>
<p style="top:322.6pt;left:340.1pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Acetazolamide</span></b></p>
<p style="top:322.5pt;left:299.6pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">BCL-2</span></p>
<p style="top:315.6pt;left:298.7pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">BCL-xL</span></p>
<p style="top:345.8pt;left:306.0pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">CUSP9</span></b></p>
<p style="top:327.6pt;left:193.8pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Metformin</span></b></p>
<p style="top:351.7pt;left:481.3pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Memantine</span></b></p>
<p style="top:111.4pt;left:359.4pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">SHH</span></p>
<p style="top:297.7pt;left:411.0pt;line-height:6.2pt"><b><span style="font-family:Arial,sans-serif;font-size:6.2pt">Lysosome</span></b></p>
<p style="top:256.6pt;left:430.8pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">ROS</span></p>
<p style="top:253.6pt;left:317.6pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt;color:#ffffff">HDAC</span></p>
<p style="top:219.0pt;left:134.3pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">PTEN</span></p>
<p style="top:315.1pt;left:138.3pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">RAS</span></p>
<p style="top:194.3pt;left:174.5pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">PLK</span></p>
<p style="top:170.9pt;left:172.0pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Disulfiram</span></b></p>
<p style="top:207.0pt;left:291.1pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Disulfiram</span></b></p>
<p style="top:343.4pt;left:254.9pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Clioquinol</span></b></p>
<p style="top:282.7pt;left:136.9pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Trametinib</span></b></p>
<p style="top:157.4pt;left:287.2pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Marizomib</span></b></p>
<p style="top:197.4pt;left:77.9pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Fimepinostat</span></b></p>
<p style="top:103.0pt;left:450.6pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Nivolumab, </span></b></p>
<p style="top:111.3pt;left:450.6pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">Pembrolizumab</span></b></p>
<p style="top:141.2pt;left:166.5pt;line-height:7.3pt"><b><span style="font-family:Arial,sans-serif;font-size:7.3pt;color:#ff0000">CLOVA</span></b></p>
<p style="top:156.2pt;left:210.3pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">GSK3B</span></p>
<p style="top:151.6pt;left:432.2pt;line-height:6.2pt"><span style="font-family:Arial,sans-serif;font-size:6.2pt">Microtubules</span></p>
<p style="top:238.2pt;left:323.7pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">MGMT</span></p>
<p style="top:121.5pt;left:300.0pt;line-height:6.2pt"><span style="font-family:Arial,sans-serif;font-size:6.2pt">VEGFR</span></p>
<p style="top:123.3pt;left:217.1pt;line-height:6.2pt"><span style="font-family:Arial,sans-serif;font-size:6.2pt">Frizzled</span></p>
<p style="top:123.3pt;left:420.0pt;line-height:6.2pt"><span style="font-family:Arial,sans-serif;font-size:6.2pt">PD-L1</span></p>
<p style="top:182.8pt;left:249.2pt;line-height:6.2pt"><span style="font-family:Arial,sans-serif;font-size:6.2pt">Proteasome</span></p>
<p style="top:268.1pt;left:315.9pt;line-height:5.7pt"><span style="font-family:Arial,sans-serif;font-size:5.7pt">BCL-3</span></p>
<p style="top:331.5pt;left:473.1pt;line-height:6.2pt"><span style="font-family:Arial,sans-serif;font-size:6.2pt">NMDAR</span></p>
<p style="top:371.5pt;left:57.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Figure 2.</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Cellular pathways and interactions detailing the key proposed mechanisms of drugs that have completed preclini-</span></p>
<p style="top:384.4pt;left:57.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">cal investigation and have also been studied in clinically. Abbreviations: Histone deacetylase (HDAC); O</span><sup><span style="font-family:URWPalladioL,serif;font-size:7.0pt">6</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.9pt">-methylguanine-</span></p>
<p style="top:397.1pt;left:57.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">DNA methyltransferase (MGMT); histone methyltransferase (HMT); carbonic anhydrase 2 (CA2); muli-drug resistance</span></p>
<p style="top:410.0pt;left:57.0pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">protein (MDR); N-methyl-D-aspartate receptor (NMDAR); Indoleamine 2,3-dioxygenase (IDO); glioma-associated oncogene</span></p>
<p style="top:422.7pt;left:57.0pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">(GLI1); protein patched homolog 1 (PTCH1); programmed death-ligand 1 (PD-L1); polo-like kinase 1 (PLK); mitogen-</span></p>
<p style="top:435.6pt;left:57.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">activated protein kinase kinase (MEK); mechanistic target of rapamycin (mTOR); hexokinase II (HKII); glycogen synthase</span></p>
<p style="top:448.5pt;left:57.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">kinase (GSK3B); phosphoinositide 3-kinase (PI3K); signal transducer and activator of transcription 3 (STAT3); phosphatase</span></p>
<p style="top:461.2pt;left:57.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">and tensin homolog (PTEN); protein kinase B (AKT); reactive oxygen species (ROS); rat sarcoma (RAS); extracellular</span></p>
<p style="top:474.0pt;left:57.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">signal-regulated kinase (ERK); vascular endothelial growth factor receptor (VEGFR); endothelial growth factor receptor</span></p>
<p style="top:486.8pt;left:57.0pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">(EGFR); Bcl-2-associated X protein (BAX); B-cell lymphoma 2 (BCL2); B-cell lymphoma-xL (BCL-XL): B-cell lymphoma</span></p>
<p style="top:499.7pt;left:57.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">3-encoded protein (BCL-3).</span></p>
<p style="top:524.5pt;left:57.0pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 2.</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Drug class, speci&#xfb01;c drug, drug target, and current clinical phase of repurposed agents currently undergoing clinical</span></p>
<p style="top:537.3pt;left:57.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">investigation.</span></p>
<p style="top:558.4pt;left:65.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Drug Class</span></b></p>
<p style="top:558.4pt;left:180.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Drugs</span></b></p>
<p style="top:558.4pt;left:282.9pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Targets</span></b></p>
<p style="top:558.4pt;left:363.2pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Clinical Trial Stage</span></b></p>
<p style="top:558.4pt;left:484.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">References</span></b></p>
<p style="top:574.2pt;left:49.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Antiepileptic Drugs</span></p>
<p style="top:574.2pt;left:165.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Valproic Acid</span></p>
<p style="top:574.2pt;left:283.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">HDAC</span></p>
<p style="top:574.2pt;left:386.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase II</span></p>
<p style="top:574.2pt;left:487.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">70</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">84</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">88</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:600.9pt;left:67.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Disul&#xfb01;ram</span></p>
<p style="top:600.9pt;left:171.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Disul&#xfb01;ram</span></p>
<p style="top:589.9pt;left:286.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PLK1,</span></p>
<p style="top:600.9pt;left:253.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Ubiquitin&#x2013;Proteasome</span></p>
<p style="top:611.8pt;left:270.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pathway, AIF</span></p>
<p style="top:600.9pt;left:379.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase II/III</span></p>
<p style="top:600.9pt;left:492.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">89</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">91</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:632.8pt;left:64.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Antifungals</span></p>
<p style="top:627.6pt;left:179.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Azoles</span></p>
<p style="top:627.6pt;left:270.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Hexokinase II</span></p>
<p style="top:627.6pt;left:388.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I</span></p>
<p style="top:627.6pt;left:492.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">92</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">94</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:638.6pt;left:171.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Clioquinol</span></p>
<p style="top:638.6pt;left:273.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">BAX, BCL-2</span></p>
<p style="top:638.6pt;left:388.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I</span></p>
<p style="top:638.6pt;left:493.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">92</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">95</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:671.7pt;left:61.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Antimalarials</span></p>
<p style="top:654.3pt;left:168.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Atovaquone</span></p>
<p style="top:654.3pt;left:284.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">STAT3</span></p>
<p style="top:654.3pt;left:381.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Preclinical</span></p>
<p style="top:654.3pt;left:499.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">31</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:665.3pt;left:168.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Chloroquine</span></p>
<p style="top:665.3pt;left:282.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Unclear</span></p>
<p style="top:665.3pt;left:381.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Preclinical</span></p>
<p style="top:665.3pt;left:477.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">86</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">96</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">97</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:676.2pt;left:151.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Hydroxychloroquine</span></p>
<p style="top:676.2pt;left:285.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">LC3-II</span></p>
<p style="top:676.2pt;left:382.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I/II</span></p>
<p style="top:676.2pt;left:499.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">98</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:687.2pt;left:170.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Me&#xfb02;oquine</span></p>
<p style="top:687.2pt;left:282.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">NMDA</span></p>
<p style="top:687.2pt;left:382.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I/II</span></p>
<p style="top:687.2pt;left:490.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">99</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">101</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:703.0pt;left:60.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Antiparasitics</span></p>
<p style="top:703.0pt;left:166.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Mebendazole</span></p>
<p style="top:703.0pt;left:257.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Microtubules, VEGF</span></p>
<p style="top:703.0pt;left:388.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I</span></p>
<p style="top:703.0pt;left:488.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">102</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">106</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:713.9pt;left:51.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Antihypertensives</span></p>
<p style="top:713.9pt;left:167.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ARBs, ACEis</span></p>
<p style="top:713.9pt;left:282.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Unclear</span></p>
<p style="top:713.9pt;left:375.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Retrospective</span></p>
<p style="top:713.9pt;left:472.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">107</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">108</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:729.7pt;left:47.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Anti-in&#xfb02;ammatories</span></p>
<p style="top:729.7pt;left:173.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Celecoxib</span></p>
<p style="top:729.7pt;left:284.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">COX-2</span></p>
<p style="top:729.7pt;left:382.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I&#x2013;II</span></p>
<p style="top:729.7pt;left:488.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">109</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">111</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:750.5pt;left:45.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Immunosuppressants</span></p>
<p style="top:745.4pt;left:166.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Temsirolimus</span></p>
<p style="top:751.1pt;left:268.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">mTOR, MCL-1</span></p>
<p style="top:745.4pt;left:388.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I</span></p>
<p style="top:745.4pt;left:499.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:756.4pt;left:170.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Everolimus</span></p>
<p style="top:756.4pt;left:382.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I/II</span></p>
<p style="top:756.4pt;left:488.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">112</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">116</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:536.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">7 of 29</span></p>
<p style="top:97.3pt;left:270.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 2.</span></b><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cont.</span></i></p>
<p style="top:118.4pt;left:65.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Drug Class</span></b></p>
<p style="top:118.4pt;left:180.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Drugs</span></b></p>
<p style="top:118.4pt;left:282.9pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Targets</span></b></p>
<p style="top:118.4pt;left:363.2pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Clinical Trial Stage</span></b></p>
<p style="top:118.4pt;left:484.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">References</span></b></p>
<p style="top:155.8pt;left:57.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Antineoplastics</span></p>
<p style="top:134.1pt;left:172.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Vorinostat</span></p>
<p style="top:134.1pt;left:283.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">HDAC</span></p>
<p style="top:134.1pt;left:382.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I/II</span></p>
<p style="top:134.1pt;left:497.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">117</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:145.1pt;left:166.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cabozantinib</span></p>
<p style="top:145.1pt;left:291.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">TK</span></p>
<p style="top:145.1pt;left:386.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase II</span></p>
<p style="top:145.1pt;left:497.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">118</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:156.0pt;left:160.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Arsenic Trioxide</span></p>
<p style="top:156.0pt;left:268.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cytochrome C</span></p>
<p style="top:156.0pt;left:382.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I/II</span></p>
<p style="top:156.0pt;left:497.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">119</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:167.0pt;left:171.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Marizomib</span></p>
<p style="top:167.0pt;left:274.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Proteasome</span></p>
<p style="top:167.0pt;left:388.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I</span></p>
<p style="top:167.0pt;left:489.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">120</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">121</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:178.0pt;left:167.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Fimepinostat</span></p>
<p style="top:178.0pt;left:271.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PI3K, HDAC</span></p>
<p style="top:178.0pt;left:388.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I</span></p>
<p style="top:178.0pt;left:497.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">122</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:193.7pt;left:46.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Carbonic-Anhydrase</span></p>
<p style="top:204.7pt;left:68.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Inhibitors</span></p>
<p style="top:199.2pt;left:163.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Acetazolamide</span></p>
<p style="top:199.2pt;left:277.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">CA, BCL3</span></p>
<p style="top:199.2pt;left:388.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I</span></p>
<p style="top:199.2pt;left:488.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">123</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">125</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:231.1pt;left:44.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Checkpoint Inhibitors</span></p>
<p style="top:220.4pt;left:170.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Nivolumab</span></p>
<p style="top:220.4pt;left:287.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PD-1</span></p>
<p style="top:220.4pt;left:379.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase II&#x2013;III</span></p>
<p style="top:220.4pt;left:488.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">126</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">131</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:231.4pt;left:161.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pembrolizumab</span></p>
<p style="top:231.4pt;left:287.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PD-1</span></p>
<p style="top:231.4pt;left:382.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I&#x2013;II</span></p>
<p style="top:231.4pt;left:488.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">132</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">134</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:242.4pt;left:169.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Ipilimumab</span></p>
<p style="top:242.4pt;left:281.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">CTLA-4</span></p>
<p style="top:242.4pt;left:388.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I</span></p>
<p style="top:242.4pt;left:497.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">129</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:263.6pt;left:56.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Diabetic Agents</span></p>
<p style="top:263.6pt;left:171.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Metformin</span></p>
<p style="top:258.1pt;left:256.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">AMPK, Cl-Channels,</span></p>
<p style="top:269.1pt;left:284.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">mTOR</span></p>
<p style="top:263.6pt;left:382.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I/II</span></p>
<p style="top:263.6pt;left:482.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">135</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">147</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:284.6pt;left:47.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Small Molecules and</span></p>
<p style="top:295.6pt;left:70.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Biologics</span></p>
<p style="top:284.8pt;left:171.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cetuximab</span></p>
<p style="top:284.8pt;left:286.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">EGFR</span></p>
<p style="top:284.8pt;left:388.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I</span></p>
<p style="top:284.8pt;left:497.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">148</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:295.8pt;left:179.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">5-ALA</span></p>
<p style="top:295.8pt;left:267.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Not Applicable</span></p>
<p style="top:295.8pt;left:385.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase III</span></p>
<p style="top:295.8pt;left:488.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">149</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">152</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:323.4pt;left:70.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cocktails</span></p>
<p style="top:311.6pt;left:177.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">CUSP-9</span></p>
<p style="top:311.6pt;left:260.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Survival Pathways</span></p>
<p style="top:311.6pt;left:388.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I</span></p>
<p style="top:311.6pt;left:484.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">5</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">153</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">157</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:322.5pt;left:177.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">CLOVA</span></p>
<p style="top:322.5pt;left:282.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">GSK-3B</span></p>
<p style="top:322.5pt;left:388.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I</span></p>
<p style="top:322.5pt;left:497.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">153</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:333.5pt;left:148.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Celecoxib, Vinblastine,</span></p>
<p style="top:344.4pt;left:154.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cyclophosphamide</span></p>
<p style="top:333.5pt;left:255.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">COX-2, Microtubules,</span></p>
<p style="top:344.4pt;left:287.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">DNA</span></p>
<p style="top:339.0pt;left:388.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase I</span></p>
<p style="top:339.0pt;left:497.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">158</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:360.4pt;left:57.3pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">Abbreviations: Histone deacetylase (HDAC); polo-like kinase 1 (PLK1); apoptosis inducing factor (AIF); Bcl-2-associated X protein (BAX);</span></p>
<p style="top:369.9pt;left:57.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">B-cell lymphoma 2 (BCL2); signal transducer and activator of transcription 3 (STAT3); light chain 3 phosphatidylethanolamine conjugate</span></p>
<p style="top:379.3pt;left:57.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">(LC3-II); N-methyl-D-aspartate receptor (NMDAR); vascular-endothelial growth factor 2 (VEGF); cyclooxygenase 2 (COX2); mechanistic</span></p>
<p style="top:388.9pt;left:57.3pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">target of rapamycin (mTOR); myeloid cell leukemia-1 (MCL-1); tyrosine kinase (TK); phosphoinositide 3-kinase (PI3K); carbonic anhydrase</span></p>
<p style="top:398.3pt;left:57.0pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">(CA); B-cell lymphoma 3-encoded protein (BCL-3); programmed cell death 1 (PD-1); cytotoxic T-lymphocyte-associated protein 4 (CTLA4);</span></p>
<p style="top:407.7pt;left:56.9pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">AMP-activated protein kinase (AMPK); epidermal growth factor receptor (EGFR); glycogen synthase kinase (GSK) 3</span><span style="font-family:EURM10,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">; deoxyribonucleic</span></p>
<p style="top:417.2pt;left:57.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">acid (DNA).</span></p>
<p style="top:435.6pt;left:167.3pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3. Discussion</span></b></p>
<p style="top:449.1pt;left:167.3pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1. Repurposed Agents in Preclinical Study</span></i></p>
<p style="top:462.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.1. Antiarrhythmics</span></p>
<p style="top:478.0pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Interest in cardiac glycosides such as digoxin, and its distant relative proscillaridin</span></p>
<p style="top:490.6pt;left:166.9pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">A, for the treatment of glioma developed following discovery of their antineoplastic prop-</span></p>
<p style="top:503.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">erties [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">18</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">20</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">159</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Primarily known for use in heart failure and arrhythmia, these agents</span></p>
<p style="top:515.6pt;left:166.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">were identi&#xfb01;ed using a systems biology approach by integrating genomic pro&#xfb01;les [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">159</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">].</span></p>
<p style="top:528.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Digoxin, at clinically appropriate concentrations, was subsequently examined</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> and</span></p>
<p style="top:540.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">shown to prolong survival in patient-derived xenograft (PDX) GBM models. However,</span></p>
<p style="top:553.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">given the narrow therapeutic index of digoxin, its potential for clinical use in patients is</span></p>
<p style="top:566.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">unclear [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">19</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Proscillaridin A also demonstrated antitumor effects in GBM both</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> and</span></p>
<p style="top:578.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in orthotopic xenografts via a mechanism involving glycogen synthase kinase (GSK) 3</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b2;</span></p>
<p style="top:591.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">activation and microtubule instability [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">20</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. These agents have not been examined clinically.</span></p>
<p style="top:613.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.2. Antibiotics-Tetracyclines, Macrolides, and Antimycobacterials</span></p>
<p style="top:628.9pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Several antibiotics were examined as potential antineoplastics in GBM after they</span></p>
<p style="top:641.6pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">were found to demonstrate ef&#xfb01;cacy in malignancies outside of the central nervous system</span></p>
<p style="top:654.1pt;left:166.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">(CNS) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">21</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">23</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Among these, the tetracyclines were identi&#xfb01;ed as possible antineoplastics</span></p>
<p style="top:666.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">due to their inhibition of mitochondrial biogenesis, a feature central to GBM pathobiol-</span></p>
<p style="top:679.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ogy [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">22</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Doxycycline induced mitochondrial dysfunction, oxidative stress and ultimately</span></p>
<p style="top:691.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">energy de&#xfb01;ciency in multiple GBM cell lines [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">21</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">22</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Additionally, doxycycline was re-</span></p>
<p style="top:704.3pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ported to behave synergistically in combination with TMZ, suggesting that it may act as</span></p>
<p style="top:716.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">a chemosensitizer [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">21</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Dapsone, an older antibiotic originally used for mycobacterial</span></p>
<p style="top:729.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">infections, was shown to decrease migratory activity and anchorage-independent growth</span></p>
<p style="top:742.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">, both of which are important features of GBM aggressiveness [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">23</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Clofazimine,</span></p>
<p style="top:754.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">another antimycobacterial agent, inhibited the gap junction protein Cx46 and caused</span></p>
<p style="top:767.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">apoptosis, decreased self-renewal and decreased tumor growth of glioma stem-like cells</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:536.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">8 of 29</span></p>
<p style="top:97.4pt;left:166.9pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">(GSCs) in combination with TMZ [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">24</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Despite these &#xfb01;ndings, it should be noted that</span></p>
<p style="top:110.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">BBB penetrance of clofazimine is limited. Although these agents remain to be studied</span></p>
<p style="top:122.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">clinically, their investigation may be warranted given their well-known safety pro&#xfb01;le and</span></p>
<p style="top:135.1pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">preclinical ef&#xfb01;cacy.</span></p>
<p style="top:157.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.3. Antidiabetics</span></p>
<p style="top:173.0pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Various diabetic agents have been shown to have antineoplastic action including</span></p>
<p style="top:185.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the meglitinide, repaglinide, which has exhibited promise in early investigations but</span></p>
<p style="top:198.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">has not yet been translated to clinical trial [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">25</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Repaglinide was identi&#xfb01;ed through a</span></p>
<p style="top:210.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">computational model analyzing differential gene expression between long-term and short-</span></p>
<p style="top:223.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">term surviving GBM patients. Repaglinide was found to decrease B-cell lymphoma 2</span></p>
<p style="top:235.8pt;left:166.9pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">(BCL-2), programmed death ligand-1 (PD-L1), and Beclin-1 levels, factors that promote</span></p>
<p style="top:248.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">GBM pathobiology. In addition to repaglinide, another well-known antidiabetic agent</span></p>
<p style="top:261.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">studied in GBM is metformin. Given that metformin has been extensively studied clinically,</span></p>
<p style="top:273.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">it is covered in detail in a later section.</span></p>
<p style="top:295.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.4. Antidepressants</span></p>
<p style="top:311.4pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">A logical step in the repurposing search for GBM therapy was considering agents</span></p>
<p style="top:324.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">known to have high BBB penetrance such as antidepressants, antiepileptic drugs (AEDs),</span></p>
<p style="top:336.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and antipsychotics [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">96</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. The observation that there is lower incidence of GBM in pa-</span></p>
<p style="top:349.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">tients receiving antidepressant therapy further supported investigation of these agents [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span></p>
<p style="top:361.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Using a computational drug screen, tricyclic antidepressants (TCAs) such as imipramine</span></p>
<p style="top:374.3pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">were identi&#xfb01;ed as a family of agents that may have anti-GBM action [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">16</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Mice bearing</span></p>
<p style="top:386.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">intracranial GBM treated with imipramine had increased survival as a result of tumor au-</span></p>
<p style="top:399.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">tophagy [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Moreover, combining imipramine with ticlopidine, an inducer of autophagy,</span></p>
<p style="top:412.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">further increased mouse survival with increased cAMP levels as well as dysregulation of au-</span></p>
<p style="top:424.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">tophagic regulatory gene 7 (ATG7). Another TCA, clomipramine, proved to be ef&#xfb01;cacious</span></p>
<p style="top:437.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">in treating GBM cells that have a phenylalanine for leucine mutation in the mitochondrial</span></p>
<p style="top:449.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">respiratory chain complex III cytochrome b subunit, a mutation enriched in GBM [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">27</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:462.0pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Selective-serotonin reuptake inhibitors (SSRIs) have also been identi&#xfb01;ed as having</span></p>
<p style="top:474.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">anti-GBM potential [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Fluvoxamine, an SSRI used in the USA for obsessive-compulsive</span></p>
<p style="top:487.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">disorder and in other countries for major depression, was found to interfere with actin</span></p>
<p style="top:499.7pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">polymerization and thus attenuate the invasiveness of GBM cells [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Fluvoxamine de-</span></p>
<p style="top:512.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">creased GBM cell migration, ruf&#xfb02;e formation and invasiveness through interaction with the</span></p>
<p style="top:524.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway. Additionally,</span></p>
<p style="top:537.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in vivo</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> experiments with intracranial xenografts showed decreased invasion and increased</span></p>
<p style="top:550.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">animal survival following treatment with &#xfb02;uvoxamine [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Another SSRI, sertraline, when</span></p>
<p style="top:562.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">combined with pterostilbene, a relative of the dietary supplement resveratrol, reduced</span></p>
<p style="top:575.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cell viability, sphere formation and migration due to synergistic mitogen-activated protein</span></p>
<p style="top:587.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">kinase (MAPK) inhibition [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">29</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Although numerous studies highlight how antidepressant</span></p>
<p style="top:600.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">medications in&#xfb02;uence cell migration, growth and invasiveness, these agents remain to be</span></p>
<p style="top:612.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">investigated clinically.</span></p>
<p style="top:635.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.5. Anti-In&#xfb02;ammatories</span></p>
<p style="top:650.6pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Non-steroidal anti-in&#xfb02;ammatory drugs (NSAIDs) are a class of agent used for ev-</span></p>
<p style="top:663.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">eryday complaints and serious systemic diseases [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">160</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. These drugs are generally well</span></p>
<p style="top:675.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">tolerated and affordable, attributes that make them excellent repurposing candidates. In</span></p>
<p style="top:688.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">addition, given that the immune response plays an central role in cancer promotion, anti-</span></p>
<p style="top:701.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">in&#xfb02;ammatory/immunosuppressive medications target pathways that are critical to tumor</span></p>
<p style="top:713.6pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">pathobiology [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">161</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. In this section, we will review the agents that have only been examined</span></p>
<p style="top:726.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">in the preclinical setting. Later, the few agents that have been translated to clinical analysis</span></p>
<p style="top:738.6pt;left:166.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">will also be discussed.</span></p>
<p style="top:751.1pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">IP1867B, a combination of aspirin, triacetin and saccharin has substantial preclinical</span></p>
<p style="top:763.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">evidence supporting its use as an anti-GBM agent. IP187B inhibits IL6/signal transducer</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:536.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">9 of 29</span></p>
<p style="top:97.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and activator of transcription 3 (STAT3), NF-</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3ba;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">B, and insulin-like growth factor recep-</span></p>
<p style="top:110.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">tor pathways and has demonstrated additive ef&#xfb01;cacy when combined with epidermal</span></p>
<p style="top:122.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">growth factor receptor (EGFR) inhibitors against primary GBM cells and intracranial GBM</span></p>
<p style="top:135.1pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">xenografts [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">30</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Aspirin itself has also been investigated as an adjunct with doxoru-</span></p>
<p style="top:147.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">bicin in several cancer cell lines [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Speci&#xfb01;cally, it was reported that aspirin induced a</span></p>
<p style="top:160.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">more active immune TME including upregulating PD-1. Furthermore, when combined</span></p>
<p style="top:172.9pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">with anti-PD-1 therapy, there was increased tumor regression in multiple solid cancers [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span></p>
<p style="top:185.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Celecoxib was also shown to affect epithelial-mesenchymal transition (EMT) and attenuate</span></p>
<p style="top:198.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">GBM cell migration and proliferation [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">34</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. While COX-2 inhibition has been considered the</span></p>
<p style="top:210.4pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">primary mechanism for the antineoplastic effects of celecoxib, deregulation of the NF-</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3ba;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">B</span></p>
<p style="top:222.9pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">pathway may also play an important role in its antineoplastic properties against GBM</span></p>
<p style="top:235.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and other malignant cells [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">36</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Celecoxib has also been examined clinically in GBM as</span></p>
<p style="top:248.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">detailed later.</span></p>
<p style="top:260.7pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">The phosphodiesterase inhibitor, ibudilast, inhibits macrophage migratory inhibitory</span></p>
<p style="top:273.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">factor (MIF), a protein upregulated in a subset of MGMT methylated GBM tumors that</span></p>
<p style="top:285.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">have worse prognosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Ibudilast treatment suppressed proliferation of GBM cells</span></p>
<p style="top:298.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and synergistically prolonged survival when combined with TMZ in PDX models [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">].</span></p>
<p style="top:310.9pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Targeting the immune system from another angle is the disease-modifying antirheumatic</span></p>
<p style="top:323.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">drug (DMARD), sulfasalazine, which increases levels of reactive oxygen species (ROS)</span></p>
<p style="top:335.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and induces apoptosis in combination with RT [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. When sulfasalazine was examined</span></p>
<p style="top:348.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in combination with radiosurgery, it synergistically prolonged survival of mice bearing</span></p>
<p style="top:361.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">intracranial GBM xenograft [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Due to the well-known chemical pro&#xfb01;le of sulfasalazine, a</span></p>
<p style="top:373.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Phase I/II study was conducted in 10 patients with anaplastic astrocytoma or GBM with a</span></p>
<p style="top:386.2pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">primary endpoint of toxicity and response [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">39</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Unfortunately, the study was halted at the</span></p>
<p style="top:398.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">interim analysis due to a lack of improved clinical response and the development of toxicity</span></p>
<p style="top:411.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in all patients including grade IV toxicity. In conclusion, despite their preclinical success,</span></p>
<p style="top:423.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">several NSAIDs such as ibudilast or sulfasalazine remain to be adequately studied clinically.</span></p>
<p style="top:446.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.6. Immunosuppressants</span></p>
<p style="top:461.7pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">First-generation mTOR inhibitors such as everolimus, sirolimus and temsirolimus</span></p>
<p style="top:474.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">are a class of immunosuppressive agent and have undergone several investigations for</span></p>
<p style="top:486.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">GBM treatment [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. While the preclinical data are presented here, these agents have</span></p>
<p style="top:499.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">also been studied clinically, as discussed in greater detail later. These agents act by a</span></p>
<p style="top:511.9pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">variety of mechanisms in addition to inhibition of mTOR such as targeting myeloid cell</span></p>
<p style="top:524.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">leukemia-1 (MCL-1) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Although monotherapy with everolimus did not change MCL-1</span></p>
<p style="top:537.1pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">protein abundance</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, combination therapy with a second mTOR inhibitor, or with</span></p>
<p style="top:549.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">olparib a poly-ADP ribose polymerase inhibitor, signi&#xfb01;cantly decreased MCL-1 [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. These</span></p>
<p style="top:562.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">combination regimens increased apoptosis and reduced growth of U87 GBM xenografts,</span></p>
<p style="top:574.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#xfb01;ndings thought to occur through a decrease in homologous recombination (HR) repair.</span></p>
<p style="top:587.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Consistent with this, combining sirolimus with chloroquine and TMZ resulted in increased</span></p>
<p style="top:599.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">apoptosis in GBM cell lines [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], a &#xfb01;nding likely due to an increase in DNA damage</span></p>
<p style="top:612.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">because of decreased HR repair and activation of the apoptotic cascade.</span></p>
<p style="top:634.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.7. Antihypertensives</span></p>
<p style="top:650.3pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Using high-throughput, cell-based drug screens, several antihypertensive and car-</span></p>
<p style="top:662.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">diovascular agents were identi&#xfb01;ed as possible repurposing agents, although the majority</span></p>
<p style="top:675.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of these remain to be studied in the clinic [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">18</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">162</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Mibefradil, a non-selective calcium</span></p>
<p style="top:688.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">channel blocker, inhibited the non-homologous end-joining (NHEJ) repair system and the</span></p>
<p style="top:700.7pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">T-type calcium channel, CAV3.2, a molecule upregulated in certain GBM patients that have</span></p>
<p style="top:713.2pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">worse prognosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">43</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. The inhibition of NHEJ and CAV3.2 decreased growth and stemness</span></p>
<p style="top:725.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">through activation of apoptotic pathways and attenuation of AKT/mTOR signaling. De-</span></p>
<p style="top:738.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">spite this, repurposing mibefradil is likely limited given its poor side-effect pro&#xfb01;le and</span></p>
<p style="top:750.8pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">potential drug interactions [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">163</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Another antihypertensive that was identi&#xfb01;ed through</span></p>
<p style="top:763.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">targeted screening against monoamine receptors is prazosin, an alpha-1 adrenergic blocker</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">10 of 29</span></p>
<p style="top:97.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">originally used for hypertension and post-traumatic stress disorder. Prazosin induced</span></p>
<p style="top:110.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">apoptosis of GSCs and prolonged survival in an orthotopic GBM model [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Unfortunately,</span></p>
<p style="top:122.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">it has not yet been studied in the clinic. Amlodipine, a dihydropyridine calcium channel</span></p>
<p style="top:135.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">blocker, and pentoxifylline, a xanthine derivative used in peripheral arterial disease, also</span></p>
<p style="top:147.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">inhibited growth of GBM cells [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. However, these agents have not undergone any</span></p>
<p style="top:160.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">meaningful clinical study. In conclusion, several antihypertensives have demonstrated</span></p>
<p style="top:172.9pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">promising preclinical &#xfb01;ndings that suggest they may have clinical ef&#xfb01;cacy, but these results</span></p>
<p style="top:185.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">remain to be recapitulated in the clinic.</span></p>
<p style="top:207.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.8. Antipsychotics</span></p>
<p style="top:223.2pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Antipsychotics are attractive antiglioma agents because of their propensity to cross</span></p>
<p style="top:235.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">the BBB and several antipsychotics have been identi&#xfb01;ed as possible GBM therapies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">55</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span></p>
<p style="top:248.5pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Thioridazine is a &#xfb01;rst-generation phenothiazine that has been extensively studied preclini-</span></p>
<p style="top:261.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cally. It increased autophagy and upregulated AMP-activated protein kinase (AMPK) and</span></p>
<p style="top:273.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">microtubule-associated protein 1A/1B-light chain 3 phosphatidylethanolamine conjugate</span></p>
<p style="top:286.1pt;left:166.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">(LC3-II) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">47</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Moreover, thioridazine also increased autophagy in &#xfb02;ank xenografts, result-</span></p>
<p style="top:298.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ing in WNT pathway alterations that promoted</span><span style="font-family:EURM10,serif;font-size:10.0pt"> &#x3b2;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">-Catenin degradation, autophagy and</span></p>
<p style="top:311.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">apoptosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">47</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Finally, thioridazine was found to act as a chemosensitizer of TMZ both</span></p>
<p style="top:323.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> and in an intracranial xenograft model [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">47</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">48</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Unfortunately, this agent has not</span></p>
<p style="top:336.3pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">yet undergone clinical investigation.</span></p>
<p style="top:348.8pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Other phenothiazine derivatives such as DS00329 or chlorpromazine have similarly</span></p>
<p style="top:361.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">had success in preclinical analysis. DS00329 decreased Cyclin A, B, and D1 protein abun-</span></p>
<p style="top:373.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">dance and increased p21, resulting in G1 phase arrest and apoptosis in U251 and U87</span></p>
<p style="top:386.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cells [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">49</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Contrastingly, chlorpromazine only demonstrated ef&#xfb01;cacy in TMZ resistant cells</span></p>
<p style="top:399.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">through inhibition of cytochrome c oxidase (CcO, complex IV) activity. This inhibition</span></p>
<p style="top:411.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">signi&#xfb01;cantly prolonged survival in an intracranial GBM model, which was hypothesized to</span></p>
<p style="top:424.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">occur due to increased binding of chlorpromazine to CcO subunit 4 isoform 1 (COX4-1),</span></p>
<p style="top:436.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the predominant isoform in chemoresistant cells [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">50</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">51</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:449.2pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Fluspirilene and pen&#xfb02;uridol, both &#xfb01;rst-generation diphenylbutylpiperidine antipsy-</span></p>
<p style="top:461.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">chotics, were also found to impair GSC function [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">52</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">53</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Fluspirilene inhibited STAT3,</span></p>
<p style="top:474.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">resulting in decreased GBM proliferation, invasion and tumor growth, pen&#xfb02;uridol de-</span></p>
<p style="top:487.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">creased colony sphere number and size with reductions in (sex determining region Y)-box</span></p>
<p style="top:499.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">2 (SOX2) and octamer-binding transcription factor 4 (OCT4) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">52</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">53</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Additionally, pen&#xfb02;uri-</span></p>
<p style="top:512.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">dol decreased migration through integrin interference and uPAR reduction and blocked</span></p>
<p style="top:524.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">EMT by attenuating ZEB1 expression. Notably, the combination of pen&#xfb02;uridol and TMZ</span></p>
<p style="top:537.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">resulted in synergistically prolonged survival in mice bearing orthotopic xenografts.</span></p>
<p style="top:549.6pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Atypical antipsychotics have also demonstrated promise as possible repurposing</span></p>
<p style="top:562.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">anti-GBM agents [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">54</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">55</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> In vitro</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> assays demonstrated that olanzapine suppressed growth</span></p>
<p style="top:574.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">and migration of GBM cell lines [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">54</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. When coupled with TMZ, olanzapine demonstrated</span></p>
<p style="top:587.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">a substantial chemosensitizing effect. Quetiapine had some promising results in orthotopic</span></p>
<p style="top:599.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">mouse GBM models both as monotherapy and in combination with TMZ, even against</span></p>
<p style="top:612.5pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">TMZ-resistant GBM [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">55</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Similar to the phenothiazine antipsychotics, quetiapine inhibited</span></p>
<p style="top:625.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the WNT signaling pathway and promoted oligodendrocyte-like differentiation [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">47</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">55</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:637.5pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Importantly, there has been concern regarding the possible dose-limiting toxicities</span></p>
<p style="top:650.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and side-effect pro&#xfb01;les of some of the aforementioned antipsychotics. Given this, newer</span></p>
<p style="top:662.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">antipsychotics such as brexpiprazole are also under investigation as anti-GBM agents.</span></p>
<p style="top:675.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Early results using brexpiprazole have shown cell growth inhibition and induction of</span></p>
<p style="top:687.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">apoptosis through reduction of survivin [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">56</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Overall, as a class, the antipsychotics have</span></p>
<p style="top:700.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">achieved signi&#xfb01;cant preclinical success warranting translation to the clinic, where careful</span></p>
<p style="top:712.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">examination of their side-effect pro&#xfb01;le and drug interactions will be important.</span></p>
<p style="top:735.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.9. Antivirals</span></p>
<p style="top:750.8pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Antiviral medications have undergone limited preclinical investigation as anti-GBM</span></p>
<p style="top:763.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">agents; however, some evidence exists for their potential ef&#xfb01;cacy. Simeprevir, a Hepatitis</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">11 of 29</span></p>
<p style="top:97.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">C (HCV) antiviral, inhibits phosphatidylinositol 4-kinase (PI4K) III</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, a factor thought to</span></p>
<p style="top:110.1pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">play a role in radiation resistance [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">57</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">58</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Simeprevir decreased phosphorylation of protein</span></p>
<p style="top:122.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">kinase C (PKC) and AKT and delayed</span><span style="font-family:EURM10,serif;font-size:10.0pt"> &#x3b3;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">H2AX focus formation, resulting in apoptosis</span></p>
<p style="top:135.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and autophagy [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">57</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Ribavirin, another HCV antiviral, decreased glioma cell growth and</span></p>
<p style="top:147.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">migration</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> by targeting the eukaryotic initiation factor, EZH2, and extracellular</span></p>
<p style="top:160.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">signal-regulated kinase (ERK) pathways [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">58</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Additionally, combining ribavirin with</span></p>
<p style="top:172.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">chemotherapy and/or RT resulted in synergistically prolonged survival in several ortho-</span></p>
<p style="top:185.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">topic GBM models. These translational &#xfb01;ndings support further analysis of this drug</span></p>
<p style="top:197.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">class clinically.</span></p>
<p style="top:220.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.10. Biologics and Small-Molecule Inhibitors</span></p>
<p style="top:235.8pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Large-scale molecular pro&#xfb01;ling of GBM such as The Cancer Genome Atlas (TCGA),</span></p>
<p style="top:248.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">have facilitated the identi&#xfb01;cation of the pathways active in GBM that can be targeted by</span></p>
<p style="top:261.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">speci&#xfb01;c inhibitors [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">164</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">165</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Many small-molecule inhibitors are now being investigated in</span></p>
<p style="top:273.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">GBM that were initially investigated in other malignancies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">59</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">63</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">97</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">148</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">164</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">166</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. These</span></p>
<p style="top:286.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">drugs will only be discussed in brief as their antineoplastic mechanisms are generally the</span></p>
<p style="top:298.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">same as their originally intended mechanism of action.</span></p>
<p style="top:311.1pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Several small-molecule inhibitors, with a wide array of original indications, never</span></p>
<p style="top:323.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">made it to market for their initially developed indication. For example, a c-Jun N-terminal</span></p>
<p style="top:336.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">kinase (JNK) inhibitor, AS602801, originally developed for endometriosis, demonstrated</span></p>
<p style="top:348.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cytotoxicity against neoplastic cells including GBM</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">59</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. CEP-1347, another JNK</span></p>
<p style="top:361.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">inhibitor originally developed as an anti-Parkinsonian drug, was subsequently found to</span></p>
<p style="top:373.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">induce differentiation, decrease self-renewal and decrease tumor initiation in GBM cell</span></p>
<p style="top:386.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">lines [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">60</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. These drugs remain to be studied clinically.</span></p>
<p style="top:399.1pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">One of the most frequently altered pathways in GBM is the AKT/phosphoinositide 3-</span></p>
<p style="top:411.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">kinase (PI3K) signaling response, reported to be altered in almost 90% of these tumors [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">167</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span></p>
<p style="top:424.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Several small molecules target this pathway and have been examined in GBM. Inhibition</span></p>
<p style="top:436.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of PI3K with LY294002 or PX-886 blocked the growth of GBM cells in combination with</span></p>
<p style="top:449.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">gamitrinib, a mitochondrial heat shock protein (HSP)-90 inhibitor [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">61</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Ibrutinib, a well-</span></p>
<p style="top:461.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">described tyrosine kinase (TK) inhibitor that targets the BMX-STAT3 pathway, suppressed</span></p>
<p style="top:474.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the growth of GSCs and sensitized them to RT [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">62</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. This inhibitor, in combination with</span></p>
<p style="top:486.8pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">TMZ, also prolonged survival of mice bearing intracranial GBM relative to TMZ alone.</span></p>
<p style="top:499.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Roscovitin, another small-molecule inhibitor targeting a wide range of cyclin-dependent</span></p>
<p style="top:511.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">kinases (CDKs), was reported to act as a chemosensitizer to TMZ in an orthotopic GBM</span></p>
<p style="top:524.5pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">xenograft model [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">63</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Finally, the MEK inhibitor, binimetinib, was investigated in a non-</span></p>
<p style="top:537.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">randomized open-label clinical study in 62 patients with encorafenib, a BRAF inhibitor, in</span></p>
<p style="top:549.8pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">patients with recurrent BRAF V600-mutated high-grade glioma (HGG) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">64</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. While primary</span></p>
<p style="top:562.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">outcome is tumor radiographic response per response assessment in neuro-oncology</span></p>
<p style="top:574.8pt;left:166.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">(RANO) criteria, no results are currently available.</span></p>
<p style="top:597.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.11. Disul&#xfb01;ram</span></p>
<p style="top:612.8pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Disul&#xfb01;ram initially came to the attention of researchers as a possible adjunctive GBM</span></p>
<p style="top:625.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">therapy because of its ability to inhibit the aldehyde dehydrogenase enzyme family, a</span></p>
<p style="top:637.9pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">proposed biomarker for self-renewing cells in tumor populations [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">65</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. It was theorized that</span></p>
<p style="top:650.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">targeting aldehyde dehydrogenase with disul&#xfb01;ram may interfere with GBM self-renewal.</span></p>
<p style="top:663.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Subsequent investigation found that disul&#xfb01;ram inhibited self-renewal and growth of TMZ</span></p>
<p style="top:675.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">resistant GBM cells through inhibition of polo-like kinase 1 (PLK1), while minimally</span></p>
<p style="top:688.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">affecting normal astrocytes [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">65</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Disul&#xfb01;ram was also found to inhibit MGMT activity in</span></p>
<p style="top:700.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">GBM cells [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">66</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Various disul&#xfb01;ram formulations decreased MGMT abundance in GBM cells</span></p>
<p style="top:713.1pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">via the ubiquitin&#x2013;proteasome pathway by modifying a cysteine residue, resulting in an</span></p>
<p style="top:725.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">increase in alkylator-induced cytotoxicity [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">66</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. These &#xfb01;ndings were supported by &#xfb01;ndings</span></p>
<p style="top:738.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in animal models where decreased MGMT activity was seen in the liver and brain.</span></p>
<p style="top:750.9pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Disul&#xfb01;ram was also noted to have enhanced cytotoxic effects in the presence of copper</span></p>
<p style="top:763.3pt;left:166.9pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">(Cu). Consequently, Cu&#x2013;disul&#xfb01;ram metal complexes were developed [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">67</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. These Cu&#x2013;</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">12 of 29</span></p>
<p style="top:97.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">disul&#xfb01;ram complexes when combined with TMZ inhibited GSC growth and prolonged</span></p>
<p style="top:110.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">survival of mice bearing intracranial PDXs. The increase in survival was thought to have</span></p>
<p style="top:122.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">occurred due to alterations in DNA repair [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">66</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">67</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Despite these &#xfb01;ndings, the instability</span></p>
<p style="top:135.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">of the Cu&#x2013;disul&#xfb01;ram compound and potentially low therapeutic ef&#xfb01;cacy raised questions</span></p>
<p style="top:147.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">regarding its use in patients. To resolve these issues, disul&#xfb01;ram based nanoparticles</span></p>
<p style="top:160.2pt;left:166.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">(termed passively-targeted DSF nanoparticles (DSFNPs)) were constructed [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">68</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. DSFNPs</span></p>
<p style="top:172.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">increased disul&#xfb01;ram drug uptake within the CNS and prolonged disul&#xfb01;ram half-life</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">.</span></p>
<p style="top:185.3pt;left:166.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Additionally, DSFNPs demonstrated high cytotoxicity</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> against intracranial glioma</span></p>
<p style="top:197.8pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">xenografts as a result of ROS generation and release of apoptosis inducing factor (AIF).</span></p>
<p style="top:210.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Notably, DSFNPs induced mild regression of intracranial medulloblastoma xenografts</span></p>
<p style="top:223.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in comparison to unencapsulated disul&#xfb01;ram, suggesting that use against GBM might be</span></p>
<p style="top:235.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">feasible. These preclinical studies have lead to several clinical trials that are discussed later.</span></p>
<p style="top:258.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.12. Methylxanthines</span></p>
<p style="top:273.6pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Methylxanthines, including theophylline, theobromine and caffeine, have undergone</span></p>
<p style="top:286.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">extensive investigation as anti-GBM therapies with mixed results. These &#xfb01;ndings have</span></p>
<p style="top:298.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">been reviewed in greater detail elsewhere [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">69</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Brie&#xfb02;y, the main mechanism by which these</span></p>
<p style="top:311.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">agents act is via phosphodiesterase (PDE) inhibition. However, they also in&#xfb02;uence other</span></p>
<p style="top:323.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">signaling and epigenetic pathways crucial to tumorigenesis. Overall, these agents appear</span></p>
<p style="top:336.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">to be potentially promising candidates.</span></p>
<p style="top:358.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.13. Neurocognitive Agents</span></p>
<p style="top:374.2pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Active neurocognitive agents are attractive as they act within the CNS. Riluzole, an</span></p>
<p style="top:386.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">antiamyotrophic lateral sclerosis (ALS) drug, has undergone several mechanistic studies</span></p>
<p style="top:399.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in conjunction with other agents but has not yet been translated to the clinic. Combining</span></p>
<p style="top:411.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">riluzole with imipramine, a TCA, and valproic acid (VPA), an AED, resulted in decreased</span></p>
<p style="top:424.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">GBM cell viability [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">70</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">71</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Riluzole also inhibited the internal ribosome entry site (IRES)</span></p>
<p style="top:437.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">trans-acting factor (ITAF) hnRNP A1, a factor involved in resistance to mTOR inhibitors [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">71</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span></p>
<p style="top:449.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">By a similar mechanism, it was found that the combination of riluzole and sirolimus</span></p>
<p style="top:462.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">increased apoptosis</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> and decreased growth in heterotopic murine GBM [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">71</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. In</span></p>
<p style="top:474.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">addition to the above, riluzole is a thought to be a sodium channel blocker that inhibits</span></p>
<p style="top:487.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">glutamate release [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">72</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. By this mechanism, riluzole was also shown to inhibit glucose</span></p>
<p style="top:499.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">transport 3 (GLUT3) in GSCs, resulting in inhibition of HIF1</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> and p-AKT signaling. Finally,</span></p>
<p style="top:512.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">riluzole was shown to downregulate DNA (cytosine-5-)-methyltransferase (DNMT1), a</span></p>
<p style="top:524.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">factor responsible for hypermethylation of tumor suppressors [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">72</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. While riluzole has</span></p>
<p style="top:537.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">not been examined in patients, clinical studies with mTOR inhibitors are discussed in</span></p>
<p style="top:550.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">detail later.</span></p>
<p style="top:562.6pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Dimethyl fumarate is currently used in relapsing-remitting multiple sclerosis, but was</span></p>
<p style="top:575.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">also found to act against GBM through ERK1/2 and AKT inhibition in GBM cell lines [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">73</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span></p>
<p style="top:587.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Dimethyl fumarate remains to be studied in large clinical trials. Idebenone, a Coenzyme</span></p>
<p style="top:600.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Q</span><span style="font-family:URWPalladioL,serif;font-size:7.6pt">10</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> analogue, primarily used for neurocognitive disorders such as Alzheimer&#x2019;s disease,</span></p>
<p style="top:612.7pt;left:166.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">was also shown to have pro-apoptotic effects [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">74</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Both U373MG and U87MG cell lines</span></p>
<p style="top:625.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">had decreased cell viability after idebenone treatment, while co-treatment with TMZ and</span></p>
<p style="top:637.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">oxaliplatin resulted in increased cytotoxicity in U373MG cells.</span></p>
<p style="top:660.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.14. Statins</span></p>
<p style="top:675.8pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Statins are widely used agents with well-established toxicity pro&#xfb01;les and pleiotropic</span></p>
<p style="top:688.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">effects that include potential antineoplastic action [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">75</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">78</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">168</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Statins were found to</span></p>
<p style="top:700.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">interfere with c-Myc through microRNA (miRNA) targeting [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">76</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Consistent with this,</span></p>
<p style="top:713.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in medulloblastoma, lovastatin was found to increase miR-33b, resulting in inhibition of</span></p>
<p style="top:726.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">c-Myc [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">76</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. In GBM, lovastatin was found to inhibit S-phase kinase protein (Skp2), an E3</span></p>
<p style="top:738.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ligase involved in tumorigenesis, and when combined with TMZ increased degradation of</span></p>
<p style="top:751.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Skp2 in cells and xenografts [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">75</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Simvastatin was found to inhibit EGFR, &#xfb01;broblast growth</span></p>
<p style="top:763.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">factor receptor (FGFR) and proto-oncogene tyrosine-kinase Src (c-SRC) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">77</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">], TKs that are</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">13 of 29</span></p>
<p style="top:97.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">highly active in GBM. Atorvastatin demonstrated therapeutic potential through inhibition</span></p>
<p style="top:110.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of RAS prenylation thereby inhibiting growth and decreasing survival of multiple GBM</span></p>
<p style="top:122.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cell lines [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">78</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. In this study, co-treatment of &#xfb02;ank GBM xenograft with atorvastatin and</span></p>
<p style="top:135.1pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">TMZ demonstrated synergistic inhibition of growth.</span></p>
<p style="top:147.7pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Despite the above observations, a retrospective study of over one thousand patients</span></p>
<p style="top:160.2pt;left:166.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">with HGG showed that statins, as well as NSAIDs, were not associated with increased</span></p>
<p style="top:172.8pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">progression free survival (PFS) or OS [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">168</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Additionally, after stratifying by WHO grade,</span></p>
<p style="top:185.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">there was no signi&#xfb01;cant association between statins and PFS/OS, although aspirin was</span></p>
<p style="top:197.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">associated with increased PFS and OS in grade III glioma. It remains unclear whether</span></p>
<p style="top:210.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">statins have a potential role in GBM therapy.</span></p>
<p style="top:232.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.15. Other</span></p>
<p style="top:248.3pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Several other therapeutics that do not fall into a general class and that have limited</span></p>
<p style="top:260.9pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">preliminary data are undergoing initial experimental evaluation as repurposing candi-</span></p>
<p style="top:273.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">dates. Aurintricarboxylic acid, a topoisomerase inhibitor, was reported to chemosensitize</span></p>
<p style="top:286.0pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">TMZ</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> by altering NF-</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3ba;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">B signaling via TWEAK [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">79</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Other medications such as</span></p>
<p style="top:298.5pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">papaverine, a non-narcotic opium alkaloid, inhibited cell proliferation of U87 and T98G</span></p>
<p style="top:311.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">GBM cells [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">80</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Bacoside A, the bioactive component of a traditional plant-based medicine,</span></p>
<p style="top:323.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">increased phosphorylation of the calcium/calmodulin-dependent protein kinase IIA dis-</span></p>
<p style="top:336.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">rupting &#xfb02;uid balance and promoting GBM cell lysis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">81</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Another agent, vertepor&#xfb01;n, a</span></p>
<p style="top:348.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">benzoporphyrin-like drug, has only demonstrated inhibitory effects against GBM cells</span></p>
<p style="top:361.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">under speci&#xfb01;c conditions such as hypoxia [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">82</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Vertepor&#xfb01;n signi&#xfb01;cantly inhibited primary</span></p>
<p style="top:374.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">and immortalized cell lines under 1% oxygen conditions through a Yes-associated protein</span></p>
<p style="top:386.4pt;left:166.9pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">(YAP)-independent mechanism and increased ROS formation. Clomiphene, a selective</span></p>
<p style="top:399.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">estrogen receptor modulator (SERM), is another agent identi&#xfb01;ed through virtual screen-</span></p>
<p style="top:411.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ing [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">83</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. This drug was found to interfere with IDH1 in GBM. Speci&#xfb01;cally, in HT1080 cells</span></p>
<p style="top:424.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and &#xfb02;ank xenografts, clomiphene allosterically inhibited mutant IDH1</span><sup><span style="font-family:URWPalladioL,serif;font-size:7.6pt">R132H</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:10.1pt">decreasing</span></p>
<p style="top:436.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">tumor size and the ability of IDH1</span><sup><span style="font-family:URWPalladioL,serif;font-size:7.6pt">R132H</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt">to reduce</span><span style="font-family:EURM10,serif;font-size:10.0pt"> &#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">-ketoglutarate [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">83</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. In sum, the agents</span></p>
<p style="top:449.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">above highlight the possible anti-GBM actions that potentially exist in a variety of drugs</span></p>
<p style="top:461.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">that are routinely and rarely used for other indications. A comprehensive list of small-</span></p>
<p style="top:474.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">molecule inhibitors that have been very preliminarily studied in GBM is available in the</span></p>
<p style="top:486.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">following recent publications [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">169</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">170</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:509.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.16. Targeting the Tumor Microenvironment (TME)</span></p>
<p style="top:524.8pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">GBM is made up of a complex of tumor cells and surrounding microenvironmental</span></p>
<p style="top:537.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">components that include in&#xfb02;ammatory cells, microvasculature and extracellular matrix</span></p>
<p style="top:550.0pt;left:166.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">(ECM) proteins [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">171</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. In addition to the malignant cells, the TME also plays a critical role</span></p>
<p style="top:562.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">in promoting GBM pathobiology, and targeting the TME (e.g., the immune compartment or</span></p>
<p style="top:575.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">the vasculature) is an important adjunct to GBM therapy [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">171</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">172</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Repurposing agents to</span></p>
<p style="top:587.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">speci&#xfb01;cally target the TME represents a potential novel avenue for GBM treatment. Perhaps</span></p>
<p style="top:600.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the best-known repurposing strategy targeting the TME has been the use of bevacizumab</span></p>
<p style="top:612.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">to block angiogenesis. In GBM, following the success of several Phase II clinical trials</span></p>
<p style="top:625.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">examining bevacizumab [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">173</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">174</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], a Phase III trial was conducted demonstrating that</span></p>
<p style="top:637.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">addition of bevacizumab increased PFS without signi&#xfb01;cantly altering OS [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">175</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Another</span></p>
<p style="top:650.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">agent targeting the TME is the antiparasitic mebendazole, an agent reported to inhibit the</span></p>
<p style="top:663.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">angiogenic factor, VEGFR2 [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">102</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">103</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">126</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">132</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Additionally, the benzoporphyrin-like drug,</span></p>
<p style="top:675.6pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">vertepor&#xfb01;n, was reported to target the hypoxic TME in GBM to induce hypoxic tumor cell</span></p>
<p style="top:688.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">death [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">82</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:700.5pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">In&#xfb02;ammatory cells represent another important component of the TME and have</span></p>
<p style="top:713.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">been targeted by a variety of agents including NSAIDs, mTOR inhibitors and checkpoint</span></p>
<p style="top:725.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">inhibitors. The use of these agents was comprehensively described in other subsections of</span></p>
<p style="top:738.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">this review.</span></p>
<p style="top:750.8pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The &#xfb01;nal component of the TME is the ECM. While targeting ECM factors such as</span></p>
<p style="top:763.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">laminin has been examined in other cancers, it has been poorly studied in GBM. In one</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">14 of 29</span></p>
<p style="top:97.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">study, pirfenidone, an anti&#xfb01;brotic agent, was shown to decrease the abundance of ECM</span></p>
<p style="top:110.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">components like collagen and hyaluronan to improve blood &#xfb02;ow and anticancer agent</span></p>
<p style="top:122.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">delivery [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">176</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:145.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.17. Inhibition of Signaling Pathway Active in GBM</span></p>
<p style="top:160.5pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">In examining drugs potentially useful for GBM therapy, it was reasoned that agents</span></p>
<p style="top:173.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">targeting the major pathways active in GBM represent a potentially important subset</span></p>
<p style="top:185.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of anti-GBM drugs. The pathways most commonly activated in GBM include signal-</span></p>
<p style="top:198.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ing downstream of receptor tyrosine kinases (RTKs); the PI3K/AKT/mTOR pathway;</span></p>
<p style="top:210.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">RAS/MAP/ERK signaling; TGF-B and NF-</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3ba;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">B [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">177</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Many of the agents targeting these</span></p>
<p style="top:223.4pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">pathways have been extensively discussed throughout this review. The PI3K/AKT/mTOR</span></p>
<p style="top:235.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">response is potentially the most active pathway in GBM. Several repurposed agents inhibit-</span></p>
<p style="top:248.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ing components of this pathway have been described in this review such as perifosine and</span></p>
<p style="top:261.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#xfb01;mepinostat [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">61</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">122</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:283.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.1.18. Targeting Glioma Stem Cells</span></p>
<p style="top:298.8pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Finally, it is important to note that repurposing has been used to speci&#xfb01;cally target</span></p>
<p style="top:311.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cancer stem cells (or glioma stem cells-GSCs). While several drugs targeting GSCs have</span></p>
<p style="top:324.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">been mentioned, certain agents were identi&#xfb01;ed speci&#xfb01;cally because of their propensity</span></p>
<p style="top:336.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">to target GSCs. Chlorpromazine is one such agent, an antipsychotic that was shown</span></p>
<p style="top:349.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">to decrease stemness markers and neurosphere formation [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">178</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Nicardipine, a calcium</span></p>
<p style="top:361.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">channel blocker used for hypertension, was shown to promote apoptosis and enhance the</span></p>
<p style="top:374.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">toxic effect of TMZ against patient-derived GSCs [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">179</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. GSCs have also been shown to</span></p>
<p style="top:386.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">have a speci&#xfb01;c dependence on mitochondrial function, and mitochondrial inhibitors such</span></p>
<p style="top:399.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">as tri&#xfb02;uoperazine, mitoxantrone or pyrvinium pamoate were reported to speci&#xfb01;cally kill</span></p>
<p style="top:412.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">GSCs [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">180</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. These agents were shown to induce selective cytotoxicity of GSCs substantially</span></p>
<p style="top:424.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">more than TMZ. Doxazosin was also found to target GSCs and increase sensitivity to the</span></p>
<p style="top:436.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">EGFR inhibitor, osimertinib [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">181</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Finally, the anti-Parkinsonian, trihexyphenidyl, was</span></p>
<p style="top:449.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">repurposed to speci&#xfb01;cally target GSCs and shown to decrease GSC proliferation [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">182</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:472.0pt;left:167.3pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.2. Repurposed Agents in Clinical Investigations</span></i></p>
<p style="top:485.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.2.1. Antiepileptic Drugs (AEDs)</span></p>
<p style="top:500.9pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Patients with GBM often have seizures during their disease course, resulting in the</span></p>
<p style="top:513.4pt;left:166.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">widespread use of AEDs in this population. Given this observation, AEDs that have</span></p>
<p style="top:526.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">antineoplastic effects represent a potentially fruitful source for repurposing [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">183</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. VPA,</span></p>
<p style="top:538.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">a histone deacetylase inhibitor (HDACi) with cytotoxic activity in other cancer types, is</span></p>
<p style="top:551.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the AED that has been most extensively studied in GBM [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">84</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. In diffuse intrinsic pontine</span></p>
<p style="top:563.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">glioma (DIPG), the combination of VPA and carboplatin increased apoptosis through</span></p>
<p style="top:576.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">acetylation of Histone H3 [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">84</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Similarly, when combined with statins, VPA synergistic</span></p>
<p style="top:588.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">induced apoptosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">85</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. On the other hand, VPA was reported to act in an additive fashion</span></p>
<p style="top:601.5pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">with tranylcypromine, a TCA, and riluzole, an agent used for ALS [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">70</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. VPA also sensitized</span></p>
<p style="top:613.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">GBM cells to TMZ, while an alkylated hybrid of TMZ and VPA decreased viability and</span></p>
<p style="top:626.5pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">proliferation of GBM cells by promoting autophagy [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">86</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:639.1pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Based on these promising preclinical results, several groups examined VPA in clinical</span></p>
<p style="top:651.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">GBM. These trials have primarily used a combinatorial approach where VPA was combined</span></p>
<p style="top:664.1pt;left:166.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">with other repurposed agents or chemotherapeutics [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">87</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">88</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. For example, in one Phase II</span></p>
<p style="top:676.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">study, VPA was used with RT or other biological agents such as bevacizumab [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">88</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. The</span></p>
<p style="top:689.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">study began in 2009, enrolled 38 pediatric patients with GBM, anaplastic astrocytoma or</span></p>
<p style="top:701.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">gliosarcoma and recently concluded. No results are yet available. The primary outcome</span></p>
<p style="top:714.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">measure was event-free survival and VPA toxicity when combined with RT. Another trial</span></p>
<p style="top:726.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">investigates VPA with sorafenib, a multikinase inhibitor that has increased ef&#xfb01;cacy in the</span></p>
<p style="top:739.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">setting of HDAC inhibition [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">87</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. This Phase II trial started in 2013 with plans to enroll 47</span></p>
<p style="top:752.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">HGG participants; it will be completed in 2022. Its primary aim is to investigate whether the</span></p>
<p style="top:764.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">combination regimen improves PFS, while secondary outcomes include OS, best response</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">15 of 29</span></p>
<p style="top:97.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">rate and adverse events. Despite the strong preclinical evidence and safety, it remains to be</span></p>
<p style="top:110.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">determined whether VPA will be bene&#xfb01;cial in patients with GBM.</span></p>
<p style="top:132.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.2.2. Disul&#xfb01;ram</span></p>
<p style="top:148.1pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">As highlighted in the &#xfb01;rst section, there is a substantial amount of preclinical evidence</span></p>
<p style="top:160.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">supporting the repurposing of disul&#xfb01;ram for GBM. Several clinical trials have examined</span></p>
<p style="top:173.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Cu&#x2013;disul&#xfb01;ram or disul&#xfb01;ram alone in GBM [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">89</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">91</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. In a Phase I study in GBM investigating</span></p>
<p style="top:185.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">disul&#xfb01;ram and TMZ following standard chemoradiotherapy, patients demonstrated dose-</span></p>
<p style="top:198.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">related toxicities in the higher disul&#xfb01;ram dose group (1000 mg vs. 500 mg daily) including</span></p>
<p style="top:210.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">grade III delirium, fatigue, ataxia and peripheral neuropathy [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">89</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. The median OS in these</span></p>
<p style="top:223.2pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">patients was 5.4 months from the time of disul&#xfb01;ram initiation. The trial concluded that</span></p>
<p style="top:235.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">disul&#xfb01;ram can be safely combined with TMZ, but may result in reversible neurotoxicity.</span></p>
<p style="top:248.4pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">The results of this Phase I study prompted an open label, randomized Phase II/III study,</span></p>
<p style="top:261.0pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">which began in 2016, with a plan to enroll 142 GBM patients at initial recurrence [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">91</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. The</span></p>
<p style="top:273.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">intended study design was a 1:1 randomization of patients to receive either Cu&#x2013;disul&#xfb01;ram</span></p>
<p style="top:286.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">and alkylating chemotherapy or alkylating chemotherapy alone (lomustine, procarbazine,</span></p>
<p style="top:298.7pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">vincristine, or temozolomide). The trial is still enrolling patients and the results are pending.</span></p>
<p style="top:311.3pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">While disul&#xfb01;ram has shown promising results in early studies, it remains to be determined</span></p>
<p style="top:323.7pt;left:166.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">whether the ef&#xfb01;cacy will be recapitulated in randomized trials.</span></p>
<p style="top:346.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.2.3. Antifungals/Antimalarials</span></p>
<p style="top:361.8pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Antifungal agents have recently been identi&#xfb01;ed as potential anti-GBM agents. Among</span></p>
<p style="top:374.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">this category of drugs, azoles have shown some potential for clinical translation [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">92</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">93</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. The</span></p>
<p style="top:386.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">current understanding of the antineoplastic action of azoles involves their ability to inhibit</span></p>
<p style="top:399.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">hexokinase II leading to restriction of GSC proliferation and GBM growth [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">93</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Speci&#xfb01;cally,</span></p>
<p style="top:412.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">in experimental GBM, ketoconazole and posaconazole decreased metabolic activity leading</span></p>
<p style="top:424.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">to increased animal survival and decreased tumor growth [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">92</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. These preclinical studies</span></p>
<p style="top:436.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">led to an ongoing open-label, non-randomized Phase I trial investigating posaconazole</span></p>
<p style="top:449.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and ketoconazole in patients with recurrent HGG [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">94</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. The trial began in 2018 with</span></p>
<p style="top:462.1pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">plans to enroll 30 patients with a primary outcome of intratumoral ketoconazole and/or</span></p>
<p style="top:474.6pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">posaconazole concentration. Clioquinol is another topical antifungal being investigated</span></p>
<p style="top:487.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in GBM [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">92</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">95</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Together, these results suggest that although there is some preclinical</span></p>
<p style="top:499.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">evidence for the potential use of azoles and clioquinol for GBM, their clinical safety and</span></p>
<p style="top:512.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ef&#xfb01;cacy remain to be determined.</span></p>
<p style="top:524.8pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Similar to the antifungal class, antimalarials have also been identi&#xfb01;ed as having</span></p>
<p style="top:537.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">antineoplastic potential. Antimalarials, including chloroquine, me&#xfb02;oquine and atovaquone</span></p>
<p style="top:550.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">have all emerged as strong repurposing candidates although their use has been hampered</span></p>
<p style="top:562.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">by technical challenges [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">31</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">99</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">101</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Atovaquone was initially found to inhibit STAT3,</span></p>
<p style="top:575.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">but did not achieve high enough tissue levels to deliver a therapeutic effect in the CNS [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">31</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span></p>
<p style="top:587.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">In an attempt to tackle this problem, an enhanced dispersion formulation was created</span></p>
<p style="top:600.1pt;left:166.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">which demonstrated increased cytotoxicity against GBM cells</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> and in an animal</span></p>
<p style="top:612.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">GBM model [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">31</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Another antimalarial, chloroquine, was shown to interfere with GBM</span></p>
<p style="top:625.4pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">progression through autophagy and apoptosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">86</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">96</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. A combination of chloroquine,</span></p>
<p style="top:637.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">sirolimus and TMZ resulted in apoptosis and decreased growth of intracranial GBM, while</span></p>
<p style="top:650.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">tri-therapy with chloroquine, crizotinib and sora&#xfb01;nib was ef&#xfb01;cacious against 3D patient-</span></p>
<p style="top:663.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">derived cell cultures [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">97</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. These preclinical results prompted a non-randomized, open-</span></p>
<p style="top:675.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">label Phase I/II clinical trial which began in 2019 and plans to enroll 75 patients with either</span></p>
<p style="top:688.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">low-grade glioma (LGG) or HGG investigating co-administration of hydroxychloroquine,</span></p>
<p style="top:700.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">98</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. The trial has a primary</span></p>
<p style="top:713.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">endpoint of maximum tolerated dose (MTD) and clinical response in the Phase II portion</span></p>
<p style="top:725.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of the trial. The Phase II trial plans to enroll 62 participants with recurrent HGG with a</span></p>
<p style="top:738.3pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">primary endpoint of tumor radiographic response and secondary outcomes of PFS and OS.</span></p>
<p style="top:750.9pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Antimalarials have also been examined in conjunction with other repurposed agents.</span></p>
<p style="top:763.3pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The combination of me&#xfb02;oquine with metformin and memantine was recently investi-</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">16 of 29</span></p>
<p style="top:97.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">gated in a Phase I/II clinical trial in newly diagnosed GBM patients receiving traditional</span></p>
<p style="top:110.1pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">TMZ</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">99</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">101</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">. The results of this trial were recently published. The most common adverse</span></p>
<p style="top:122.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">effect was lymphopenia, while OS from study entry was 21 months with a 43% two-year</span></p>
<p style="top:135.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">OS. The conclusion from this study was that tri-therapy is safe in combination with TMZ</span></p>
<p style="top:147.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in newly diagnosed GBM. Although there was no comparison group and the study was</span></p>
<p style="top:160.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">not powered to study ef&#xfb01;cacy, the results appeared promising as a possible component of</span></p>
<p style="top:172.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">future multipharmacologic therapy.</span></p>
<p style="top:185.3pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">It is important to note that antimalarials have side-effects that may be a signi&#xfb01;cant</span></p>
<p style="top:197.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">barrier to their use in GBM. [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">184</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">185</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Speci&#xfb01;cally, while nausea, vomiting and diarrhea</span></p>
<p style="top:210.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">can restrict their use, neurotoxicity has also been reported. In addition, their immunomod-</span></p>
<p style="top:223.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ulatory actions might also effect their ef&#xfb01;cacy against GBM.</span></p>
<p style="top:245.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.2.4. Antiparasitics</span></p>
<p style="top:260.9pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">The antiparasitic, mebendazole, was recently identi&#xfb01;ed as a potential antineoplastic</span></p>
<p style="top:273.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">agent in medulloblastoma and was subsequently examined in GBM [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">102</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">103</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Mebendazole</span></p>
<p style="top:286.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">inhibits vascular signaling by competing with ATP for binding vascular-endothelial growth</span></p>
<p style="top:298.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">factor 2 (VEGF2), resulting in decreased tumor angiogenesis and microvascular density</span></p>
<p style="top:311.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in murine medulloblastoma. Mebendazole also inhibits microtubule formation leading</span></p>
<p style="top:323.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">to decreased tumor burden via metaphase arrest [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">104</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">105</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. A Phase I study investigating</span></p>
<p style="top:336.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">oral mebendazole opened in 2016 and will enroll 21 patients with recurrent or resistant-to-</span></p>
<p style="top:348.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">standard-therapy tumors including pediatric GBM [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">106</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. As a non-randomized, open-label</span></p>
<p style="top:361.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">trial, it will primarily analyze adverse events. This trial will conclude in 2022.</span></p>
<p style="top:383.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.2.5. Antihypertensives</span></p>
<p style="top:399.4pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">In the United States, angiotensin-converting enzyme (ACE) inhibitors and angiotensin</span></p>
<p style="top:411.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">II receptor blockers (ARBs) make up a large percentage of prescribed antihypertensives.</span></p>
<p style="top:424.5pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">They act by interfering with the renin-angiotensin-aldosterone-system (RAAS). Their well-</span></p>
<p style="top:437.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">known safety pro&#xfb01;le and low cost make them excellent candidates for repurposing [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">107</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:449.6pt;left:166.9pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Although these agents have undergone some degree of clinical investigation, they remain</span></p>
<p style="top:462.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">to be studied in randomized controlled trials [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">107</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. A recent analysis of two large</span></p>
<p style="top:474.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">clinical studies in GBM, comprising a total of 810 patients, was investigated by stratifying</span></p>
<p style="top:487.1pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">patients by their use of ACE inhibitors, ARBs or statins while in the trial. No signi&#xfb01;cant</span></p>
<p style="top:499.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">bene&#xfb01;t with regard to PFS and OS was seen for any of the drug classes. Of course, these</span></p>
<p style="top:512.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">clinical trials were not speci&#xfb01;cally designed to study ACE inhibitors or ARBs. Interestingly,</span></p>
<p style="top:524.8pt;left:166.9pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ARBs were studied in a randomized trial as a possible adjunct to reduce steroid use by</span></p>
<p style="top:537.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">decreasing peritumoral edema [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">108</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. In this trial, known as the ASTER trial, researchers</span></p>
<p style="top:550.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">looked to see if losartan could reduce the steroid requirement during RT in patients with</span></p>
<p style="top:562.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">newly diagnosed GBM. In the 75 patients enrolled, it was determined that losartan was</span></p>
<p style="top:575.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">not effective at reducing steroid requirement, although it was well tolerated. Secondary</span></p>
<p style="top:587.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">analyses also revealed that losartan had no impact on OS alone or when strati&#xfb01;ed by MGMT</span></p>
<p style="top:600.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">status. Finally, the ACE inhibitor, captopril, was studied as a component of a combination</span></p>
<p style="top:612.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">treatment trial that is discussed in further detail below. The above observations indicate</span></p>
<p style="top:625.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">that in non-randomized retrospective analyses these antihypertensives have not yielded</span></p>
<p style="top:637.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">fruitful results. It is unclear whether a signi&#xfb01;cant effect would be observed in a more</span></p>
<p style="top:650.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">controlled setting.</span></p>
<p style="top:672.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.2.6. Anti-In&#xfb02;ammatories and Immunosuppressants</span></p>
<p style="top:688.4pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">As noted earlier, mTOR inhibitors are immunosuppressive agents that range in their</span></p>
<p style="top:700.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">clinical indications from in&#xfb02;ammatory bowel disease to dermatological disease and trans-</span></p>
<p style="top:713.5pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">plant rejection. Preclinical evidence for mTOR inhibitors as antiglioma agents is plentiful</span></p>
<p style="top:726.1pt;left:166.9pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">(see above). Temsirolimus was investigated in a Phase I study in GBM in combination with</span></p>
<p style="top:738.6pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">perifosine, a novel AKT/PI3K inhibitor, with primary outcomes of safety and determining</span></p>
<p style="top:751.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Phase II dosing [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. The trial began in 2014 and was completed in 2017. Although the</span></p>
<p style="top:763.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">trial found the combination was tolerable in 35 patients, no Phase II study has been con-</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">17 of 29</span></p>
<p style="top:97.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ducted. Another mTOR inhibitor, everolimus, is being investigated in multiple Phase I and</span></p>
<p style="top:110.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Phase II studies in GBM in combination with repurposed small-molecule inhibitors such as</span></p>
<p style="top:122.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">sorafenib, ribociclib and dasatinib [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">112</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">116</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. One of these studies is a non-randomized,</span></p>
<p style="top:135.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">open-label Phase I study which planned to enroll 24 participants who have DIPG or HGG</span></p>
<p style="top:147.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">using the combination of ribociclib and everolimus to determine MTD [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">112</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. The trial</span></p>
<p style="top:160.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">began in 2017 and was completed in July 2020. No results are yet available. Another</span></p>
<p style="top:172.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">non-randomized Phase I study with a goal of 24 recurrent GBM participants opened in De-</span></p>
<p style="top:185.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cember 2018 and examines OS and PFS in patients receiving ribociclib and everolimus [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">114</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span></p>
<p style="top:198.0pt;left:166.9pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">An additional single-institution combined Phase I&#x2013;II trial conducted by the National Cancer</span></p>
<p style="top:210.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Institute that started in April 2016 using everolimus with sorafenib has a target enrollment</span></p>
<p style="top:222.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of 118 patients who have recurrent HGG and primary outcomes of MTD and PFS [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">113</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">].</span></p>
<p style="top:235.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Finally, a Phase II study that will investigate dasatinib with everolimus in a single group</span></p>
<p style="top:248.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">assignment of 24 patients including both recurrent or newly diagnosed DIPG or HGG,</span></p>
<p style="top:260.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">began in December 2017 and is estimated to be completed in December 2023 [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">115</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Primary</span></p>
<p style="top:273.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">outcome measures of the study include PFS and overall response rate (ORR). In sum, de-</span></p>
<p style="top:285.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">spite the preclinical excitement of mTOR inhibitors, their ef&#xfb01;cacy has not yet been proven</span></p>
<p style="top:298.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in the clinical setting.</span></p>
<p style="top:311.0pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Celecoxib, an NSAID and selective COX-2 inhibitor, has been investigated in multiple</span></p>
<p style="top:323.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">clinical trials [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">109</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">111</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. A Phase II trial examined 37 patients treated with the combination</span></p>
<p style="top:336.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">of irinotecan and celecoxib in recurrent malignant glioma patients with a primary endpoint</span></p>
<p style="top:348.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of radiographic response and secondary endpoints of PFS, OS and safety [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">109</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Six pa-</span></p>
<p style="top:361.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">tients achieved radiographic response and 13 achieved stable disease following treatment.</span></p>
<p style="top:373.7pt;left:166.9pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Another Phase II study using TMZ, thalidomide and celecoxib in a cohort of 50 newly diag-</span></p>
<p style="top:386.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">nosed GBM patients found that although the combination was well tolerated, no bene&#xfb01;t</span></p>
<p style="top:398.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in the primary outcome of PFS at four months was seen [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">110</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. In a different Phase II trial,</span></p>
<p style="top:411.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">celecoxib was examined with 13-cis-retinoic acid in 25 patients with recurrent GBM [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">111</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:423.9pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">The combination was found to have no greater effect on PFS than 13-cis-retinoic acid alone</span></p>
<p style="top:436.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">although the combination was well tolerated. Based on the results of these Phase II studies,</span></p>
<p style="top:449.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">celecoxib has not recapitulated the success seen in preclinical models, suggesting that it is</span></p>
<p style="top:461.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">likely not a clinically useful adjunct for GBM treatment.</span></p>
<p style="top:483.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.2.7. Antineoplastics</span></p>
<p style="top:499.4pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">The topic of antineoplastic repurposing will only be brie&#xfb02;y discussed given that the</span></p>
<p style="top:511.9pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">mechanisms of action of these drugs against GBM are the same as their original hypoth-</span></p>
<p style="top:524.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">esized mechanism. Many of these agents have been investigated preclinically including</span></p>
<p style="top:537.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">hydroxyurea, actinomycin D, carmofur, eribulin and paclitaxel [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">186</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">195</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. With regard</span></p>
<p style="top:549.6pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">to clinical trials, vorinostat, an antineoplastic agent used for cutaneous T-cell lymphoma,</span></p>
<p style="top:562.2pt;left:166.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">was studied in a Phase I study in combination with TMZ [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">117</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. This study began in 2005</span></p>
<p style="top:574.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and ended in 2011 demonstrating that the combination was well tolerated and led to a</span></p>
<p style="top:587.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Phase I/II study that concluded there was no increase in the primary endpoint of PFS in</span></p>
<p style="top:599.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">39 patients. Although it was suggested that the lack of increased PFS was due to a heavily</span></p>
<p style="top:612.5pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">pretreated group, further investigations have not been reported.</span></p>
<p style="top:625.1pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Other antineoplastic agents include cabozantinib, a TK inhibitor being investigated in</span></p>
<p style="top:637.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">a Phase II study of 10 pediatric patients with GBM or other HGG with a primary endpoint of</span></p>
<p style="top:650.2pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">disease response at six months [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">118</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Arsenic trioxide, an inorganic compound used to treat</span></p>
<p style="top:662.7pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">leukemia, is being investigated in a Phase I/II study as adjuvant therapy with TMZ and RT</span></p>
<p style="top:675.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in a group of 50 participants with GBM, AA or other primary pediatric CNS tumor [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">119</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:687.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Marizomib, a proteasome inhibitor, has been added to standard chemoradiation therapy,</span></p>
<p style="top:700.2pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">TTF or in combination with bevacizumab in different Phase I studies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">120</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">121</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. One of</span></p>
<p style="top:712.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">these trials started in 2016 and recruited a cohort of 66 newly diagnosed GBM patients.</span></p>
<p style="top:725.4pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">The trial has recently concluded and at the time of writing of this article, the study results</span></p>
<p style="top:738.1pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">were unavailable. Primary outcome measures include adverse events and marizomib MTD.</span></p>
<p style="top:750.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Fimepinostat, a PI3K inhibitor and HDAC inhibitor that originally received orphan drug</span></p>
<p style="top:763.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">designation for diffuse large B-cell lymphoma, is also under investigation in combination</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">18 of 29</span></p>
<p style="top:97.4pt;left:166.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">with standard treatments to con&#xfb01;rm BBB permeability [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">122</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. The study began in 2019</span></p>
<p style="top:110.0pt;left:166.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">with a goal of recruiting 30 patients with DIPG, recurrent GBM or other primary CNS</span></p>
<p style="top:122.7pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">pathology and will assess primary outcome of &#xfb01;mepinostat BBB penetration. In conclusion,</span></p>
<p style="top:135.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">although a variety of antineoplastic agents have been repurposed for GBM therapy, it</span></p>
<p style="top:147.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">remains unclear whether their success in other cancers will show similar results in GBM.</span></p>
<p style="top:170.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.2.8. Carbonic-Anhydrase Inhibitors</span></p>
<p style="top:185.7pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Through examination of patterns of chemoresistance, novel repurposing agents have</span></p>
<p style="top:198.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">been identi&#xfb01;ed such as acetazolamide. Acetazolamide, a carbonic anhydrase (CA) inhibitor,</span></p>
<p style="top:210.8pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">was reported to improve the cytotoxic effect of TMZ despite lacking any cytotoxic effect on</span></p>
<p style="top:223.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">its own. It was also found to augment the ef&#xfb01;cacy of TMZ in PDX models of GBM [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">123</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">124</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span></p>
<p style="top:235.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Mechanistic studies suggested that this response involved inhibition of carbonic anhydrase</span></p>
<p style="top:248.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">II (CAII) downstream of the proto-oncogene, BCL-3, and that this pathway promotes</span></p>
<p style="top:261.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">chemoresistance in patients with a methylated MGMT promoter [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">123</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Based on promising</span></p>
<p style="top:273.4pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">preclinical results, acetazolamide was investigated in a Phase I study as an adjunct to</span></p>
<p style="top:286.0pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">TMZ. This study began in 2018 and plans to conclude by 2022 [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">125</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. The trial will enroll</span></p>
<p style="top:298.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">60 patients with newly diagnosed, MGMT methylated GBM to evaluate the primary</span></p>
<p style="top:311.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">endpoint of toxicity and the secondary outcomes of OS, PFS and ORR. As part of the study,</span></p>
<p style="top:323.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">secondary outcomes will be compared to intratumoral BCL-3 abundance.</span></p>
<p style="top:346.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.2.9. Checkpoint Inhibitors</span></p>
<p style="top:361.6pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Immune checkpoint inhibitors function as a class of biologics that interact with the</span></p>
<p style="top:374.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">immune system to encourage an antitumor response by immune cells. This may mean inter-</span></p>
<p style="top:386.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">fering with antidestruction signals upregulated by tumor cells, or by altering the immune</span></p>
<p style="top:399.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">microenvironment to encourage immune cell in&#xfb01;ltration. Two of the most-commonly used</span></p>
<p style="top:412.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">checkpoint inhibitors, nivolumab and pembrolizumab, interfere with the programmed cell</span></p>
<p style="top:424.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">death pathway. These drugs were originally developed for other oncological diseases but</span></p>
<p style="top:437.0pt;left:166.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">were recently repurposed as potential anti-GBM therapeutics.</span></p>
<p style="top:449.5pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Nivolumab, a monoclonal antibody targeting the interaction between programmed</span></p>
<p style="top:462.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cell death 1 (PD-1), and its ligand PD-L1, has already undergone extensive clinical study</span></p>
<p style="top:474.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in GBM. A Phase II study completed in 2017 investigated neoadjuvant nivolumab in 30</span></p>
<p style="top:487.1pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">primary or recurrent GBM patients with a primary outcome of percent change in PD-L1</span></p>
<p style="top:499.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">expression in tumor cells and lymphocytes following neoadjuvant nivolumab [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">127</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Sec-</span></p>
<p style="top:512.3pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ondary outcomes included RANO response rate and safety. Treatment was well tolerated,</span></p>
<p style="top:524.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">OS was 7.3 months and resected tumors demonstrated upregulation of immune pathway</span></p>
<p style="top:537.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">components [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">128</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Following demonstration of safety and tolerability in an initial Phase I</span></p>
<p style="top:550.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">trial, the Checkmate 143 Phase III open label, randomized trial was subsequently conducted</span></p>
<p style="top:562.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">comparing nivolumab against bevacizumab in 369 patients with recurrent GBM [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">126</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">129</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span></p>
<p style="top:575.2pt;left:167.0pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">The primary endpoint of OS demonstrated that nivolumab was comparable to bevacizumab,</span></p>
<p style="top:587.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">suggesting that nivolumab monotherapy did not improve OS in recurrent GBM. Other</span></p>
<p style="top:600.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">clinical trials investigating these agents include Checkmate 498, a Phase III trial enrolling</span></p>
<p style="top:612.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">550 newly diagnosed, MGMT unmethylated GBM patients comparing nivolumab to TMZ</span></p>
<p style="top:625.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">both in combination with RT. Unfortunately, it was recently announced that the primary</span></p>
<p style="top:637.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">outcome of OS was not met [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">130</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Checkmate 548 was another Phase III trial investigating</span></p>
<p style="top:650.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">550 patients with newly diagnosed, MGMT methylated GBM comparing nivolumab to</span></p>
<p style="top:663.0pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">TMZ both with RT [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">131</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Again, nivolumab demonstrated no increase in OS.</span></p>
<p style="top:675.4pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Pembrolizumab is also under investigation in a variety of Phase I studies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">133</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">134</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">].</span></p>
<p style="top:688.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">One of these studies aims to enroll 110 participants in a single group with primary end-</span></p>
<p style="top:700.5pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">points of adverse events, sustained objective response and percentage of PD1+ CD8+ T</span></p>
<p style="top:713.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cells in peripheral blood after 6 weeks of pembrolizumab therapy [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">133</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. In another Phase</span></p>
<p style="top:725.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">I study, pembrolizumab was added to RT and bevacizumab in 32 patients with glioma</span></p>
<p style="top:738.4pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">with the primary endpoint of MTD, preliminary results demonstrated safety. Subsequently,</span></p>
<p style="top:750.8pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">pembrolizumab was investigated in a Phase II study with or without concurrent beva-</span></p>
<p style="top:763.4pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cizumab in 80 GBM patients with a primary outcome of PFS at six months [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">132</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Notably,</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">19 of 29</span></p>
<p style="top:97.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">PFS was 26% at six months in pembrolizumab alone compared to 6.7% at six months when</span></p>
<p style="top:110.0pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">pembrolizumab was combined with bevacizumab.</span></p>
<p style="top:122.5pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Overall, as a class, although checkpoint inhibitors initially appeared to have thera-</span></p>
<p style="top:135.1pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">peutic bene&#xfb01;t, this has not been recapitulated in large randomized trials. Nevertheless,</span></p>
<p style="top:147.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the data have raised important questions regarding the role of immunotherapy and have</span></p>
<p style="top:160.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">spurred new trials using these agents in novel ways such as in the neoadjuvant setting or</span></p>
<p style="top:172.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in speci&#xfb01;c sub-cohorts of patients [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">196</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">197</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:195.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.2.10. Diabetic Agents</span></p>
<p style="top:210.8pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Epidemiological studies previously noted decreased incidence, and possibly favorable</span></p>
<p style="top:223.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">outcome, for GBM patients actively taking metformin, a diabetic biguanide drug [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">135</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">136</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span></p>
<p style="top:235.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Metformin has potential antineoplastic mechanisms that include chloride channel inhibi-</span></p>
<p style="top:248.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">tion, AMPK activation and mTOR interference [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">135</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Treatment of human GSCs with</span></p>
<p style="top:260.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">metformin induced G1 phase arrest and promoted apoptosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">135</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">137</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Other biguanide</span></p>
<p style="top:273.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">derivatives similar to metformin were also found to inhibit GSC proliferation and xenograft</span></p>
<p style="top:286.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">growth [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">138</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:298.5pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">These preclinical &#xfb01;ndings suggested that metformin might be effective in patients</span></p>
<p style="top:311.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and the use of metformin was analyzed retrospectively in GBM cancer registries [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">139</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span></p>
<p style="top:323.7pt;left:166.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">140</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. In a retrospective analysis of 1093 patients with HGG, metformin was linked to</span></p>
<p style="top:336.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">increased OS and PFS in patients with grade III glioma, while no bene&#xfb01;t was found in</span></p>
<p style="top:348.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">grade IV tumors [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">139</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. It was speculated that this was due to the greater proportion of IDH</span></p>
<p style="top:361.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">mutations in grade III tumors. Consistent with this, in a second retrospective analysis of</span></p>
<p style="top:374.0pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">1731 patients, no bene&#xfb01;cial effect was observed with metformin. However, if patients were</span></p>
<p style="top:386.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">taking metformin prior to their glioma diagnosis, they had a signi&#xfb01;cant survival bene&#xfb01;t in</span></p>
<p style="top:399.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">comparison to those who began the drug after diagnosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">140</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:411.5pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Recently, a Phase Ib/II study of 18 patients with various solid tumors including</span></p>
<p style="top:424.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">GBM was completed with a planned 3 + 3 drug escalation scheme to evaluate metformin</span></p>
<p style="top:436.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">MTD [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">141</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Results from this study are still pending. Another Phase I clinical trial is</span></p>
<p style="top:449.2pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">investigating metformin in combination with TMZ [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">142</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. This trial began in 2011 and is</span></p>
<p style="top:461.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">estimated to conclude in 2022 with a plan to recruit a total of 144 GBM patients with a</span></p>
<p style="top:474.3pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">primary endpoint of safety and tolerability. Several other ongoing smaller clinical trials</span></p>
<p style="top:486.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">also look at metformin in GBM, although it remains unclear whether these trials have the</span></p>
<p style="top:499.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cohort size necessary to evaluate ef&#xfb01;cacy [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">143</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">145</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:512.1pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Beyond these preliminary studies, a Phase II study enrolling 50 GBM patients started</span></p>
<p style="top:524.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in 2015 and examined two-weeks of neoadjuvant metformin and TMZ followed by RT</span></p>
<p style="top:537.1pt;left:166.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">with a primary outcome measure of OS [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">146</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. This study will likely be completed in 2022.</span></p>
<p style="top:549.6pt;left:166.9pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Another Phase II study comprised of 108 GBM patients randomized to either TMZ plus</span></p>
<p style="top:562.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">metformin or TMZ and placebo began in 2016 and will conclude soon [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">147</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. The primary</span></p>
<p style="top:574.7pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">outcome measure is PFS, with secondary measures of response rate, six month survival</span></p>
<p style="top:587.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and overall quality of life. While metformin has promising preclinical data and possible</span></p>
<p style="top:599.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">therapeutic bene&#xfb01;t in retrospective cohorts, it remains to be determined whether this will</span></p>
<p style="top:612.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">be recapitulated in randomized controlled trials.</span></p>
<p style="top:634.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.2.11. Other Clinical Use of Small Molecules and Biologics</span></p>
<p style="top:650.5pt;left:188.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">In addition to direct antineoplastic effect, biologic agents have also been repurposed as</span></p>
<p style="top:663.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">imaging aids [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">148</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Cetuximab, an EGFR inhibitor, was used as a &#xfb02;uorescently labeled dye</span></p>
<p style="top:675.6pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">delivered at the time of surgery as an intraoperative guide to improve tumor resection [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">148</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span></p>
<p style="top:688.1pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">5-aminolevulinic acid (ALA) is perhaps the best known &#xfb02;uorescent agent that was studied</span></p>
<p style="top:700.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">as an intraoperative adjunct for tumor resection in GBM [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">149</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">152</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. A phase III trial</span></p>
<p style="top:713.2pt;left:167.0pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">published in 2006, demonstrated that intraoperative 5-ALA &#xfb02;uorescence in HGG patients</span></p>
<p style="top:725.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">allowed for more complete resections and better outcomes in comparison to traditional</span></p>
<p style="top:738.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">microsurgery [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">152</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">20 of 29</span></p>
<p style="top:97.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.2.12. The Cocktails</span></p>
<p style="top:112.9pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">A number of multidrug regimens that involve using repurposed agents with stan-</span></p>
<p style="top:125.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">dard treatments are being investigated for the treatment of GBM. These regimens target</span></p>
<p style="top:138.1pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">multiple pathways in the hope of inducing a greater overall effect than with monother-</span></p>
<p style="top:150.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">apy</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">153</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">155</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">158</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">198</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">. Some of these combinations have transitioned to clinical trials,</span></p>
<p style="top:163.2pt;left:166.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">while others remain in the preclinical phase.</span></p>
<p style="top:175.7pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">One cocktail is the coordinated undermining of survival paths (CUSP) regimen that</span></p>
<p style="top:188.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">uses nine drugs: aprepitant, aurano&#xfb01;n, captopril, celecoxib, disul&#xfb01;ram, itraconazole,</span></p>
<p style="top:201.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">minocycline, ritonavir, and sertraline [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">5</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">153</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">155</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">156</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> In vitro</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">, the CUSP9 regimen in combi-</span></p>
<p style="top:213.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">nation with TMZ had a greater effect than TMZ alone acting primarily via inhibition of the</span></p>
<p style="top:226.1pt;left:166.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">WNT pathway [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">155</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Additive effects were also seen when CUSP9 was combined with BCL-</span></p>
<p style="top:238.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2 pathway inhibition [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">154</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Subsequently, CUSP9 was investigated in a proof-of-concept</span></p>
<p style="top:251.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">study involving 10 patients with GBM and metronomic TMZ with a primary endpoint of</span></p>
<p style="top:263.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">toxicity [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">157</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. The trial is not currently recruiting and no results have been released.</span></p>
<p style="top:276.2pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Another cocktail, known as CLOVA, consists of cimetidine, lithium, olanzapine, and</span></p>
<p style="top:288.7pt;left:166.9pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">VPA, was speci&#xfb01;cally designed to inhibit the GSK-3</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b2;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> pathway. Preclinical work using a</span></p>
<p style="top:301.4pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">retrovirus-induced GBM model found that the cocktail with TMZ decreased cellular prolif-</span></p>
<p style="top:313.8pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">eration but did not statistically affect tumor size when compared to the control of TMZ</span></p>
<p style="top:326.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">alone [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">153</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. The same study also examined seven patients with recurrent GBM, demon-</span></p>
<p style="top:338.9pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">strating safety. Finally, the combination of celecoxib, vinblastine and cyclophosphamide</span></p>
<p style="top:351.5pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">alternating with methotrexate in a metronomic fashion was examined in a heterogenous</span></p>
<p style="top:364.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">group of pediatric patients with brain tumors including &#xfb01;ve HGG and 11 LGG [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">158</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. The</span></p>
<p style="top:376.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">results found that in the 11 patients with LGG, those who received the treatment combi-</span></p>
<p style="top:389.2pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">nation did better in terms of disease stabilization, as de&#xfb01;ned in the protocol, compared to</span></p>
<p style="top:401.7pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">historical controls. In general, the available data suggest that combination cocktails have</span></p>
<p style="top:414.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">not been shown to signi&#xfb01;cantly improve outcome above that seen with standard therapy,</span></p>
<p style="top:426.8pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">although no randomized studies have been conducted.</span></p>
<p style="top:449.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3.2.13. Limitations</span></p>
<p style="top:464.7pt;left:188.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">In many studies, there is a high risk of bias due to small sample size and the lack of</span></p>
<p style="top:477.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">control patients. However, for the purposes of a complete review, they were included for</span></p>
<p style="top:490.0pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">discussion. In addition, it is possible that some published studies were not captured by the</span></p>
<p style="top:502.5pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">search terms used. For clinical studies, the study size, primary endpoint, patient population,</span></p>
<p style="top:515.0pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">study type and intervention were documented to enable ef&#xfb01;cient and critical review.</span></p>
<p style="top:537.4pt;left:167.3pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">4. Conclusions</span></b></p>
<p style="top:552.9pt;left:188.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Here, a comprehensive review of repurposing therapeutics for GBM is provided,</span></p>
<p style="top:565.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">highlighting many attractive candidates. While a large group of agents have yielded</span></p>
<p style="top:578.0pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">positive preclinical data, translation to the clinic has been modest. Of course, given</span></p>
<p style="top:590.6pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">that many of these agents have already been used clinically, Phase I safety studies have</span></p>
<p style="top:603.1pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">often had good results. Despite this, potential disadvantages to repurposing include the</span></p>
<p style="top:615.8pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">interaction of these agents with other drugs and concerns with regulatory and intellectual</span></p>
<p style="top:628.2pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">properties. Such consequences can potentially offset the cost savings of repurposing. It</span></p>
<p style="top:640.9pt;left:167.3pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">remains to be determined whether repurposed agents will in fact reveal therapeutic ef&#xfb01;cacy</span></p>
<p style="top:653.3pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in randomized studies. General observations suggest that improved effects can be seen</span></p>
<p style="top:665.9pt;left:166.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">when repurposed agents are combined with each other or when added to the current</span></p>
<p style="top:678.4pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">standard-of-care regimens, suggesting that this should be considered when planning</span></p>
<p style="top:691.0pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">future trials. Finally, it is important to highlight the potential role of immunotherapy</span></p>
<p style="top:703.5pt;left:167.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and cell-based therapies, such as CAR-T cell therapy, in the treatment of GBM [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">199</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">200</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">].</span></p>
<p style="top:716.1pt;left:167.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">These novel modalities represent the latest agents to have been studied in clinical trials.</span></p>
<p style="top:728.6pt;left:166.9pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Although these strategies have not yet proven to be effective clinically, their potential</span></p>
<p style="top:741.3pt;left:167.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">remains exciting [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">201</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">202</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">21 of 29</span></p>
<p style="top:98.3pt;left:166.9pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Author Contributions:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Conceptualization, S.B.L. and B.Y.; Methodology, S.B.L. and B.Y.; Software,</span></p>
<p style="top:110.0pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">S.B.L. and B.Y.; Validation, S.B.L. and B.Y.; Formal Analysis, S.B.L. and B.Y.; Investigation, S.B.L. and</span></p>
<p style="top:121.7pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">B.Y.; Resources, S.B.L. and B.Y; Data Curation, S.B.L. and B.Y.; Writing&#x2014;Original Draft Preparation,</span></p>
<p style="top:133.5pt;left:167.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">S.B.L. and B.Y.; Writing&#x2014;Review and Editing, S.B.L. and B.Y.; Visualization, S.B.L. and B.Y.; Supervi-</span></p>
<p style="top:145.1pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">sion, B.Y.; Project Administration, B.Y.; Funding Acquisition, B.Y. All authors have read and agreed</span></p>
<p style="top:156.9pt;left:167.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">to the published version of the manuscript.</span></p>
<p style="top:174.6pt;left:167.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Funding:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> This study was supported by funding from NCI/NIH (R01 CA136937).</span></p>
<p style="top:192.2pt;left:167.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Data Availability Statement:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> No new data were created or analyzed in this study.</span></p>
<p style="top:209.9pt;left:167.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Con&#xfb02;icts of Interest:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> The authors declare no con&#xfb02;ict of interest.</span></p>
<p style="top:231.6pt;left:36.0pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">References</span></b></p>
<p style="top:246.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">1.</span></p>
<p style="top:246.8pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Hanif, F.; Muzaffar, K.; Perveen, K.; Malhi, S.M.; Simjee Sh, U. Glioblastoma Multiforme: A Review of its Epidemiology and</span></p>
<p style="top:258.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pathogenesis through Clinical Presentation and Treatment.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Asian Pac. J. Cancer Prev.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 18</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 3&#x2013;9. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:269.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2.</span></p>
<p style="top:269.9pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Ostrom, Q.T.; Ciof&#xfb01;, G.; Gittleman, H.; Patil, N.; Waite, K.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS Statistical Report: Primary</span></p>
<p style="top:281.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012&#x2013;2016.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Neuro Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, v1&#x2013;v100.</span></p>
<p style="top:292.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:304.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">3.</span></p>
<p style="top:304.3pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Stupp, R.; Taillibert, S.; Kanner, A.; Read, W.; Steinberg, D.; Lhermitte, B.; Toms, S.; Idbaih, A.; Ahluwalia, M.S.; Fink, K.; et al.</span></p>
<p style="top:315.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients</span></p>
<p style="top:327.4pt;left:57.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">with Glioblastoma: A Randomized Clinical Trial.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> JAMA</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 318</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 2306&#x2013;2316. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:338.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">4.</span></p>
<p style="top:338.8pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Cantrell, J.N.; Waddle, M.R.; Rotman, M.; Peterson, J.L.; Ruiz-Garcia, H.; Heckman, M.G.; Quinones-Hinojosa, A.; Rosenfeld,</span></p>
<p style="top:350.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">S.S.; Brown, P.D.; Tri&#xfb01;letti, D.M. Progress Toward Long-Term Survivors of Glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Mayo Clin. Proc.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 94</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1278&#x2013;1286.</span></p>
<p style="top:361.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:373.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">5.</span></p>
<p style="top:373.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Kast, R.E.; Boockvar, J.A.; Bruning, A.; Cappello, F.; Chang, W.W.; Cvek, B.; Dou, Q.P.; Duenas-Gonzalez, A.; Efferth, T.; Focosi,</span></p>
<p style="top:384.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">D.; et al. A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with</span></p>
<p style="top:396.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncotarget</span></i></p>
<p style="top:407.9pt;left:57.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2013</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 4</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 502&#x2013;530. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:419.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">6.</span></p>
<p style="top:419.4pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Hernandez, J.J.; Pryszlak, M.; Smith, L.; Yanchus, C.; Kurji, N.; Shahani, V.M.; Molinski, S.V. Giving Drugs a Second Chance:</span></p>
<p style="top:431.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Front. Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 7</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span></p>
<p style="top:442.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">273. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:454.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">7.</span></p>
<p style="top:453.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Ghofrani, H.A.; Osterloh, I.H.; Grimminger, F. Sildena&#xfb01;l: From angina to erectile dysfunction to pulmonary hypertension and</span></p>
<p style="top:465.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">beyond.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Nat. Rev. Drug Discov.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2006</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 5</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 689&#x2013;702. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:477.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">8.</span></p>
<p style="top:476.9pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Zhou, J.; Patel, T.R.; Sirianni, R.W.; Strohbehn, G.; Zheng, M.Q.; Duong, N.; Schafbauer, T.; Huttner, A.J.; Huang, Y.; Carson,</span></p>
<p style="top:488.6pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">R.E.; et al. Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Proc. Natl. Acad. Sci. USA</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 110</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span></p>
<p style="top:500.0pt;left:57.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">11751&#x2013;11756. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:511.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">9.</span></p>
<p style="top:511.6pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients with High</span></p>
<p style="top:523.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Grade Gliomas. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT03971734</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:534.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">10.</span></p>
<p style="top:534.6pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients with Grade III/ IV Glioma. Available</span></p>
<p style="top:546.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://www.clinicaltrials.gov/ct2/show/NCT03927274</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:557.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">11.</span></p>
<p style="top:557.6pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Neftel, C.; Laffy, J.; Filbin, M.G.; Hara, T.; Shore, M.E.; Rahme, G.J.; Richman, A.R.; Silverbush, D.; Shaw, M.L.; Hebert, C.M.; et al.</span></p>
<p style="top:569.0pt;left:57.2pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Cell</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 178</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 835&#x2013;849.e21. [</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">]</span></p>
<p style="top:580.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:592.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">12.</span></p>
<p style="top:592.0pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Phillips, H.S.; Kharbanda, S.; Chen, R.; Forrest, W.F.; Soriano, R.H.; Wu, T.D.; Misra, A.; Nigro, J.M.; Colman, H.; Soroceanu,</span></p>
<p style="top:603.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">L.; et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble</span></p>
<p style="top:615.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">stages in neurogenesis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancer Cell</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2006</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 157&#x2013;173. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:626.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">13.</span></p>
<p style="top:626.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Cohen, A.L.; Holmen, S.L.; Colman, H. IDH1 and IDH2 mutations in gliomas.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Curr. Neurol. Neurosci. Rep.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 345. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:638.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">14.</span></p>
<p style="top:638.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Verhaak, R.G.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.; Mesirov, J.P.; et al.</span></p>
<p style="top:649.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Integrated genomic analysis identi&#xfb01;es clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA,</span></p>
<p style="top:661.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">IDH1, EGFR, and NF1.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancer Cell</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2010</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 17</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 98&#x2013;110. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:672.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">15.</span></p>
<p style="top:672.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Parker, N.R.; Khong, P.; Parkinson, J.F.; Howell, V.M.; Wheeler, H.R. Molecular heterogeneity in glioblastoma: Potential clinical</span></p>
<p style="top:684.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">implications.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Front. Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 5</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 55. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:695.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">16.</span></p>
<p style="top:695.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Rutherford, K.D.; Mazandu, G.K.; Mulder, N.J. A systems-level analysis of drug-target-disease associations for drug repositioning.</span></p>
<p style="top:707.1pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Brief. Funct. Genom.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 17</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 34&#x2013;41. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:718.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">17.</span></p>
<p style="top:718.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Chen, Y.; Gao, Z.; Wang, B.; Xu, R. Towards precision medicine-based therapies for glioblastoma: Interrogating human disease</span></p>
<p style="top:730.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">genomics and mouse phenotypes.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> BMC Genom.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 17</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (Suppl. S7), 516. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:741.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">18.</span></p>
<p style="top:741.6pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Spina, R.; Voss, D.M.; Asnaghi, L.; Sloan, A.; Bar, E.E. Flow Cytometry-based Drug Screening System for the Identi&#xfb01;cation of</span></p>
<p style="top:753.2pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Vis. Exp.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">22 of 29</span></p>
<p style="top:98.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">19.</span></p>
<p style="top:98.3pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Yang, E.H.; Shah, S.; Criley, J.M. Digitalis toxicity: A fading but crucial complication to recognize.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Am. J. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2012</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 125</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 337&#x2013;343.</span></p>
<p style="top:109.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:121.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">20.</span></p>
<p style="top:121.4pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Berges, R.; Denicolai, E.; Tchoghandjian, A.; Baeza-Kallee, N.; Honore, S.; Figarella-Branger, D.; Braguer, D. Proscillaridin A exerts</span></p>
<p style="top:132.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">anti-tumor effects through GSK3beta activation and alteration of microtubule dynamics in glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cell Death Dis.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span></p>
<p style="top:144.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">984. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:155.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">21.</span></p>
<p style="top:155.7pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Tan, Q.; Yan, X.; Song, L.; Yi, H.; Li, P.; Sun, G.; Yu, D.; Li, L.; Zeng, Z.; Guo, Z. Induction of Mitochondrial Dysfunction and</span></p>
<p style="top:167.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Oxidative Damage by Antibiotic Drug Doxycycline Enhances the Responsiveness of Glioblastoma to Chemotherapy.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Med. Sci.</span></i></p>
<p style="top:178.8pt;left:57.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Monit.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 23</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 4117&#x2013;4125. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:190.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">22.</span></p>
<p style="top:190.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Lamb, R.; Ozsvari, B.; Lisanti, C.L.; Tanowitz, H.B.; Howell, A.; Martinez-Outschoorn, U.E.; Sotgia, F.; Lisanti, M.P. Antibiotics</span></p>
<p style="top:201.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious</span></p>
<p style="top:213.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">disease.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 6</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 4569&#x2013;4584. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:224.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">23.</span></p>
<p style="top:224.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Karpel-Massler, G.; Kast, R.E.; Siegelin, M.D.; Dwucet, A.; Schneider, E.; Westhoff, M.A.; Wirtz, C.R.; Chen, X.Y.; Halatsch, M.E.;</span></p>
<p style="top:236.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Bolm, C. Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modi&#xfb01;cation.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Neurochem. Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 42</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span></p>
<p style="top:247.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">3382&#x2013;3389. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:259.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">24.</span></p>
<p style="top:259.4pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Mulkearns-Hubert, E.E.; Torre-Healy, L.A.; Silver, D.J.; Eurich, J.T.; Bayik, D.; Serbinowski, E.; Hitomi, M.; Zhou, J.; Przychodzen,</span></p>
<p style="top:270.9pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">B.; Zhang, R.; et al. Development of a Cx46 Targeting Strategy for Cancer Stem Cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Cell Rep.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 27</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 1062&#x2013;1072.e5. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:282.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">25.</span></p>
<p style="top:282.5pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Xiao, Z.X.; Chen, R.Q.; Hu, D.X.; Xie, X.Q.; Yu, S.B.; Chen, X.Q. Identi&#xfb01;cation of repaglinide as a therapeutic drug for glioblastoma</span></p>
<p style="top:293.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">multiforme.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Biochem. Biophys. Res. Commun.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 488</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 33&#x2013;39. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:305.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">26.</span></p>
<p style="top:305.3pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Shchors, K.; Massaras, A.; Hanahan, D. Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed</span></p>
<p style="top:316.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Drugs Elicits Cell-Lethal Autophagy and Therapeutic Bene&#xfb01;t.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancer Cell</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 28</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 456&#x2013;471. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:328.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">27.</span></p>
<p style="top:328.3pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Keatley, K.; Stromei-Cleroux, S.; Wiltshire, T.; Rajala, N.; Burton, G.; Holt, W.V.; Littlewood, D.T.J.; Briscoe, A.G.; Jung, J.;</span></p>
<p style="top:340.0pt;left:57.2pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Ashkan, K.; et al. Integrated Approach Reveals Role of Mitochondrial Germ-Line Mutation F18L in Respiratory Chain, Oxidative</span></p>
<p style="top:351.4pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Alterations, Drug Sensitivity, and Patient Prognosis in Glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 20</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 3364. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:362.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">28.</span></p>
<p style="top:362.9pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Hayashi, K.; Michiue, H.; Yamada, H.; Takata, K.; Nakayama, H.; Wei, F.Y.; Fujimura, A.; Tazawa, H.; Asai, A.; Ogo, N.; et al.</span></p>
<p style="top:374.4pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Sci. Rep.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 6</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span></p>
<p style="top:386.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">23372. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:397.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">29.</span></p>
<p style="top:397.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Schmidt, L.; Baskaran, S.; Johansson, P.; Padhan, N.; Matuszewski, D.; Green, L.C.; El&#xfb01;neh, L.; Wee, S.; Haggblad, M.; Martens,</span></p>
<p style="top:409.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">U.; et al. Case-speci&#xfb01;c potentiation of glioblastoma drugs by pterostilbene.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 7</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 73200&#x2013;73215. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:420.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">30.</span></p>
<p style="top:420.4pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Mihajluk, K.; Simms, C.; Reay, M.; Madureira, P.A.; Howarth, A.; Murray, P.; Nasser, S.; Duckworth, C.A.; Pritchard, D.M.;</span></p>
<p style="top:431.9pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Pilkington, G.J.; et al. IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor</span></p>
<p style="top:443.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">receptor inhibitor resistance in adult high grade gliomas.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancer Lett.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 458</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 29&#x2013;38. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:455.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">31.</span></p>
<p style="top:455.1pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Takabe, H.; Warnken, Z.N.; Zhang, Y.; Davis, D.A.; Smyth, H.D.C.; Kuhn, J.G.; Weitman, S.; Williams Iii, R.O. A Repurposed Drug</span></p>
<p style="top:466.5pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component</span></p>
<p style="top:478.0pt;left:57.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">with a Polymer Carrier.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Pharmaceutics</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 10</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 60. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:489.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">32.</span></p>
<p style="top:489.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Assad Kahn, S.; Costa, S.L.; Gholamin, S.; Nitta, R.T.; Dubois, L.G.; Feve, M.; Zeniou, M.; Coelho, P.L.; El-Habr, E.; Cadusseau,</span></p>
<p style="top:501.0pt;left:57.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">J.; et al. The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKCdelta-dependent inhibition of the AKT</span></p>
<p style="top:512.5pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">pathway.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> EMBO Mol. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 511&#x2013;526. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:524.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">33.</span></p>
<p style="top:524.1pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Huang, H.; Huang, Y.; Chen, Y.; Luo, Z.; Zhang, Z.; Sun, R.; Wan, Z.; Sun, J.; Lu, B.; Zhang, L.; et al. A novel immunochemotherapy</span></p>
<p style="top:535.5pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">based on targeting of cyclooxygenase and induction of immunogenic cell death.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Biomaterials</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 270</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 120708. [</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">]</span></p>
<p style="top:547.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:558.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">34.</span></p>
<p style="top:558.6pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Assefnia, S.; Dakshanamurthy, S.; Guidry Auvil, J.M.; Hampel, C.; Anastasiadis, P.Z.; Kallakury, B.; Uren, A.; Foley, D.W.; Brown,</span></p>
<p style="top:570.1pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">M.L.; Shapiro, L.; et al. Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: Common target, common therapies.</span></p>
<p style="top:581.6pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 5</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1458&#x2013;1474. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:593.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">35.</span></p>
<p style="top:593.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Sareddy, G.R.; Geeviman, K.; Ramulu, C.; Babu, P.P. The nonsteroidal anti-in&#xfb02;ammatory drug celecoxib suppresses the growth</span></p>
<p style="top:604.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and induces apoptosis of human glioblastoma cells via the NF-</span><span style="font-family:EURM10,serif;font-size:9.0pt">&#x3ba;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">B pathway.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Neurooncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2012</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 106</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 99&#x2013;109. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:616.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">36.</span></p>
<p style="top:616.2pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Shishodia, S.; Koul, D.; Aggarwal, B.B. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation</span></p>
<p style="top:627.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: Correlation with</span></p>
<p style="top:639.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">suppression of COX-2 synthesis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Immunol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2004</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 173</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 2011&#x2013;2022. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:650.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">37.</span></p>
<p style="top:650.5pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Ha, W.; Sevim-Nalkiran, H.; Zaman, A.M.; Matsuda, K.; Khasraw, M.; Nowak, A.K.; Chung, L.; Baxter, R.C.; McDonald, K.L.</span></p>
<p style="top:662.1pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Sci. Rep.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span></p>
<p style="top:673.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2905. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:685.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">38.</span></p>
<p style="top:685.1pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Sleire, L.; Skeie, B.S.; Netland, I.A.; Forde, H.E.; Dodoo, E.; Selheim, F.; Leiss, L.; Heggdal, J.I.; Pedersen, P.H.; Wang, J.; et al.</span></p>
<p style="top:696.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Drug repurposing: Sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-,</span></p>
<p style="top:708.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">leading to glutathione depletion.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncogene</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 34</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 5951&#x2013;5959. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:719.7pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">39.</span></p>
<p style="top:719.6pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Robe, P.A.; Martin, D.H.; Nguyen-Khac, M.T.; Artesi, M.; Deprez, M.; Albert, A.; Vanbelle, S.; Cali&#xfb01;ce, S.; Bredel, M.; Bours,</span></p>
<p style="top:731.1pt;left:57.2pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">V. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of</span></p>
<p style="top:742.7pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">progressing malignant gliomas in adults.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> BMC Cancer</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2009</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 372. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:754.2pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">40.</span></p>
<p style="top:754.1pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Mattoo, A.R.; Joun, A.; Jessup, J.M. Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP</span></p>
<p style="top:765.7pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Inhibition.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Mol. Cancer Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 17</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 42&#x2013;53. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">23 of 29</span></p>
<p style="top:98.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">41.</span></p>
<p style="top:98.2pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Hsu, S.P.C.; Kuo, J.S.; Chiang, H.C.; Wang, H.E.; Wang, Y.S.; Huang, C.C.; Huang, Y.C.; Chi, M.S.; Mehta, M.P.; Chi, K.H.</span></p>
<p style="top:109.8pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Temozolomide, sirolimus and chloroquine is a new therapeutic combination that synergizes to disrupt lysosomal function and</span></p>
<p style="top:121.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">cholesterol homeostasis in GBM cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 6883&#x2013;6896. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:132.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">42.</span></p>
<p style="top:132.9pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7"> https://clinicaltrials.gov/</span></p>
<p style="top:144.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">ct2/show/NCT02238496</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:155.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">43.</span></p>
<p style="top:155.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Zhang, Y.; Cruickshanks, N.; Yuan, F.; Wang, B.; Pahuski, M.; Wulfkuhle, J.; Gallagher, I.; Koeppel, A.F.; Hatef, S.; Papanicolas,</span></p>
<p style="top:167.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">C.; et al. Targetable T-type Calcium Channels Drive Glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancer Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 77</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 3479&#x2013;3490. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:178.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">44.</span></p>
<p style="top:178.9pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Chen, Y.; Xu, R. Drug repurposing for glioblastoma based on molecular subtypes.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> J. Biomed. Inform.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 64</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 131&#x2013;138. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:190.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">45.</span></p>
<p style="top:190.4pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Lee, H.; Kang, S.; Kim, W. Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures.</span></p>
<p style="top:201.8pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PLoS ONE</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 11</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, e0150460. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:213.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">46.</span></p>
<p style="top:213.3pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Cheng, H.W.; Liang, Y.H.; Kuo, Y.L.; Chuu, C.P.; Lin, C.Y.; Lee, M.H.; Wu, A.T.; Yeh, C.T.; Chen, E.I.; Whang-Peng, J.; et al.</span></p>
<p style="top:224.8pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Identi&#xfb01;cation of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene</span></p>
<p style="top:236.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">expression data.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cell Death Dis.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 6</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, e1753. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:247.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">47.</span></p>
<p style="top:247.9pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Chu, C.W.; Ko, H.J.; Chou, C.H.; Cheng, T.S.; Cheng, H.W.; Liang, Y.H.; Lai, Y.L.; Lin, C.Y.; Wang, C.; Loh, J.K.; et al. Thioridazine</span></p>
<p style="top:259.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Enhances P62-Mediated Autophagy and Apoptosis Through Wnt/beta-Catenin Signaling Pathway in Glioma Cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Int. J. Mol.</span></i></p>
<p style="top:270.9pt;left:57.3pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 20</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 473. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:282.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">48.</span></p>
<p style="top:282.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Johannessen, T.C.; Hasan-Olive, M.M.; Zhu, H.; Denisova, O.; Grudic, A.; Latif, M.A.; Saed, H.; Varughese, J.K.; Rosland, G.V.;</span></p>
<p style="top:293.8pt;left:57.2pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Yang, N.; et al. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Int. J. Cancer</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 144</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span></p>
<p style="top:305.4pt;left:57.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">1735&#x2013;1745. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:316.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">49.</span></p>
<p style="top:317.0pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Omoruyi, S.I.; Ekpo, O.E.; Semenya, D.M.; Jardine, A.; Prince, S. Exploitation of a novel phenothiazine derivative for its anti-cancer</span></p>
<p style="top:328.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">activities in malignant glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Apoptosis</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 25</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 261&#x2013;274. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:339.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">50.</span></p>
<p style="top:339.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Oliva, C.R.; Zhang, W.; Langford, C.; Suto, M.J.; Griguer, C.E. Repositioning chlorpromazine for treating chemoresistant glioma</span></p>
<p style="top:351.5pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 37568&#x2013;37583. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:362.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:374.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">51.</span></p>
<p style="top:374.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Kang, S.; Lee, J.M.; Jeon, B.; Elkamhawy, A.; Paik, S.; Hong, J.; Oh, S.J.; Paek, S.H.; Lee, C.J.; Hassan, A.H.E.; et al. Repositioning</span></p>
<p style="top:385.9pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">of the antipsychotic tri&#xfb02;uoperazine: Synthesis, biological evaluation and in silico study of tri&#xfb02;uoperazine analogs as anti-</span></p>
<p style="top:397.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">glioblastoma agents.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Eur. J. Med. Chem.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 151</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 186&#x2013;198. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:409.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">52.</span></p>
<p style="top:409.0pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Dong, Y.; Furuta, T.; Sabit, H.; Kitabayashi, T.; Jiapaer, S.; Kobayashi, M.; Ino, Y.; Todo, T.; Teng, L.; Hirao, A.; et al. Identi&#xfb01;cation</span></p>
<p style="top:420.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">of antipsychotic drug &#xfb02;uspirilene as a potential anti-glioma stem cell drug.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 111728&#x2013;111741. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:432.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">53.</span></p>
<p style="top:431.9pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Kim, H.; Chong, K.; Ryu, B.K.; Park, K.J.; Yu, M.O.; Lee, J.; Chung, S.; Choi, S.; Park, M.J.; Chung, Y.G.; et al. Repurposing</span></p>
<p style="top:443.5pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Pen&#xfb02;uridol in Combination with Temozolomide for the Treatment of Glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 11</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 1310. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:455.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">54.</span></p>
<p style="top:455.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Karpel-Massler, G.; Kast, R.E.; Westhoff, M.A.; Dwucet, A.; Welscher, N.; Nonnenmacher, L.; Hlavac, M.; Siegelin, M.D.; Wirtz,</span></p>
<p style="top:466.6pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">C.R.; Debatin, K.M.; et al. Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma</span></p>
<p style="top:478.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">cell lines and enhances temozolomide&#x2019;s antiproliferative effect.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Neurooncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 122</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 21&#x2013;33. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:489.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">55.</span></p>
<p style="top:489.4pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Wang, Y.; Huang, N.; Li, H.; Liu, S.; Chen, X.; Yu, S.; Wu, N.; Bian, X.W.; Shen, H.Y.; Li, C.; et al. Promoting oligodendroglial-</span></p>
<p style="top:501.0pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">oriented differentiation of glioma stem cell: A repurposing of quetiapine for the treatment of malignant glioma.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span></p>
<p style="top:512.5pt;left:57.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 37511&#x2013;37524. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:524.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">56.</span></p>
<p style="top:524.0pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Suzuki, S.; Yamamoto, M.; Togashi, K.; Sanomachi, T.; Sugai, A.; Seino, S.; Yoshioka, T.; Kitanaka, C.; Okada, M.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> In vitro</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> and</span></p>
<p style="top:535.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">in vivo</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety</span></p>
<p style="top:547.0pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">pro&#xfb01;le.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 10</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 3547&#x2013;3558. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:558.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">57.</span></p>
<p style="top:558.6pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Kwon, J.; Kim, D.H.; Park, J.M.; Park, Y.H.; Hwang, Y.H.; Wu, H.G.; Shin, K.H.; Kim, I.A. Targeting Phosphatidylinositol 4-Kinase</span></p>
<p style="top:570.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">IIIalpha for Radiosensitization: A Potential Model of Drug Repositioning Using an Anti-Hepatitis C Viral Agent.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Int. J. Radiat.</span></i></p>
<p style="top:581.6pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Oncol. Biol. Phys.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 96</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 867&#x2013;876. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:593.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">58.</span></p>
<p style="top:593.1pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Volpin, F.; Casaos, J.; Sesen, J.; Mangraviti, A.; Choi, J.; Gorelick, N.; Frikeche, J.; Lott, T.; Felder, R.; Scotland, S.J.; et al. Use of an</span></p>
<p style="top:604.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncogene</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 36</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 3037&#x2013;3047. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:616.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">59.</span></p>
<p style="top:616.2pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Okada, M.; Kuramoto, K.; Takeda, H.; Watarai, H.; Sakaki, H.; Seino, S.; Seino, M.; Suzuki, S.; Kitanaka, C. The novel JNK inhibitor</span></p>
<p style="top:627.6pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">AS602801 inhibits cancer stem cells in vitro and in vivo.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 7</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 27021&#x2013;27032. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:639.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">60.</span></p>
<p style="top:639.0pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Okada, M.; Takeda, H.; Sakaki, H.; Kuramoto, K.; Suzuki, S.; Sanomachi, T.; Togashi, K.; Seino, S.; Kitanaka, C. Repositioning</span></p>
<p style="top:650.5pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">CEP-1347, a chemical agent originally developed for the treatment of Parkinson&#x2019;s disease, as an anti-cancer stem cell drug.</span></p>
<p style="top:662.1pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 94872&#x2013;94882. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:673.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">61.</span></p>
<p style="top:673.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Ghosh, J.C.; Siegelin, M.D.; Vaira, V.; Faversani, A.; Tavecchio, M.; Chae, Y.C.; Lisanti, S.; Rampini, P.; Giroda, M.; Caino, M.C.; et al.</span></p>
<p style="top:685.1pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Adaptive mitochondrial reprogramming and resistance to PI3K therapy.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Natl. Cancer Inst.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 107</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:696.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">62.</span></p>
<p style="top:696.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Shi, Y.; Guryanova, O.A.; Zhou, W.; Liu, C.; Huang, Z.; Fang, X.; Wang, X.; Chen, C.; Wu, Q.; He, Z.; et al. Ibrutinib inactivates</span></p>
<p style="top:708.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Sci. Transl. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 10</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:719.7pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">63.</span></p>
<p style="top:719.6pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Pandey, V.; Ranjan, N.; Narne, P.; Babu, P.P. Roscovitine effectively enhances antitumor activity of temozolomide</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> and</span></p>
<p style="top:731.2pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Sci. Rep.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 5012. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:742.7pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">64.</span></p>
<p style="top:742.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Study of Binimetinib with Encorafenib in Adults with Recurrent BRAF V600-Mutated HGG. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7"> https://clinicaltrials.</span></p>
<p style="top:754.2pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">gov/ct2/show/NCT03973918</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">24 of 29</span></p>
<p style="top:98.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">65.</span></p>
<p style="top:98.2pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Triscott, J.; Lee, C.; Hu, K.; Fotovati, A.; Berns, R.; Pambid, M.; Luk, M.; Kast, R.E.; Kong, E.; Toyota, E.; et al. Disul&#xfb01;ram, a</span></p>
<p style="top:109.8pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.</span></p>
<p style="top:121.3pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2012</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 3</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1112&#x2013;1123. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:132.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">66.</span></p>
<p style="top:132.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Paranjpe, A.; Zhang, R.; Ali-Osman, F.; Bobustuc, G.C.; Srivenugopal, K.S. Disul&#xfb01;ram is a direct and potent inhibitor of human</span></p>
<p style="top:144.4pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating</span></p>
<p style="top:155.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">DNA damage.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Carcinogenesis</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 35</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 692&#x2013;702. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:167.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">67.</span></p>
<p style="top:167.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Lun, X.; Wells, J.C.; Grinshtein, N.; King, J.C.; Hao, X.; Dang, N.H.; Wang, X.; Aman, A.; Uehling, D.; Datti, A.; et al. Disul&#xfb01;ram</span></p>
<p style="top:178.9pt;left:57.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Clin. Cancer</span></i></p>
<p style="top:190.3pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 22</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 3860&#x2013;3875. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:201.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">68.</span></p>
<p style="top:201.8pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Madala, H.R.; Punganuru, S.R.; Ali-Osman, F.; Zhang, R.; Srivenugopal, K.S. Brain- and brain tumor-penetrating disul&#xfb01;ram</span></p>
<p style="top:213.4pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">nanoparticles: Sequence of cytotoxic events and ef&#xfb01;cacy in human glioma cell lines and intracranial xenografts.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span></p>
<p style="top:224.9pt;left:57.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 3459&#x2013;3482. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:236.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">69.</span></p>
<p style="top:236.4pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Perez-Perez, D.; Reyes-Vidal, I.; Chavez-Cortez, E.G.; Sotelo, J.; Magana-Maldonado, R. Methylxanthines: Potential Therapeutic</span></p>
<p style="top:247.9pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Agents for Glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Pharmaceuticals</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 130. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:259.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">70.</span></p>
<p style="top:259.3pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Sachkova, A.; Sperling, S.; Mielke, D.; Schatlo, B.; Rohde, V.; Ninkovic, M. Combined Applications of Repurposed Drugs and</span></p>
<p style="top:270.9pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Their Detrimental Effects on Glioblastoma Cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Anticancer Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 39</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 207&#x2013;214. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:282.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">71.</span></p>
<p style="top:282.4pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Benavides-Serrato, A.; Saunders, J.T.; Holmes, B.; Nishimura, R.N.; Lichtenstein, A.; Gera, J. Repurposing Potential of Riluzole as</span></p>
<p style="top:293.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 344. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:305.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">72.</span></p>
<p style="top:305.3pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Grif&#xfb01;n, M.; Khan, R.; Basu, S.; Smith, S. Ion Channels as Therapeutic Targets in High Grade Gliomas.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 3068.</span></p>
<p style="top:316.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:328.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">73.</span></p>
<p style="top:328.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Booth, L.; Malkin, M.; Dent, P. Repurposing Tec&#xfb01;dera for cancer.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Aging</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1289&#x2013;1290. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:339.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">74.</span></p>
<p style="top:339.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Damiani, E.; Yuecel, R.; Wallace, H.M. Repurposing of idebenone as a potential anti-cancer agent.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Biochem. J.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 476</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 245&#x2013;259.</span></p>
<p style="top:351.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:362.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">75.</span></p>
<p style="top:363.0pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Wu, J.; Su, H.K.; Yu, Z.H.; Xi, S.Y.; Guo, C.C.; Hu, Z.Y.; Qu, Y.; Cai, H.P.; Zhao, Y.Y.; Zhao, H.F.; et al. Skp2 modulates proliferation,</span></p>
<p style="top:374.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">senescence and tumorigenesis of glioma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancer Cell Int.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 20</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 71. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:386.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">76.</span></p>
<p style="top:386.0pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Takwi, A.A.; Li, Y.; Becker Buscaglia, L.E.; Zhang, J.; Choudhury, S.; Park, A.K.; Liu, M.; Young, K.H.; Park, W.Y.; Martin, R.C.; et al.</span></p>
<p style="top:397.4pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">A statin-regulated microRNA represses human c-Myc expression and function.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> EMBO Mol. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2012</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 4</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 896&#x2013;909. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:409.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:420.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">77.</span></p>
<p style="top:420.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Li, Y.; Wei, X.; Wang, Q.; Li, W.; Yang, T. Inverse screening of Simvastatin kinase targets from glioblastoma druggable kinome.</span></p>
<p style="top:432.0pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Comput. Biol. Chem.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 86</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 107243. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:443.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">78.</span></p>
<p style="top:443.4pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Peng, P.; Wei, W.; Long, C.; Li, J. Atorvastatin augments temozolomide&#x2019;s ef&#xfb01;cacy in glioblastoma via prenylation-dependent</span></p>
<p style="top:455.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">inhibition of Ras signaling.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Biochem. Biophys. Res. Commun.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 489</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 293&#x2013;298. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:466.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">79.</span></p>
<p style="top:466.4pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Roos, A.; Dhruv, H.D.; Mathews, I.T.; Inge, L.J.; Tuncali, S.; Hartman, L.K.; Chow, D.; Millard, N.; Yin, H.H.; Kloss, J.; et al.</span></p>
<p style="top:477.9pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Identi&#xfb01;cation of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.</span></p>
<p style="top:489.5pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 12234&#x2013;12246. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:501.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">80.</span></p>
<p style="top:500.9pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Inada, M.; Shindo, M.; Kobayashi, K.; Sato, A.; Yamamoto, Y.; Akasaki, Y.; Ichimura, K.; Tanuma, S.I. Anticancer effects of a</span></p>
<p style="top:512.5pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">non-narcotic opium alkaloid medicine, papaverine, in human glioblastoma cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> PLoS ONE</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 14</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, e0216358. [</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">]</span></p>
<p style="top:524.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:535.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">81.</span></p>
<p style="top:535.5pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">John, S.; Sivakumar, K.C.; Mishra, R. Bacoside A Induces Tumor Cell Death in Human Glioblastoma Cell Lines through</span></p>
<p style="top:547.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Catastrophic Macropinocytosis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Front. Mol. Neurosci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 10</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 171. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:558.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">82.</span></p>
<p style="top:558.5pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Eales, K.L.; Wilkinson, E.A.; Cruickshank, G.; Tucker, J.H.R.; Tennant, D.A. Vertepor&#xfb01;n selectively kills hypoxic glioma cells</span></p>
<p style="top:570.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">through iron-binding and increased production of reactive oxygen species.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Sci. Rep.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 14358. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:581.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">83.</span></p>
<p style="top:581.6pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Zheng, M.; Sun, W.; Gao, S.; Luan, S.; Li, D.; Chen, R.; Zhang, Q.; Chen, L.; Huang, J.; Li, H. Structure based discovery of clomifene</span></p>
<p style="top:593.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">as a potent inhibitor of cancer-associated mutant IDH1.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 44255&#x2013;44265. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:604.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">84.</span></p>
<p style="top:604.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Killick-Cole, C.L.; Singleton, W.G.B.; Bienemann, A.S.; Asby, D.J.; Wyatt, M.J.; Boulter, L.J.; Barua, N.U.; Gill, S.S. Repurposing the</span></p>
<p style="top:616.1pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> PLoS ONE</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, e0176855.</span></p>
<p style="top:627.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:639.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">85.</span></p>
<p style="top:639.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Liao, J.K.; Laufs, U. Pleiotropic effects of statins.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Annu. Rev. Pharmacol. Toxicol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2005</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 45</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 89&#x2013;118. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:650.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">86.</span></p>
<p style="top:650.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pinheiro, R.; Braga, C.; Santos, G.; Bronze, M.R.; Perry, M.J.; Moreira, R.; Brites, D.; Falcao, A.S. Targeting Gliomas: Can a New</span></p>
<p style="top:662.1pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Alkylating Hybrid Compound Make a Difference?</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> ACS Chem. Neurosci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 50&#x2013;59. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:673.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">87.</span></p>
<p style="top:673.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Sorafenib Tosylate, Valproic Acid, and Sildena&#xfb01;l Citrate in Treating Patients with Recurrent High-Grade Glioma. Available online:</span></p>
<p style="top:685.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">https://clinicaltrials.gov/ct2/show/NCT01817751</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:696.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">88.</span></p>
<p style="top:696.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children with High Grade Gliomas or</span></p>
<p style="top:708.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Diffuse Intrinsic Pontine Glioma. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT00879437</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February</span></p>
<p style="top:719.7pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2021).</span></p>
<p style="top:731.2pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">89.</span></p>
<p style="top:731.2pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Huang, J.; Campian, J.L.; Gujar, A.D.; Tran, D.D.; Lockhart, A.C.; DeWees, T.A.; Tsien, C.I.; Kim, A.H. A phase I study to repurpose</span></p>
<p style="top:742.6pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">disul&#xfb01;ram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> J. Neurooncol.</span></i></p>
<p style="top:754.2pt;left:57.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 128</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 259&#x2013;266. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">25 of 29</span></p>
<p style="top:98.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">90.</span></p>
<p style="top:98.3pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Jakola, A.S.; Werlenius, K.; Mudaisi, M.; Hylin, S.; Kinhult, S.; Bartek, J., Jr.; Salvesen, O.; Carlsen, S.M.; Strandeus, M.; Lindskog,</span></p>
<p style="top:109.7pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">M.; et al. Disul&#xfb01;ram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent</span></p>
<p style="top:121.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">glioblastoma (DIRECT): Study protocol for a randomized controlled trial.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> F1000Res</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 7</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1797. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:132.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">91.</span></p>
<p style="top:132.7pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Disul&#xfb01;ram in Recurrent Glioblastoma. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT02678975</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> (accessed on 1</span></p>
<p style="top:144.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">February 2021).</span></p>
<p style="top:155.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">92.</span></p>
<p style="top:155.9pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Poser, S.W.; Otto, O.; Arps-Forker, C.; Ge, Y.; Herbig, M.; Andree, C.; Gruetzmann, K.; Adasme, M.F.; Stodolak, S.; Nikolakopoulou,</span></p>
<p style="top:167.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">P.; et al. Controlling distinct signaling states in cultured cancer cells provides a new platform for drug discovery.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> FASEB J.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span></p>
<p style="top:178.8pt;left:57.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">33</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 9235&#x2013;9249. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:190.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">93.</span></p>
<p style="top:190.4pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Agnihotri, S.; Mansouri, S.; Burrell, K.; Li, M.; Mamatjan, Y.; Liu, J.; Nejad, R.; Kumar, S.; Jalali, S.; Singh, S.K.; et al. Ketoconazole</span></p>
<p style="top:201.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Clin. Cancer Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 25</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 844&#x2013;855. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:213.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">94.</span></p>
<p style="top:213.4pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Azoles Targeting Recurrent High Grade Gliomas. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT03763396</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> (accessed</span></p>
<p style="top:224.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">on 1 February 2021).</span></p>
<p style="top:236.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">95.</span></p>
<p style="top:236.4pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Wehbe, M.; Malhotra, A.K.; Anantha, M.; Lo, C.; Dragowska, W.H.; Dos Santos, N.; Bally, M.B. Development of a copper-clioquinol</span></p>
<p style="top:247.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">formulation suitable for intravenous use.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Drug Deliv. Transl. Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 239&#x2013;251. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:259.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">96.</span></p>
<p style="top:259.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Shipman, L. Glioma: Repurposed drugs combined to amplify autophagy.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Nat. Rev. Cancer</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 15</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 636. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:270.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">97.</span></p>
<p style="top:270.9pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Hribar, K.C.; Wheeler, C.J.; Bazarov, A.; Varshneya, K.; Yamada, R.; Buckley, P.; Patil, C.G. A Simple Three-dimensional Hydrogel</span></p>
<p style="top:282.4pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Platform Enables Ex Vivo Cell Culture of Patient and PDX Tumors for Assaying Their Response to Clinically Relevant Therapies.</span></p>
<p style="top:293.9pt;left:57.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Mol. Cancer Ther.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 18</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 718&#x2013;725. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:305.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">98.</span></p>
<p style="top:305.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients with Recurrent LGG or HGG with a BRAF Aberration.</span></p>
<p style="top:316.9pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT04201457</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:328.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">99.</span></p>
<p style="top:328.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Maraka, S.; Groves, M.D.; Penas-Prado, M. Reply to Unexpectedly low rates of neuropsychiatric adverse effects associated with</span></p>
<p style="top:339.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">me&#xfb02;oquine repurposed for the treatment of glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancer</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 125</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1385&#x2013;1386. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:351.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">100.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Nevin, R.L. Unexpectedly low rates of neuropsychiatric adverse effects associated with me&#xfb02;oquine repurposed for the treatment</span></p>
<p style="top:362.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">of glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancer</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 125</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1384&#x2013;1385. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:374.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">101.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Maraka, S.; Groves, M.D.; Mammoser, A.G.; Melguizo-Gavilanes, I.; Conrad, C.A.; Tremont-Lukats, I.W.; Loghin, M.E.; O&#x2019;Brien,</span></p>
<p style="top:386.0pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">B.J.; Puduvalli, V.K.; Sulman, E.P.; et al. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, me&#xfb02;oquine,</span></p>
<p style="top:397.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancer</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 125</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 424&#x2013;433. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:409.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">102.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Bai, R.Y.; Staedtke, V.; Rudin, C.M.; Bunz, F.; Riggins, G.J. Effective treatment of diverse medulloblastoma models with</span></p>
<p style="top:420.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">mebendazole and its impact on tumor angiogenesis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Neuro Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 17</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 545&#x2013;554. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:432.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">103.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Bodhinayake, I.; Symons, M.; Boockvar, J.A. Repurposing mebendazole for the treatment of medulloblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Neurosurgery</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span></p>
<p style="top:443.5pt;left:57.3pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">76</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, N15&#x2013;N16. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:455.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">104.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> De Witt, M.; Gamble, A.; Hanson, D.; Markowitz, D.; Powell, C.; Al Dimassi, S.; Atlas, M.; Boockvar, J.; Ruggieri, R.; Symons,</span></p>
<p style="top:466.4pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">M. Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Mol. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 23</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 50&#x2013;56.</span></p>
<p style="top:478.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:489.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">105.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Larsen, A.R.; Bai, R.Y.; Chung, J.H.; Borodovsky, A.; Rudin, C.M.; Riggins, G.J.; Bunz, F. Repurposing the antihelmintic</span></p>
<p style="top:501.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">mebendazole as a hedgehog inhibitor.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Mol. Cancer Ther.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 14</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 3&#x2013;13. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:512.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">106.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7"> https://clinicaltrials.</span></p>
<p style="top:524.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">gov/ct2/show/results/NCT02644291</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:535.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">107.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Happold, C.; Gorlia, T.; Nabors, L.B.; Erridge, S.C.; Reardon, D.A.; Hicking, C.; Picard, M.; Stupp, R.; Weller, M.; Group,</span></p>
<p style="top:547.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">E.B.T.; et al. Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Neurooncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 138</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 163&#x2013;171.</span></p>
<p style="top:558.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:570.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">108.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Ursu, R.; Thomas, L.; Psimaras, D.; Chinot, O.; Le Rhun, E.; Ricard, D.; Charissoux, M.; Cuzzubbo, S.; Sejalon, F.; Quillien, V.; et al.</span></p>
<p style="top:581.5pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An</span></p>
<p style="top:593.1pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ANOCEF study.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Eur. J. Cancer</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 109</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 129&#x2013;136. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:604.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">109.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Reardon, D.A.; Quinn, J.A.; Vredenburgh, J.; Rich, J.N.; Gururangan, S.; Badruddoja, M.; Herndon, J.E.; Dowell, J.M.; Friedman,</span></p>
<p style="top:616.0pt;left:57.2pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">A.H.; Friedman, H.S. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Cancer</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2005</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 103</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span></p>
<p style="top:627.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">329&#x2013;338. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:639.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">110.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Kesari, S.; Schiff, D.; Henson, J.W.; Muzikansky, A.; Gigas, D.C.; Doherty, L.; Batchelor, T.T.; Longtine, J.A.; Ligon, K.L.; Weaver,</span></p>
<p style="top:650.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">S.; et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Neuro Oncol.</span></i></p>
<p style="top:662.1pt;left:57.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2008</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 10</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 300&#x2013;308. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:673.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">111.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Levin, V.A.; Giglio, P.; Puduvalli, V.K.; Jochec, J.; Groves, M.D.; Yung, W.K.; Hess, K. Combination chemotherapy with 13-cis-</span></p>
<p style="top:685.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">retinoic acid and celecoxib in the treatment of glioblastoma multiforme.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Neurooncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2006</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 78</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 85&#x2013;90. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:696.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">112.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse</span></p>
<p style="top:708.2pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG). Available online:</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7"> https://www.clinicaltrials.</span></p>
<p style="top:719.7pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">gov/ct2/show/NCT03355794</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:731.2pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">113.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Phase I&#x2013;II Everolimus and Sorafenib in Recurrent High-Grade Gliomas. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/</span></p>
<p style="top:742.7pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">NCT01434602</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">26 of 29</span></p>
<p style="top:98.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">114.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> A Phase 0 II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma</span></p>
<p style="top:109.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Patients Scheduled for Resection. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT03834740</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February</span></p>
<p style="top:121.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2021).</span></p>
<p style="top:132.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">115.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Study of Dasatinib in Combination with Everolimus for Children and Young Adults with Gliomas Harboring PDGFR Alterations.</span></p>
<p style="top:144.3pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT03352427</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:155.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">116.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Ribociclib and Everolimus in Treating Children with Recurrent or Refractory Malignant Brain Tumors. Available online:</span></p>
<p style="top:167.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">https://clinicaltrials.gov/ct2/show/NCT03387020</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:178.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">117.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Vorinostat and Temozolomide in Treating Patients with Malignant Gliomas. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt;color:#0774b7"> https://clinicaltrials.gov/ct2</span></p>
<p style="top:190.3pt;left:56.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">/show/NCT00268385</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:201.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">118.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7"> https://clinicaltrials.</span></p>
<p style="top:213.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">gov/ct2/show/NCT02885324</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:224.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">119.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients with Malignant Glioma That Has Been Removed by</span></p>
<p style="top:236.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Surgery. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT00275067</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:247.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">120.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM.; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and</span></p>
<p style="top:259.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Bevacizumab. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT02330562</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:270.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">121.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Brain Cancer. Available online:</span></p>
<p style="top:282.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">https://www.clinicaltrials.gov/ct2/show/NCT02903069</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:293.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">122.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Fimepinostat in Treating Brain Tumors in Children and Young Adults. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/</span></p>
<p style="top:305.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">NCT03893487</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:316.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">123.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Wu, L.; Bernal, G.M.; Cahill, K.E.; Pytel, P.; Fitzpatrick, C.A.; Mashek, H.; Weichselbaum, R.R.; Yamini, B. BCL3 expression</span></p>
<p style="top:328.4pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">promotes resistance to alkylating chemotherapy in gliomas.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Sci. Transl. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 10</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:339.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">124.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Das, A.; Banik, N.L.; Ray, S.K. Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in</span></p>
<p style="top:351.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">human glioblastoma T98G and U87MG cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancer Investig.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2008</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 26</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 352&#x2013;358. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:362.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">125.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Study of Acetazolamide with Temozolomide in Adults with Newly Diagnosed or Recurrent Malignant Glioma. Available online:</span></p>
<p style="top:374.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">https://clinicaltrials.gov/ct2/show/NCT03011671</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:386.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">126.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Reardon, D.A.; Brandes, A.A.; Omuro, A.; Mulholland, P.; Lim, M.; Wick, A.; Baehring, J.; Ahluwalia, M.S.; Roth, P.; B&#xe4;hr, O.; et al.</span></p>
<p style="top:397.5pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical</span></p>
<p style="top:409.0pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Trial.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> JAMA Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 6</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1003&#x2013;1010. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:420.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">127.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Neoadjuvant Nivolumab in Glioblastoma. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT02550249</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1</span></p>
<p style="top:432.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">February 2021).</span></p>
<p style="top:443.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">128.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Schalper, K.A.; Rodriguez-Ruiz, M.E.; Diez-Valle, R.; L</span><span style="font-family:VnURWPalladioL,serif;font-size:9.0pt">&#xf3;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">pez-Janeiro, A.; Porciuncula, A.; Idoate, M.A.; Inog</span><span style="font-family:VnURWPalladioL,serif;font-size:9.0pt">&#xe9;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">s, S.; de Andrea, C.;</span></p>
<p style="top:455.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">L</span><span style="font-family:VnURWPalladioL,serif;font-size:9.0pt">&#xf3;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">pez-Diaz de Cerio, A.; Tejada, S.; et al. Neoadjuvant nivolumab modi&#xfb01;es the tumor immune microenvironment in resectable</span></p>
<p style="top:466.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Nat. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 25</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 470&#x2013;476. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:478.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">129.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Omuro, A.; Vlahovic, G.; Lim, M.; Sahebjam, S.; Baehring, J.; Cloughesy, T.; Voloschin, A.; Ramkissoon, S.H.; Ligon, K.L.; Latek,</span></p>
<p style="top:489.4pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">R.; et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: Results from exploratory phase I</span></p>
<p style="top:501.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">cohorts of CheckMate 143.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Neuro Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 20</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 674&#x2013;686. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:512.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">130.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> An Investigational Immuno-Therapy Study of Nivolumab Compared to Temozolomide, Each Given with Radiation Therapy, for</span></p>
<p style="top:524.1pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Newly-Diagnosed Patients with Glioblastoma (GBM, a Malignant Brain Cancer). Available online:</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7"> https://clinicaltrials.gov/ct2</span></p>
<p style="top:535.5pt;left:56.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">/show/NCT02617589</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:547.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">131.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> An Investigational Immuno-Therapy Study of Temozolomide Plus Radiation Therapy with Nivolumab or Placebo, for Newly</span></p>
<p style="top:558.6pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Diagnosed Patients with Glioblastoma (GBM, a Malignant Brain Cancer). Available online:</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/</span></p>
<p style="top:570.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">NCT02667587</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:581.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">132.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Reardon, D.A.; Nayak, L.; Peters, K.B.; Clarke, J.L.; Jordan, J.T.; Groot, J.F.D.; Nghiemphu, P.L.; Kaley, T.J.; Colman, H.; Gaffey,</span></p>
<p style="top:593.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">S.C.; et al. Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients.</span></p>
<p style="top:604.6pt;left:57.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">J. Clin. Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 36</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 2006. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:616.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">133.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Pembrolizumab in Treating Younger Patients with Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic</span></p>
<p style="top:627.6pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7"> https://clinicaltrials.gov/</span></p>
<p style="top:639.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">ct2/show/NCT02359565</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:650.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">134.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Hypofractionated Stereotactic Irradiation (HFSRT) with Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas.</span></p>
<p style="top:662.1pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT02313272</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:673.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">135.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Gritti, M.; Wurth, R.; Angelini, M.; Barbieri, F.; Peretti, M.; Pizzi, E.; Pattarozzi, A.; Carra, E.; Sirito, R.; Daga, A.; et al.</span></p>
<p style="top:685.2pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Metformin repositioning as antitumoral agent: Selective antiproliferative effects in human glioblastoma stem cells, via inhibition</span></p>
<p style="top:696.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">of CLIC1-mediated ion current.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 5</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 11252&#x2013;11268. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:708.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">136.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Jiralerspong, S.; Palla, S.L.; Giordano, S.H.; Meric-Bernstam, F.; Liedtke, C.; Barnett, C.M.; Hsu, L.; Hung, M.C.; Hortobagyi, G.N.;</span></p>
<p style="top:719.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Gonzalez-Angulo, A.M. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with</span></p>
<p style="top:731.2pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">breast cancer.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Clin. Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2009</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 27</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 3297&#x2013;3302. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:742.7pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">137.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Rezaei, N.; Neshasteh-Riz, A.; Mazaheri, Z.; Koosha, F.; Hoormand, M. The Combination of Metformin and Disul&#xfb01;ram-Cu for</span></p>
<p style="top:754.2pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Effective Radiosensitization on Glioblastoma Cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cell J.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 22</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 263&#x2013;272. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">27 of 29</span></p>
<p style="top:98.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">138.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Jiang, W.; Finniss, S.; Cazacu, S.; Xiang, C.; Brodie, Z.; Mikkelsen, T.; Poisson, L.; Shackelford, D.B.; Brodie, C. Repurposing</span></p>
<p style="top:109.8pt;left:57.2pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">phenformin for the targeting of glioma stem cells and the treatment of glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 7</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 56456&#x2013;56470. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:121.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">139.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Seliger, C.; Luber, C.; Gerken, M.; Schaertl, J.; Proescholdt, M.; Riemenschneider, M.J.; Meier, C.R.; Bogdahn, U.; Leitzmann, M.F.;</span></p>
<p style="top:132.7pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Klinkhammer-Schalke, M.; et al. Use of metformin and survival of patients with high-grade glioma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Int. J. Cancer</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 144</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span></p>
<p style="top:144.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">273&#x2013;280. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:155.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">140.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Seliger, C.; Genbrugge, E.; Gorlia, T.; Chinot, O.; Stupp, R.; Nabors, B.; Weller, M.; Hau, P.; Group, E.B.T. Use of metformin and</span></p>
<p style="top:167.4pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">outcome of patients with newly diagnosed glioblastoma: Pooled analysis.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Int. J. Cancer</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 146</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 803&#x2013;809. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:178.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">141.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Molenaar, R.J.; Coelen, R.J.S.; Khurshed, M.; Roos, E.; Caan, M.W.A.; van Linde, M.E.; Kouwenhoven, M.; Bramer, J.A.M.; Bovee,</span></p>
<p style="top:190.4pt;left:57.4pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">J.; Mathot, R.A.; et al. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated</span></p>
<p style="top:201.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">or IDH2-mutated solid tumours.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> BMJ Open</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 7</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, e014961. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:213.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">142.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Temozolomide, Memantine Hydrochloride, Me&#xfb02;oquine, and Metformin Hydrochloride in Treating Patients with Glioblastoma</span></p>
<p style="top:224.9pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Multiforme after Radiation Therapy. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT01430351</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> (accessed on 1 February</span></p>
<p style="top:236.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2021).</span></p>
<p style="top:247.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">143.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Metformin and Chloroquine in IDH1/2-Mutated Solid Tumors. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT024</span></p>
<p style="top:259.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">96741</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:270.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">144.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined with Radiotherapy. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt;color:#0774b7"> https://</span></p>
<p style="top:282.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">clinicaltrials.gov/ct2/show/NCT02149459</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:293.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">145.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Bioavailability of Disul&#xfb01;ram and Metformin in Glioblastomas. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT03151</span></p>
<p style="top:305.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">772</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:316.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">146.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Metformin, Neo-Adjuvant Temozolomide and Hypo-Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients with</span></p>
<p style="top:328.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">GBM. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT02780024</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:339.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">147.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient with Recurrent or Refractory Glioblastoma. Available</span></p>
<p style="top:351.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT03243851</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:362.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">148.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Miller, S.E.; Tummers, W.S.; Teraphongphom, N.; van den Berg, N.S.; Hasan, A.; Ertsey, R.D.; Nagpal, S.; Recht, L.D.; Plowey, E.D.;</span></p>
<p style="top:374.5pt;left:57.2pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Vogel, H.; et al. First-in-human intraoperative near-infrared &#xfb02;uorescence imaging of glioblastoma using cetuximab-IRDye800.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> J.</span></i></p>
<p style="top:386.0pt;left:57.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Neurooncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 139</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 135&#x2013;143. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:397.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">149.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> A Study of the Speci&#xfb01;city and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors. Available</span></p>
<p style="top:409.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT01128218</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:420.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">150.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> ALA-induced PpIX Fluorescence during Brain Tumor Resection. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7"> https://clinicaltrials.gov/ct2/show/NCT021</span></p>
<p style="top:432.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">91488</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:443.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">151.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7"> https://clinicaltrials.gov/</span></p>
<p style="top:455.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">ct2/show/NCT02691923</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:466.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">152.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Stummer, W.; Pichlmeier, U.; Meinel, T.; Wiestler, O.D.; Zanella, F.; Reulen, H.J.; Group, A.-G.S. Fluorescence-guided surgery with</span></p>
<p style="top:478.0pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Lancet Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2006</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span></p>
<p style="top:489.5pt;left:57.3pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">7</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 392&#x2013;401. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:501.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">153.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Furuta, T.; Sabit, H.; Dong, Y.; Miyashita, K.; Kinoshita, M.; Uchiyama, N.; Hayashi, Y.; Hayashi, Y.; Minamoto, T.; Nakada, M.</span></p>
<p style="top:512.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Biological basis and clinical study of glycogen synthase kinase- 3beta-targeted therapy by drug repositioning for glioblastoma.</span></p>
<p style="top:524.0pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 22811&#x2013;22824. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:535.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">154.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Halatsch, M.E.; Kast, R.E.; Dwucet, A.; Hlavac, M.; Heiland, T.; Westhoff, M.A.; Debatin, K.M.; Wirtz, C.R.; Siegelin, M.D.;</span></p>
<p style="top:547.0pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Karpel-Massler, G. Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose</span></p>
<p style="top:558.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">CUSP9 repurposed drug regime against glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Br. J. Pharmacol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 176</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 3681&#x2013;3694. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:570.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">155.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Skaga, E.; Skaga, I.O.; Grieg, Z.; Sandberg, C.J.; Langmoen, I.A.; Vik-Mo, E.O. The ef&#xfb01;cacy of a coordinated pharmacological</span></p>
<p style="top:581.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Cancer Res. Clin. Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 145</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span></p>
<p style="top:593.1pt;left:57.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">1495&#x2013;1507. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:604.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">156.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Kast, R.E.; Karpel-Massler, G.; Halatsch, M.E. CUSP9* treatment protocol for recurrent glioblastoma: Aprepitant, artesunate,</span></p>
<p style="top:616.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">aurano&#xfb01;n, captopril, celecoxib, disul&#xfb01;ram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.</span></p>
<p style="top:627.6pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 5</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 8052&#x2013;8082. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:639.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">157.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> A Proof-of-Concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed</span></p>
<p style="top:650.6pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Drugs Combined with Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma. Available online:</span></p>
<p style="top:662.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">https://clinicaltrials.gov/ct2/show/NCT02770378</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:673.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">158.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Verschuur, A.; Heng-Maillard, M.A.; Dory-Lautrec, P.; Truillet, R.; Jouve, E.; Chastagner, P.; Leblond, P.; Aerts, I.; Honore, S.;</span></p>
<p style="top:685.2pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Entz-Werle, N.; et al. Metronomic Four-Drug Regimen Has Anti-tumor Activity in Pediatric Low-Grade Glioma; The Results of a</span></p>
<p style="top:696.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phase II Clinical Trial.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Front. Pharmacol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 00950. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:708.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">159.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Huang, L.; Garrett Injac, S.; Cui, K.; Braun, F.; Lin, Q.; Du, Y.; Zhang, H.; Kogiso, M.; Lindsay, H.; Zhao, S.; et al. Systems</span></p>
<p style="top:719.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">biology-based drug repositioning identi&#xfb01;es digoxin as a potential therapy for groups 3 and 4 medulloblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Sci. Transl. Med.</span></i></p>
<p style="top:731.2pt;left:57.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 10</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:742.7pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">160.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Ong, C.K.; Lirk, P.; Tan, C.H.; Seymour, R.A. An evidence-based update on nonsteroidal anti-in&#xfb02;ammatory drugs.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Clin. Med. Res.</span></i></p>
<p style="top:754.2pt;left:57.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2007</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 5</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 19&#x2013;34. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">28 of 29</span></p>
<p style="top:98.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">161.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Galvao, R.P.; Zong, H. In&#xfb02;ammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor</span></p>
<p style="top:109.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Progression.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Curr. Pathobiol. Rep.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 19&#x2013;28. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:121.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">162.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Goglia, A.G.; Delsite, R.; Luz, A.N.; Shahbazian, D.; Salem, A.F.; Sundaram, R.K.; Chiaravalli, J.; Hendrikx, P.J.; Wilshire, J.A.;</span></p>
<p style="top:132.7pt;left:57.4pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Jasin, M.; et al. Identi&#xfb01;cation of novel radiosensitizers in a high-throughput, cell-based screen for DSB repair inhibitors.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Mol.</span></i></p>
<p style="top:144.3pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cancer Ther.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 14</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 326&#x2013;342. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:155.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">163. Grif&#xfb01;n, J.P. The withdrawal of mibefradil (Posicor).</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Advers. Drug React. Toxicol. Rev.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1998</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 17</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 59&#x2013;60.</span></p>
<p style="top:167.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">164.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Vellichirammal, N.N.; Albahrani, A.; Banwait, J.K.; Mishra, N.K.; Li, Y.; Roychoudhury, S.; Kling, M.J.; Mirza, S.; Bhakat, K.K.;</span></p>
<p style="top:178.8pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Band, V.; et al. Pan-Cancer Analysis Reveals the Diverse Landscape of Novel Sense and Antisense Fusion Transcripts.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Mol. Ther.</span></i></p>
<p style="top:190.3pt;left:57.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Nucleic Acids</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 19</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1379&#x2013;1398. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:201.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">165.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Brennan, C.W.; Verhaak, R.G.; McKenna, A.; Campos, B.; Noushmehr, H.; Salama, S.R.; Zheng, S.; Chakravarty, D.; Sanborn, J.Z.;</span></p>
<p style="top:213.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Berman, S.H.; et al. The somatic genomic landscape of glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cell</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 155</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 462&#x2013;477. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:224.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">166.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Chatziathanasiadou, M.V.; Stylos, E.K.; Giannopoulou, E.; Spyridaki, M.H.; Briasoulis, E.; Kalofonos, H.P.; Crook, T.; Syed, N.;</span></p>
<p style="top:236.3pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Sivolapenko, G.B.; Tzakos, A.G. Development of a validated LC-MS/MS method for the</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> and</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> quantitation of</span></p>
<p style="top:247.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">sunitinib in glioblastoma cells and cancer patients.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Pharm. Biomed. Anal.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 164</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 690&#x2013;697. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:259.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">167.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Network, C.G.A.R. Comprehensive genomic characterization de&#xfb01;nes human glioblastoma genes and core pathways.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Nature</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2008</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span></p>
<p style="top:270.9pt;left:57.3pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">455</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1061&#x2013;1068. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:282.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">168.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Seliger, C.; Schaertl, J.; Gerken, M.; Luber, C.; Proescholdt, M.; Riemenschneider, M.J.; Leitzmann, M.F.; Hau, P.; Klinkhammer-</span></p>
<p style="top:293.9pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Schalke, M. Use of statins or NSAIDs and survival of patients with high-grade glioma.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> PLoS ONE</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, e0207858. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:305.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">169.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Pointer, K.B.; Clark, P.A.; Eliceiri, K.W.; Salamat, M.S.; Robertson, G.A.; Kuo, J.S. Administration of Non-Torsadogenic human</span></p>
<p style="top:317.0pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Ether-a-go-go-Related Gene Inhibitors Is Associated with Better Survival for High hERG-Expressing Glioblastoma Patients.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Clin.</span></i></p>
<p style="top:328.4pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cancer Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 23</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 73&#x2013;80. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:339.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">170.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Brown, B.M.; Pressley, B.; Wulff, H. KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Curr.</span></i></p>
<p style="top:351.4pt;left:57.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Neuropharmacol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 16</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 618&#x2013;626. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:362.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">171.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Quail, D.F.; Joyce, J.A. The Microenvironmental Landscape of Brain Tumors.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Cancer Cell</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 31</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 326&#x2013;341. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:374.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">172.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Hambardzumyan, D.; Gutmann, D.H.; Kettenmann, H. The role of microglia and macrophages in glioma maintenance and</span></p>
<p style="top:386.0pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">progression.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Nat. Neurosci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 19</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 20&#x2013;27. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:397.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">173.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Lai, A.; Tran, A.; Nghiemphu, P.L.; Pope, W.B.; Solis, O.E.; Selch, M.; Filka, E.; Yong, W.H.; Mischel, P.S.; Liau, L.M.; et al. Phase II</span></p>
<p style="top:408.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma</span></p>
<p style="top:420.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">multiforme.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Clin. Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2011</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 29</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 142&#x2013;148. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:432.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">174.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Vredenburgh, J.J.; Desjardins, A.; Reardon, D.A.; Peters, K.B.; Herndon, J.E.; Marcello, J.; Kirkpatrick, J.P.; Sampson, J.H.; Bailey,</span></p>
<p style="top:443.4pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">L.; Threatt, S.; et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab,</span></p>
<p style="top:455.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">temozolomide, and irinotecan for newly diagnosed glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Clin. Cancer Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2011</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 17</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 4119&#x2013;4124. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:466.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">175.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Gilbert, M.R.; Dignam, J.J.; Armstrong, T.S.; Wefel, J.S.; Blumenthal, D.T.; Vogelbaum, M.A.; Colman, H.; Chakravarti, A.; Pugh,</span></p>
<p style="top:477.9pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">S.; Won, M.; et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> N. Engl. J. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 370</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 699&#x2013;708.</span></p>
<p style="top:489.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:501.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">176.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Polydorou, C.; Mpekris, F.; Papageorgis, P.; Voutouri, C.; Stylianopoulos, T. Pirfenidone normalizes the tumor microenvironment</span></p>
<p style="top:512.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">to improve chemotherapy.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 24506&#x2013;24517. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:524.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">177.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Pearson, J.R.D.; Regad, T. Targeting cellular pathways in glioblastoma multiforme.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Signal. Transduct. Target. Ther.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 17040.</span></p>
<p style="top:535.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:547.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">178.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Matteoni, S.; Matarrese, P.; Ascione, B.; Buccarelli, M.; Ricci-Vitiani, L.; Pallini, R.; Villani, V.; Pace, A.; Paggi, M.G.; Abbruzzese, C.</span></p>
<p style="top:558.6pt;left:57.2pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Anticancer Properties of the Antipsychotic Drug Chlorpromazine and Its Synergism with Temozolomide in Restraining Human</span></p>
<p style="top:570.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Glioblastoma Proliferation.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Front. Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 11</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 635472. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:581.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">179.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Shi, J.; Dong, X.; Li, H.; Wang, H.; Jiang, Q.; Liu, L.; Wang, L.; Dong, J. Nicardipine sensitizes temozolomide by inhibiting</span></p>
<p style="top:593.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">autophagy and promoting cell apoptosis in glioma stem cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Aging</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 6820&#x2013;6831. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:604.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">180.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Datta, S.; Sears, T.; Cortopassi, G.; Woolard, K.; Angelastro, J.M. Repurposing FDA approved drugs inhibiting mitochondrial</span></p>
<p style="top:616.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">function for targeting glioma-stem like cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Biomed. Pharmacother.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 133</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 111058. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:627.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">181.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Suzuki, S.; Yamamoto, M.; Sanomachi, T.; Togashi, K.; Sugai, A.; Seino, S.; Okada, M.; Yoshioka, T.; Kitanaka, C. Doxazosin, a</span></p>
<p style="top:639.2pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy</span></p>
<p style="top:650.6pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">as Drug Repurposing.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Biomedicines</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 273. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:662.1pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">182.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Vargas-Toscano, A.; Khan, D.; Nickel, A.C.; Hewera, M.; Kamp, M.A.; Fischer, I.; Steiger, H.J.; Zhang, W.; Muhammad, S.; H&#xe4;nggi,</span></p>
<p style="top:673.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">D.; et al. Robot technology identi&#xfb01;es a Parkinsonian therapeutics repurpose to target stem cells of glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> CNS Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span></p>
<p style="top:685.1pt;left:57.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, CNS58. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:696.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">183.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Knudsen-Baas, K.M.; Engeland, A.; Gilhus, N.E.; Storstein, A.M.; Owe, J.F. Does the choice of antiepileptic drug affect survival in</span></p>
<p style="top:708.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">glioblastoma patients?</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Neurooncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 129</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 461&#x2013;469. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:719.7pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">184. Toovey, S. Me&#xfb02;oquine neurotoxicity: A literature review.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Travel Med. Infect. Dis.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2009</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 7</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 2&#x2013;6. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:731.2pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">185.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Brazil, L.; Swampillai, A.L.; Mak, K.M.; Edwards, D.; Mesiri, P.; Clifton-Hadley, L.; Shaffer, R.; Lewis, J.; Watts, C.; Jeffries, S.; et al.</span></p>
<p style="top:742.7pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: A randomized</span></p>
<p style="top:754.2pt;left:57.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">phase II trial.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Neurooncol. Adv.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, vdaa046. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:53.2pt;left:35.7pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2021</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 1953</span></p>
<p style="top:53.2pt;left:532.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">29 of 29</span></p>
<p style="top:98.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">186.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Teng, J.; Hejazi, S.; Hiddingh, L.; Carvalho, L.; de Gooijer, M.C.; Wakimoto, H.; Barazas, M.; Tannous, M.; Chi, A.S.; Noske,</span></p>
<p style="top:109.7pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">D.P.; et al. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo</span></p>
<p style="top:121.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">DNA synthesis, irrespective of molecular subtype.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Neuro Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 20</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 642&#x2013;654. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:132.8pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">187.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Yamashita, A.S.; da Costa Rosa, M.; Borodovsky, A.; Festuccia, W.T.; Chan, T.; Riggins, G.J. Demethylation and epigenetic</span></p>
<p style="top:144.3pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">modi&#xfb01;cation with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Neuro Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span></p>
<p style="top:155.8pt;left:57.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">189&#x2013;200. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:167.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">188.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Taylor, J.T.; Ellison, S.; Pandele, A.; Wood, S.; Nathan, E.; Forte, G.; Parker, H.; Zindy, E.; Elvin, M.; Dickson, A.; et al. Actinomycin</span></p>
<p style="top:178.8pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">D Downregulates Sox2 and Improves Survival in Preclinical Models of Recurrent Glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Neuro Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:190.3pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">189.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Wehbe, M.; Anantha, M.; Shi, M.; Leung, A.W.; Dragowska, W.H.; Sanche, L.; Bally, M.B. Development and optimization of</span></p>
<p style="top:201.8pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Int. J. Nanomed.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 4129&#x2013;4146.</span></p>
<p style="top:213.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:224.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">190.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Takahashi, M.; Miki, S.; Fujimoto, K.; Fukuoka, K.; Matsushita, Y.; Maida, Y.; Yasukawa, M.; Hayashi, M.; Shinkyo, R.; Kikuchi,</span></p>
<p style="top:236.3pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">K.; et al. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts.</span></p>
<p style="top:247.9pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cancer Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 110</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 2247&#x2013;2257. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:259.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">191.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Whitehead, C.A.; Nguyen, H.P.T.; Morokoff, A.P.; Luwor, R.B.; Paradiso, L.; Kaye, A.H.; Mantamadiotis, T.; Stylli, S.S. Inhibition</span></p>
<p style="top:271.0pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Transl. Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span></p>
<p style="top:282.4pt;left:57.1pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">11</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1406&#x2013;1418. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:293.9pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">192.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Paulmurugan, R.; Afjei, R.; Sekar, T.V.; Babikir, H.A.; Massoud, T.F. A protein folding molecular imaging biosensor monitors</span></p>
<p style="top:305.3pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">the effects of drugs that restore mutant p53 structure and its downstream function in glioblastoma cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span></p>
<p style="top:316.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">21495&#x2013;21511. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:328.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">193.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Dave, N.; Chow, L.M.; Gudelsky, G.A.; LaSance, K.; Qi, X.; Desai, P.B. Preclinical pharmacological evaluation of letrozole as a</span></p>
<p style="top:339.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">novel treatment for gliomas.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Mol. Cancer Ther.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 14</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 857&#x2013;864. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:351.4pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">194.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Tivnan, A.; Heilinger, T.; Ramsey, J.M.; O&#x2019;Connor, G.; Pokorny, J.L.; Sarkaria, J.N.; Stringer, B.W.; Day, B.W.; Boyd, A.W.;</span></p>
<p style="top:362.9pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Kim, E.L.; et al. Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-speci&#xfb01;c delivery of the aromatase</span></p>
<p style="top:374.5pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span></p>
<p style="top:386.0pt;left:57.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 16605&#x2013;16620. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:397.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">195.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Doan, N.B.; Alhajala, H.; Al-Gizawiy, M.M.; Mueller, W.M.; Rand, S.D.; Connelly, J.M.; Cochran, E.J.; Chitambar, C.R.; Clark, P.;</span></p>
<p style="top:409.0pt;left:57.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Kuo, J.; et al. Acid ceramidase and its inhibitors: A de novo drug target and a new class of drugs for killing glioblastoma cancer</span></p>
<p style="top:420.5pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">stem cells with high ef&#xfb01;ciency.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 112662&#x2013;112674. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:432.0pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">196.</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> A Pilot Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the PD-1 Checkpoint Inhibitor, Pem-</span></p>
<p style="top:443.4pt;left:57.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">brolizumab (MK-3475), in Patients with Surgically Accessible Recurrent/Progressive Glioblastoma. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt;color:#0774b7"> https:</span></p>
<p style="top:455.0pt;left:56.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">//clinicaltrials.gov/ct2/show/NCT02852655</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:466.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">197.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Ef&#xfb01;cacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas. Available online:</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> https://www.clinicaltrials.gov/ct2</span></p>
<p style="top:478.0pt;left:56.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">/show/NCT03925246</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> (accessed on 1 February 2021).</span></p>
<p style="top:489.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">198. Kast, R.E.; Skuli, N.; Karpel-Massler, G.; Frosina, G.; Ryken, T.; Halatsch, M.E. Blocking epithelial-to-mesenchymal transition in</span></p>
<p style="top:501.0pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">glioblastoma with a sextet of repurposed drugs: The EIS regimen.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Oncotarget</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 8</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 60727&#x2013;60749. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:512.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">199.</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Migliorini, D.; Dietrich, P.Y.; Stupp, R.; Linette, G.P.; Posey, A.D.; June, C.H. CAR T-Cell Therapies in Glioblastoma: A First Look.</span></p>
<p style="top:524.0pt;left:57.2pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Clin. Cancer Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 24</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 535&#x2013;540. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:535.5pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">200.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> McGranahan, T.; Therkelsen, K.E.; Ahmad, S.; Nagpal, S. Current State of Immunotherapy for Treatment of Glioblastoma.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Curr.</span></i></p>
<p style="top:547.0pt;left:57.0pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Treat. Options Oncol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 20</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 24. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:558.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">201.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Akhavan, D.; Alizadeh, D.; Wang, D.; Weist, M.R.; Shepphird, J.K.; Brown, C.E. CAR T cells for brain tumors: Lessons learned</span></p>
<p style="top:570.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and road ahead.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Immunol. Rev.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 290</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 60&#x2013;84. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:581.6pt;left:36.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">202.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Weenink, B.; French, P.J.; Sillevis Smitt, P.A.E.; Debets, R.; Geurts, M. Immunotherapy in Glioblastoma: Current Shortcomings</span></p>
<p style="top:593.1pt;left:57.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and Future Perspectives.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cancers</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 751. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>

</div>
